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ABSTRACT 
Superantigens (SAgs) are microbial toxins that cross-link T cell receptors with major 
histocompatibility complex (MHC) class II (MHC II) molecules leading to the activation 
of large numbers of T cells. Herein, the development and preclinical testing of a novel 
tumour-targeted SAg (TTS) therapeutic built using the streptococcal pyrogenic exotoxin 
C (SpeC) SAg and targeting cancer cells expressing the 5T4 tumour-associated antigen 
(TAA) was described. To inhibit potentially harmful widespread immune cell activation, 
a SpeC mutation within the high-affinity MHC II binding interface was generated 
(SpeCD203A) that demonstrated a pronounced reduction in mitogenic activity, yet this 
mutant could still induce immune cell-mediated cancer cell death in vitro. To target 5T4+ 
cancer cells, a humanized single-chain variable fragment (scFv) antibody to recognize 
5T4 (scFv5T4) was engineered. Specific targeting of scFv5T4 was verified. SpeCD203A 
fused to scFv5T4 maintained the ability to activate and induce immune cell-mediated 
cytotoxicity of colon cancer cells. Using a xenograft model of established human colon 
cancer, it was demonstrated that the SpeC-based TTS was able to control the growth and 
spread of large tumours in vivo. This required both TAA targeting by scFv5T4 and 
functional SAg activity. These studies lay the foundation for the development of 
streptococcal SAgs as 'next-generation' TTSs for cancer immunotherapy. 
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1.1 General overview of cancer 
Cancer is a leading cause of both disease and death worldwide, with a recent incidence 
rate of approximately 14.1 million new cases and 8.2 million deaths annually (1). A 
generic term for a large group of diseases, cancer is “the rapid creation of abnormal cells 
that grow beyond their usual boundaries,” as described by the World Health Organization 
(WHO) (2). Initially affecting any part of the body, cancers can further spread and invade 
tissues and organs, with these metastases generating the bulk of death from cancer (2). 
According to the WHO, the multistage transition of normal cells to malignant tumours 
results from a combination of fundamental factors including an individual’s genetics, 
ageing processes, and external agents comprising of physical (e.g. ultraviolet, radiation), 
chemical (e.g. tobacco), or biological (e.g. infection) carcinogens (2). As such, the most 
common causes of cancer death worldwide, in descending order, are those of lung, breast, 
colorectal, prostate, stomach, and liver cancer (1), coordinating with the associated key 
risk factors of tobacco use, alcohol use, unhealthy diet, and physical inactivity (2). 
Additionally, in many developing countries, chronic infections are major risk factors. By 
modifying or avoiding these major factors, it has been estimated that more than 30% of 
cancer deaths could be prevented (2). Although strides in preventative screening and 
early diagnosis are aiding in the overall outcome of this disease, it is still expected that 
the number of new cases will rise approximately 70% over the next 20 years, nearing 22 
million new cases annually (2). 
Specifically within Canada, cancer is responsible for nearly 30% of all deaths (3). 
According to statistics from the Canadian Cancer Society for 2015, approximately 196 
900 new cases of cancer will develop and 78 000 patients will die of this disease; 
numbers that are ever increasing with each year (3). As a result, almost half of all 
Canadians will be expected to develop this disease within their lifetime, and consequently 
one quarter are predicted to die of cancer. Related to worldwide estimations, it is 
expected that new cases will dramatically rise (79%) in Canada over the next 15 years, 
largely due to the ever-increasing aging population (3). Indeed, despite that this 
devastating disease can occur at any age, the vast majority (89%) of individuals who 
currently develop cancer are over the age of 50 (3). The importance of continued research 
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and development of additional heath resources for managing this disease is highlighted 
from this staggering predicted increase in incidence rate. Cancers of the lung, breast, 
colorectal, and prostate, similar to other developed, westernized countries, are responsible 
for more than half of new cancer cases (51%) annually and although all cancers are of 
importance, may warrant particular focus due to their sheer prevalence. Current efforts, 
despite ongoing challenges, have made significant progress in the fight against cancer. 
Today, with the continuous knowledge growing in cancer biology, the risk factors, 
surveillance, and treatments, many improvements have been made; most notably 
resulting in the steady decline of the cancer mortality rate since its peak in 1988 within 
Canada (3). 
1.2 Colorectal cancer  
Colorectal cancer (CRC) represents a major health concern worldwide, being accountable 
for more than 600 000 deaths per year (4). Despite advances in screening and treatment, 
CRC remains the third most common cancer in men, 10% of the total, and the second in 
women, 9.4% of the total, worldwide (1). Similar to the rest of the Western world, CRC 
is one of the four major contributors to new cancer diagnoses in Canada, accounting for 
more than half of all cancers and is the second and third most common cause of cancer-
related death for males and females, respectively (3). The overall 5-year survival rate is 
65% (5), but varies extensively depending on the stage of CRC progression at diagnosis 
(Table 1).  
Although the risk factors of developing CRC can have a hereditary component, it is more 
common that environmental factors are influential in its high incidence rate. These risk 
factors are outlined in Table 2. As an example, epidemiological studies have 
demonstrated that individuals who have immigrated to the Western world from a once 
CRC low-incidence country, eventually developed CRC at a similar rate to those native-
born (6, 7). Moreover, evidence during the past decade suggests that the Western 
influence globally, in particular with diet, has caused incidence rates of CRC in these 
once low-rate countries to rise dramatically (6-8). Such preventable influences include 
elevated consumption of dairy, meat, eggs, and oil or fat, which remain preeminent in 
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Table 1. TNM classification of CRC malignant tumours 
Stages are based on the UICC and AJCC groups with associated 5-year survival rate 
percentage. Modified from Meyerhardt et al. 2005, Sobin LH et al. 2011, and O’Connell 
et al. 2004 (9-11). 
Stage  TNM classification  Dukes’ classification 
5-year  
survival (%) 
0 Tis, N0, M0    
I T1, N0, M0 T2, N0, M0 
A 
B1 >90 
IIA 
IIB 
IIC 
T3, N0, M0 
T4a, N0, M0 
T4b, N0, M0 
B2 70-85 
IIIA 
IIIB 
IIIC 
T1-2, N1, M0 or T1, N2a, M0 
T3-4a, N1, M0 or T2-3, N2a, M0 or T1-2, N2b, M0 
T4a, N2a, M0 or T3-4a, N2b, M0 or T4b, N1-2, M0 
C1 
C2 
C2 
40-55 
IVA 
IVB 
T(any), N(any), M1a 
T(any), N(any), M1b D <10 
TX Cannot be assessed   
Tis Carcinoma in situ   
T1 Invades submucosa   
T2 Invades muscularis propria (muscle layer)   
T3 Penetrates muscularis propria and invades subserosa   
T4 Direct invasion of other organs or structures, or perforates membrane lining 
4a - perforates visercal peritoneum 
4b - directly invades other organs or structures 
NX Regional lymph nodes cannot be assessed    
N0 No metastases    
N1 Metastases in 1-3 nodes 
1a – metastasis in 1 regional lymph node 
1b – metastasis in 2-3 regional lymph nodes 
1c – satellites in the lymph drainage areas of the subserosa or the surrounding tissue without 
regional lymph node metastasis 
N2 Metastases in 4 or more nodes 
2a – metastasis in 4-6 regional lymph nodes 
2b – metastasis in 7 or more regional lymph nodes 
 
  
MX Presence or absence cannot be determined    
M0 None detected    
M1 Detected 
1a – metastasis confined to 1 organ or non-regional lymph node(s) 
1b – metastasis in more than 1 organ or the peritoneum 
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Table 2. Risk factors for the development of CRC 
 Risk factor associated with increased incidence
a 
Unpreventable/hereditary Age 50+ years  
 Previous CRC or polyps 
 Family history of CRC 
 Inflammatory bowel disease: ulcerative colitis, Crohn’s disease 
Preventable  High-fat diet 
 Diet low in fruits and vegetables 
 Physical inactivity 
 Obesity 
 Tobacco use 
 Alcohol use 
a Modified from Benson, 2007 (6) 
 
  
6 
high-fat diets of many countries today, lacking in a regular intake of fruit and vegetables 
(6). Furthermore, increased risk is also associated with lifestyle; inactivity, obesity, 
tobacco, and alcohol use of the most common factors (6, 12, 13). Indeed, location and 
socioeconomic status continue to be the main correlations with the incidence rate of CRC 
globally. 
This carcinoma, unlike many other malignancies, may be potentially curable if early 
stage tumours are able to be removed. As such, it has been predicted that the 
implementation of screening programs aimed at early detection are imperative to 
reducing overall incidence and associated mortality of CRC (14). However, CRC is 
difficult to diagnose with few symptoms until the onset of stage III or IV, based on the 
Tumour-Node-Metastasis (TNM) classification (Table 1). At the time of diagnosis, 
approximately 20% of patients will present with inoperable CRC, and 20-25% with pre-
existing metastatic disease (5, 15). Although tumour resection is performed when 
possible (10, 15), high mortality rates remain associated with CRC. Of those patients 
receiving surgical intervention, 40-50% will relapse or die from metastatic disease, the 
majority due to complications of liver metastases (6, 10, 15).  
1.2.1 CRC development and carcinogenesis 
The first CRC carcinogenesis model was described by Fearon and Vogelstein in 1990 
(16) and since, the multi-stage progression of CRC and contributing influences has had 
significant progress in understanding its molecular pathogenesis, as well as remaining 
challenges, which have been the focus of many comprehensive studies and reviews (16-
21). Foremost, CRCs develop gradually as a multifaceted result of epithelial cells 
transforming into adenocarcinomas through a sequential accumulation of genetic and 
epigenetic changes across multiple molecular pathways. As such, CRCs are known to be 
genetically diverse; each tumour has a unique combination of genetic alterations, and 
only a few mutations are common to CRCs (22). The pathological progression begins as 
a benign adenomatous polyp from a microscopic mucosal lesion, that further spreads and 
localizes within the submucosa and muscularis propria (muscle layer) (23). Further 
progression advances into high-dysplasia adenoma, potentially disseminating into 
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regional lymph nodes and surrounding tissues. Without intervention, non-regional lymph 
nodes and/or other organs may be invaded, advancing into late stage CRC of invasive 
metastatic disease (23). 
The majority of CRC occurrences are sporadic, nonhereditary, and have complex, 
heterogeneous etiological factors for carcinogenesis (24). To date, at least three molecular 
pathways for sporadic CRC have been described. The most common subgroup, termed 
chromosomal instability pathway, is characteristic for accumulations of point mutations 
in specific oncogenes and tumour suppressor genes (e.g APC, BRAF, KRAS, TP53) 
causing numerical and structural chromosomal irregularities (25). This pathway is mainly 
associated with 1) a mutation and/or loss of APC, functionally interrupting the 
suppression of the Wnt-signaling pathway, 2) mutation of the KRAS oncogene, 
consequently constitutively activating downstream signaling (RAS-RAF-MEK-ERK 
pathway) and 3) either mutation or chromosomal loss that contains TP53, encoding p53, 
an important tumour suppressor gene (26). Second, the microsatellite instability (MSI) 
pathway leads to genetic hypermutability as an outcome of misregulation of DNA 
mismatch repair genes (MMR) (27). In this pathway, single point or frameshift mutations 
occur in areas of the genome containing microsatellites, short repeat nucleotide sequences 
that can be inserted or deleted, from a defective mechanism (27). Although a hallmark 
trait of Lynch syndrome, also often called hereditary nonpolyposis colorectal cancer 
(HNPCC), this genetic irregularity occurs in ~13% of sporadic CRC (27, 28). Lastly, 
known as the CpG island methylator phenotype (CIMP) pathway, the expression of key 
tumour suppression genes (e.g. MLH1, a MMR gene) is epigenetically silenced and 
inactivated with hypermethylation of genetic promoter regions (29). Although there is not 
one universally recognized panel of CIMP markers, CRC carcinogenesis has associations 
with two separate genetic mutations, KRAS and BRAF (downstream of KRAS signaling) 
(30). Notably, these pathways are not mutually exclusive in the development of sporadic 
CRC, with this disease frequently presenting features from all three pathways (24).  
A lesser proportion of CRC cases are of known hereditary decent (~20-30%) (31); ~5% 
of cases are associated with highly penetrant inherited mutations with well-characterized 
clinical presentations (32). Currently, the etiologies of the remaining 15%–25% of 
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inherited CRCs are not completely understood or clarified. Conditions characterized are 
HNPCC, commonly known as Lynch syndrome described briefly above, familial 
adenomatous polyposis (FAP), attenuated FAP, and MUTYH-associated polyposis 
(MAP). Lynch syndrome is caused by genomic instability from an autosomal dominant 
inherited germline mutation in MMR genes, eventually leading to MSI (28, 31). 
Although the term nonpolyposis is used for this disease, the CRC frequently develops 
from polyps that, once formed, tend to become rapidly malignant, affecting sufferers at 
an early age (mean 45 years) (28, 31). Similarly, in patients with FAP, untreated CRC 
develops at an early age (mean 39 years), arising from autosomal dominant germline 
mutations in the APC gene, leading to constitutively activate Wnt signaling (31, 32). 
Consequentially, a characteristic feature of FAP includes the cellular over-growth and 
development of hundreds to thousands of colonic adenomas, beginning in early 
adolescence, and inevitable CRC progression in untreated individuals (32). Also 
presenting with autosomal dominant mutations in APC, attenuated FAP is a less-severe 
form of the disease, characterized on average of thirty colonic adenomatous polyps and a 
later age of polyp and CRC development (32). Lastly, MAP, an autosomal recessive form 
of FAP and mimics presence of adenomatous polyps increasing the risk of CRC at an 
early age, but is caused by bi-allelic mutations in MUTYH (also referred to as MYH). 
Characterized as part of the base-excision repair pathway, a mechanism for DNA 
corrections from spontaneous and environmentally induced genotoxic or miscoding base 
lesions, the MUTYH product, a DNA glycosylase, is specifically involved in defending 
against oxidative DNA damage (32, 33).  
1.2.2 Standard treatments for CRC 
Current treatment strategies for CRC include surgical intervention when possible (34-36), 
chemotherapy (37-39), anti-angiogenic therapies (40-43), and epidermal growth factor 
receptor (EGFR) inhibitors (44, 45). To date, surgical procedures remain the basis of 
curative treatment for CRC, however, disease management is typically a multimodal 
approach of conventional chemotherapy and local radiation therapies; the combination of 
surgery followed with chemotherapy being most widely accepted (46). Some patients 
with metastases confined to liver and/or lung can be cured of initially unresectable 
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disease using such approaches with intensive chemotherapy and secondary resection (15), 
however targeted therapies have largely impacted the treatment of metastatic disease 
(mCRC). In particular, anti-angiogenic drugs have had an advantageous role in treatment 
of mCRC where they are becoming components of standard-of-care therapy, as with their 
incorporation into combination chemotherapy regimens, there is improvement in patient 
survival outcomes (41, 47-50). mCRCs unfortunately have a tendency to develop 
resistance to the currently available anti-angiogenic therapies, and further, conventional 
approaches are highly limited due to toxicity and lack of tumour specificity, ultimately 
maintaining a poor prognosis of metastatic disease (51) and CRC in general. The 
predictive and prognostic biomarkers for biological therapies of mCRC are summarized 
in Table 3. 
Specifically, the standard first-line drug treatments are fluoropyrimidine-based regimes 
classically comprised of 5-fluorouracil (5-FU) plus folinic acid (FA, also known as 
leucovorin, LV) in combination with irinotecan (FOLRIRI) or oxaliplatin (FOLFOX) (46, 
52). Regimes may also include cytotoxic drugs capecitabine or raltitrexed, (37, 53), with 
the combination of capecitabine and oxaliplatin (XELOX) as a common adjuvant 
chemotherapy (15). As described above, patients with advanced CRC may also have 
treatments including monoclonal antibody (mAb) targeted anti-angiogenic agents [(anti- 
vascular endothelial growth factor (VEGF)], such as bevacizumab (Avastin) (41, 54, 55) 
or anti-EGFR antagonists cetuximab (Erbitux) or panitumumab (Vectibix) for indicated 
KRAS wild-type mCRCs (44, 45, 52, 56, 57). Unfortunately, a predictive marker of 
EGFR-inhibitor therapy is the presence of active mutations in KRAS or BRAF (V600E), 
in that those CRC sufferers do not respond to their therapeutic effect (58, 59). Novel 
antiangiogenic drugs, such as regorafenib (a novel multikinase inhibitor) and aflibercept 
(Zaltrap; a recombinant protein inhibitor of VEGF), have also been recently licensed by 
Health Canada in 2013 and 2014, respectively. Approved for the treatment of patients 
with mCRC, regorafenib is reserved for those who have been previously treated with 
fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and 
anti-EGFR therapy (60). The use of aflibercept is approved for use in combination with 
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Table 3. Predictive and prognostic biomarkers for biological therapy in mCRC 
Biomarker Prevalence Available evidence Predictive and prognostic value 
KRAS mutations 40% Conclusive 
 
Insufficient 
Negative predictive biomarker for anti-
EGFR mAbs 
Predicts poor prognosis, but not an 
independent prognostic factor 
BRAF mutations 10% Substantial 
 
Insufficient 
Prognostic marker for poor outcome 
 
Potential predictive marker for resistance 
to anti-EGFR mAbs 
NRAS mutations 3%-5% Insufficienta Potential predictive marker for resistance 
to anti-EGFR mAbs 
PIK3CA mutations 15%-20% Insufficienta Potential predictive marker for resistance 
to cetuximab (exon 20 mutations) 
Potential prognostic marker for poor 
outcome 
PTEN (loss of 
expression) 
20%-40% Insufficienta Potential predictive marker for resistance 
to cetuximab 
Associated with activation of the 
PIK3CA pathway and adverse disease 
outcome 
P53 mutations 1%-5% Insufficienta An independent predictive factor for 
cetuximab benefit 
Not prognostic 
Epiregulin, 
amphiregulin (high 
expression) 
50%-60% Insufficienta Associated with resistance to anti-EGFR 
antibody therapy and adverse clinical 
outcome 
VEGF-D 40%-75% Insufficienta Potential predictive marker for response 
to bevacizumab 
VEGF-A nd Insufficienta Not predictive of response to 
bevacizumab 
Modified from Luo and Xu, 2014 (61) 
a Insufficient: The current clinical evidence cannot definitively demonstrate that the biomarker has predictive or 
prognostic value in mCRC. nd, not determined. 
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FOLFIRI, for patients with mCRC that are resistant to or progressed following an 
oxaliplatin-containing regimen (42, 60). The potential treatment combinations have been 
recently compiled in an extensive review by Schmoll et al., highlighting the benefits of 
an overall personalized patient approach when defining treatment regimens (15). 
Due to its prevalence and preventative nature, CRC has been a focus in the field of 
oncology; though much progression hindered by the broad range of its stages at diagnosis, 
complexity of progression, heterogeneity, and diversity among patients. Optimal 
treatment choice for an individual highly depends on the disease extent and localization, 
overall tumour biology, and ultimately, considerations for sustaining quality of life while 
enabling long-term survival (15). Toxicity and lack of tumour specificity are the most 
important limits of conventional approaches. Evidence from the widening range of 
available tailored regimens, or those in development, advocates that the use of 
personalized medicine techniques will remain fundamental in how CRC, and cancer in 
general, will be treated in the future (15).  
1.3 Cancer immunology: immunosurveillance and immunoediting 
The concept that arising nascent malignant cells are recognized and eliminated as a 
function of the immune system has been a dynamic debate in tumour immunology since 
its original proposal in 1909 by Ehrlich (62), later formally designated as the theory of 
cancer immunosurveillance by Burnet and Thomas (63, 64). However, in the mid-20th 
century, this concept remained controversial with lack of sufficient evidence in some 
tumour-bearing models (65). Over the past two decades, this concept has seen a 
resurgence of interest and with extensive work and advancements in the experimental 
field of tumour immunology, there is now a much broader understanding of the 
interactions between the immune system and tumour cells. As such during this integral 
time, according to a recent review by Mittal et al. (2014) (66), the long-lasting dispute of 
the immune system effects on tumour development has diminished with clear evidence 
that intact immunity can, in fact, have three contradictory complex functions: facilitating 
cellular transformation, prevention or control of tumour development, and influence on 
the immunogenicity of tumours (66). With recognition that immunosurveillance 
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represents only one part of a broader process, this concept was refined to accurately 
capture the dynamic process, termed ‘cancer immunoediting’ (67, 68). This theory 
includes the dual role of the immune system in the active elimination of tumour cells but 
also highlights its importance in tumour-shaping and promoting tumour outgrowth. 
Overall, the immunogenicity of developing tumour cells can be shaped by the immune 
system. This occurs most notably by adaptive immunity (particularly T cells), but recent 
evidence suggests that innate immunity, such as natural killer (NK) cells and M1 
macrophages, to some degree, also contribute to this editing process (69). A fundamental 
principle in this process of immunological destruction or sculpting of a developing cancer 
is the T-cell recognition of tumour antigens (70). Indeed, T cell-dependent 
immunoselection has been demonstrated as one crucial mechanism of cancer 
immunoediting, allowing the outgrowth of less immunogenic tumour cells that lack 
strong antigens, as a result of either reduced expression or presentation on major 
histocompatibility complex (MHC) class I (MHC I) (70-72). Additionally, the evidence 
for immunoediting is not only restricted to tumour-bearing animals, but has also been 
clinically observed in human patients receiving targeted vaccine immunotherapy (73, 74). 
With the complex progression from immune surveillance to immune escape, cancer 
immunoediting comprises of three proposed sequential phases: elimination, equilibrium, 
and escape (67, 68, 75, 76). As a hallmark of the original immunesurveillance concept, 
the elimination phase is a process in which innate and adaptive immunity cohesively 
detect and destroy developing tumour cells, prior to clinical appearance. In the 
equilibrium phase, some tumour cell variants may not be entirely eliminated and the 
immune system maintains the tumour in a state of ‘functional dormancy’ in which the 
balance between anti-tumour (e.g. interferon [IFN]-γ, interleukin [IL]-12) and tumour 
promoting cytokines (e.g. IL-10, IL-23) in the tumour microenvironment and the adaptive 
immunity controls the growth of clinically undetectable, occult tumour cells. Due to 
constant immune pressure however, some tumour cells may undergo genetic and 
epigenetic changes (immunoselection), and begin evolving mechanisms that resist 
immune recognition such as antigen loss or expression deficiency, or induce 
immunosuppression, such as upregulation of programmed death-ligand 1 (PD-L1). 
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During the final step, the escape phase, progressive growth of edited tumour cells 
presents as clinical disease after the immune system fails to restrict the tumour cell 
population. Tumours may escape by a variety of complementary mechanisms of 
immunosuppression and tolerance, often exhibited simultaneously. This can include 
reduced immune recognition (e.g. loss of MHC I or tumour antigen expression), 
increased resistance or survival (e.g. upregulation of anti-apoptotic molecules), or 
establishment of a complex immunosuppressive microenvironment (e.g. VEGF, 
transforming growth factor [TGF]-β expression, induction of immunomodulatory 
molecules indoleamine-2,3-dioxygenase [IDO], PD-L1, T cell immunoglobulin mucin-3 
[TIM-3]). Importantly, escape from immune control is now recognized to be one of the 
‘hallmarks of cancer’ (77). Extensive work has been undertaken to elucidate the 
mechanisms involved in cancer immunoediting and reviewed in great detail (66, 71, 76, 
78).  
CRCs are collectively known to be able to manipulate and evade the immune system with 
increasing evidence that immune cells have an important role in tumour development and 
metastasis. Efforts to evaluate these mechanisms are continually ongoing [reviewed in 
(79-82)], some of which will be highlighted. CRC, among other solid tumours, contain a 
diverse subset of leukocytes, including both myeloid- and lymphoid lineages. Notably, 
immunogenicity of CRC tissues was demonstrated with increased activation, cytotoxic 
activity, and functional reactivity of tumour-infiltrating T lymphocytes (TILs) correlated 
with the presence of systemic functional tumour antigen-reactive T cells (83). However, 
the proportion of the activated tumour-associated T lymphocytes decreased significantly 
with higher tumour stage and was inversely correlated with the overall stage of the 
tumour (83). In another study, while adjacent normal mucosa contained normal levels of 
NK cells, impaired migration of these cells was apparent during tumour development. 
These cells were largely scarce within CRC tumours, despite high local tumour 
chemokine levels that was also independent of human leukocyte antigen (HLA) class I 
expression (84). While the role in CRC remains controversial, tumour-associated 
macrophages (TAMs) play an overall role in CRC progression. TAMs can both promote 
immunoselection by further inducing an inflammatory response (M1) or in response to 
immunosuppressive cytokines, generate a tumour-promoting TAM (M2). These TAMs 
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can secrete a variety of growth factors including epidermal growth factors (EGF), TGF-β, 
VEGF, and proteolytic enzymes such as matrix metalloproteinases that can degrade 
collagen of basement membranes, supporting the movement and metastasis of tumour 
cells (79). 
Immune escape of CRC has also been closely associated with the establishment of a 
microenvironment that actively suppresses anti-tumour immunity.  A prominent increase 
of myeloid-derived suppressor cells (MDSC) (characterized as Lin−/lowHLA-
DR−CD11b+CD33+) was identified both in tumour tissue and systemically when 
compared to a healthy population and correlated with tumour stage and metastasis. With 
further analysis ex vivo, these cells were able to inhibit the proliferative function of 
autologous T cells (85). Regulatory T cells (Tregs) have a complex role in CRC that may 
be dependent on the tumour type and stage; however, Tregs are in general associated with 
interference of anti-tumour immune responses, but their presence seem to correlate with a 
favourable prognosis (80, 81, 86). Although it is clear that an enhanced number of the 
tumour infiltrating T cells, among the other T cell subsets, express FoxP3+ (87), a 
hallmark marker of Tregs, the contributory role remains unsettled and paradoxical within 
CRCs (86, 88). In addition to immune cell suppression within the microenvironment, 
CRC evasion has also been associated with the pro-tumour inflammatory responses, in 
particular IL-17, shown to increase inflammation and promote carcinogenesis in some 
tumours (89), as well as increased IL-6 expression has correlated with advanced stages of 
CRC and decreased survival (90). Observed within the tumour microenvironment of 
tumour-bearing mouse models of liver metastasis, high expression of IL-10, TGF-β, and 
TGF-α were associated with enhanced tumour growth (79, 82). Lastly, CRC tumour cells 
can actively suppress the immune response by downregulation or reduced expression of 
MHC I (91), and upregulation of PD-L1 (92). 
Overall, based on the current knowledge and ever widening field of cancer immunology, 
in consensus, an important obstacle to overcome when treating cancers is tumour 
immunosuppression and tolerance (93). 
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1.4 Immunotherapy for the treatment of cancer 
Cancer immunotherapy collectively refers to a number of intended strategies to harness 
and manipulate immune-mediated mechanisms to specifically target cancer for 
stabilization or eradication (94). The concept of immunotherapy, although increasingly 
prominent over the past two decades, has been well documented for over a century. In 
1881, a young surgeon in New York, Dr. William Coley, initiated efforts to reproduce the 
observed spontaneous remissions of sarcomas in patients whom had developed erysipelas, 
an acute bacterial infection commonly associated with group A Streptococcus, by 
administering intratumoural injections of live or heat-inactivated Streptococcus pyogenes 
and subsequently, mixed with Serratia marcescens, later known as ‘Coley’s Toxin’ (95). 
Coley speculated that the infection localized around the tumour site would induce a direct 
cytotoxic reaction and as a secondary event, lead to regression, and even cure, of a 
malignant disease (95). The first streptococcal culture injection treatment encouragingly 
resulted in the extensive necrosis of an inoperable tumour and a disease-free outcome for 
eight years (96, 97). However, subsequent clinical responses remained variable from 
patient to patient, attributed primarily to disease heterogeneity and infection severity 
among patients, Coley also importantly noted that injections in a remote anatomic site 
could result in impressive tumour responses. From this, he concluded that even a 
systemic response to an infection, though mechanistically unclear, resulted in tumour 
destruction (95).  
Following forty-years of treating a variety of malignant diseases, successes were sporadic, 
difficult to reproduce (98), and were controversial among clinicians. One notable 
exception however is the further application of this theory in intravesical injection of 
Bacillus Calmette-Guérin (BCG), prepared from Mycobacterium bovis, for treatment of 
superficial bladder cancer after surgical resection, which has shown to prolong patient 
survival and remains an acceptable treatment today (94, 99). During this period of time 
however, oncologists, excluding the BGC application, continued to rely heavily on 
surgery, and increasingly, on effective new emerging methods, such as radiation therapy 
and eventually chemotherapy. Due to the risks associated with administering infectious 
agents to already weakened cancer patients, Coley’s strategy was never fully embraced 
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and became generally disregarded until the middle of 20th century; a present irony given 
the trauma associated with the treatments that were becoming common practice (94). 
Cancer immunotherapy applications began to re-emerge as in vivo chemical inducible 
tumour models were developed, allowing for readily accessible testing of various cancer 
treatments (99). 
Today, dramatic advances in the field of cancer immunotherapy have been made, with 
several broad therapeutic strategies now recognized. These approaches comprise of 
cancer vaccines, adoptive T lymphocyte transfer, immunomodulatory/immune check 
point blockade, and antibody-based therapies. In the subsequent sections, each treatment 
avenue will be introduced, with emphasis on antibody-based therapies, in addition to 
summaries of potential avenues directed specifically for CRC. It is recognized that the 
great breadth of knowledge that has developed within this field to date is beyond the 
scope of the purposes for this discussion, but have been comprehensively reviewed 
elsewhere (94, 99-102).  
To broaden the response of cancer and to treat resistance, the combinational use of 
chemotherapeutic drugs has traditionally been the foundation for treatment. A significant 
advantage of immune-based therapies is that they can be combined rationally with these 
conventional treatments for optimal therapeutic effect, as well as with other emerging 
immunotherapies (94). For reference throughout subsequent sections, the standard 
clinical trial outcome and phase definitions have been included with Appendix 3 and 
Appendix 4.  
1.4.1 Vaccine therapy 
Cancer vaccines aim to actively prime and stimulate the immune system against tumour 
cells for a specific and directed anti-tumour response. The vaccines can be designed for 
the prevention of tumour formation (prophylactic) or, as in the majority of those in study, 
the therapeutic format, for the inhibition of growing tumours and directed immune 
responses; both forms having the intent to generate prolonged protection (94). Antigen-
based vaccines are generated through short peptides (~20-mer), with a suitable dendritic 
cell (DC) activating adjuvant, full length proteins with a broader epitope range, or 
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through viral vectors encoding tumour antigens (94). Cellular-based vaccines use either 
whole tumour cells or lysates (autologous or allogeneic), which contain a wide range of 
antigens for targeting including mutated proteins. Lastly, DC-based vaccines, where DCs 
are isolated from the patient, loaded with antigens ex vivo, activated, and then re-infused 
into the patient are also being explored as potential approaches, though remain in early 
development (94).  
Despite the promising success of prophylactic vaccines used for cancers of viral origin 
(e.g. human papillomavirus [HPV]), to date, therapeutic vaccines have been less 
successful (94, 103). One limitation is that vaccine effectiveness relies largely on the 
induction and regulation of T cells, DCs, and other cell-mediated immune responses such 
as Treg suppression (104). Indeed, although a large number of T cells are present that are 
capable of recognizing tumour antigens (in preclinical models), this has been insufficient 
to mediate tumour regression (105-107) suggesting that T cells, in order to mediate anti-
tumour effects, must be in the correct state of activation and differentiation (105). Cancer 
vaccines are usually administered with adjuvants, such as BCG, to enhance the immune 
response, and are often combined with cytokines such as granulocyte macrophage 
colony-stimulating factor (GM-CSF) (108, 109). Recently, co-administration of IL-2 with 
a short peptide derived from glycoprotein 100 (gp100), a melanocyte antigen, augmented 
tumour responses and progression-free survival (PFS) was prolonged (110). Ongoing 
advancements to understand the basic immune responses of therapeutic cancer vaccines 
have suggested that effective strategies may require the integration of immunomodulators 
through checkpoint blockade (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-
4], programmed cell death protein 1 [PD-1]) to interfere with immune regulatory control 
to maximize the vaccine effectiveness (94, 111). 
Vaccination trials for CRC have largely been tumour cell–based vaccines, consisting of 
irradiated autologous tumour cells (112). From meta-analyses, there was evidence of 
significant improvement in disease-free survival (DFS), however none in overall survival 
(OS). Encouragingly, in subsets of patients with resected liver metastases, there has been 
a significant advantage in OS and metastases-free survival (113). To date, 
carcinoembryonic antigen (CEA) has been the most common peptide-based vaccine in 
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CRC trials, however, despite supporting preclinical evidence, the results and tumour 
response of the studies have not remained consistent (112, 114). Alternative targeted 
antigens remain ongoing in clinical trials however, for further evaluation of cancer 
vaccines in the treatment of CRC (Table 4). 
1.4.2 Adoptive cell therapy 
In the treatment of cancer, adoptive cell therapy (ACT) is the transfer of lymphocytes 
bearing tumouricidal properties to the patient for directed anti-cancer effects (115, 116). 
A variety of cellular therapies have been incorporated into cancer treatment, including the 
infusion of polyclonal or antigen-specific T cells, NK cells, DC, and macrophages (Mϕ). 
Most recognized for transfer are the naturally occurring TILs, isolated from resected 
tumours of the patient, expanded in culture (with exogenous IL-2) and subsequently re-
infused into the patient for therapeutic effect (115). Contradictory to other forms of 
immunotherapy, ACT does not rely on the in vivo mediation of T cell activation for 
tumour regression but allows for the ex vivo selection and expansion of high-avidity, 
autologous effector T cells. Importantly, developing the T cells as such also breaks 
tolerance to the tumour antigen, removes in vivo inhibitory or suppressive signals, and 
enables the manipulation of the recipient host (e.g. lymphodepletion), generating a 
favorable environment for effective cell transfer and engraftment (94, 115). Although 
limited to the identification of T cells that target tumour antigens exclusively, with this 
treatment approach, patients with melanoma have had marked clinical responses, 
experiencing tumour regressions that were durable and complete (115, 117).  
Initially beneficial to patients with reactive T cells from resectable tumours, advances in 
genetic engineering technology of T cells has expanded ACT opportunities to patients 
with unresectable, solid tumours (116). Expression of specific conventional TCRs or 
recombinant chimeric antigen receptors (CARs) (118) in ‘normal’ T cells isolated from 
peripheral blood enable directed T cell effects to cognate targets. As recombinant 
receptors that provide both antigen-binding and T-cell-activating functions, CARs allow 
the immediate activation of the T cell upon recognition of the intact surface protein (118). 
With the use of these approaches, ACT has demonstrated discernible regressions in a 
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Table 4. Select representation of immunotherapy trials for the treatment of CRC 
currently under investigation 
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variety of cancer indications, including melanoma, leukemia, lymphoma, and cervical 
cancer (115, 119-123). To date, issues remain surrounding the selection of safe targets 
and the scarcity of such targets, toxicity, and manufacturing complexity. Additionally, in 
clinical assessment, the lack of durable responses in some patients indicates that to 
properly direct and activate T cells within the tumour microenvironment, further 
interventions may be required to have lasting treatment effects (94). 
While ACT has predominantly been applied to the treatment of haematological 
malignancies to date (124), this therapy may be beneficial for epithelial solid cancers 
with advancements in identification of suitable targets. Indeed, ACT clinical trials for the 
treatment of CRC are currently ongoing, with focus on metastatic disease (Table 4). 
1.4.3 Immunomodulatory molecule and immune checkpoint therapy 
Within anti-cancer therapies, immunomodulatory molecules can function to indirectly 
increase the activity of effector lymphocytes, or directly by reducing tumour growth 
(109). Clinical evaluations have foremost focused on systemic administration or direct 
tumour injection of immunostimulatory cytokines IFN-α and IL-2 (109). Independent 
administration of IFN-α and IL-2 has demonstrated increased survival responses in a 
subset of advanced melanoma and renal cell cancers (109, 125-127). Associated with low 
response rates in general, these treatments can also have a considerable risk of high-dose 
toxicity and systemic inflammation due to lack of specificity (94, 125). To date, even 
though IFN-α and IL-2 have been supportive therapies in particular for these cancers, as 
well as haematological malignancies, the mechanism and why the therapeutic effect is 
limited to select patients is not fully understood. With focus on T cell activation, the use 
of antibodies targeting known receptors (e.g. 4-1BB, CD27, OX40, GITR) has progressed 
as the next generation of immunomodulators undergoing clinical evaluations (Table 4) 
(94).	  
In advanced CRC patients, modest immune responses have been demonstrated with the 
combination of IL-2 and GM-CSF (128). Recent evaluations in mCRC patients has 
further indicated that chemotherapy (FOLFOX) in combination with IL-2 and GM-CSF, 
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has a marked improvement in overall response rate and progression free survival 
compared to chemotherapy alone, with a trend towards improved overall survival (129). 
Cancer immunotherapy has significantly progressed over the last decade with the 
development of immune checkpoint antagonists. Inherently, the immune system regulates 
induced responses by feedback inhibitory loops to minimize tissue damage, suppress 
autoimmunity, and maintain proper immune homeostatsis. Importantly, these 
mechanisms control T cell responses influencing communication between T cells and 
antigen presenting cells (APCs) through inhibitory receptors on the lymphocytes and 
respective ligands, two of which are currently clinically active for blockade, CTLA-4 and 
PD-1 (101). Though these checkpoint receptors act through different mechanisms (130), 
both are expressed on activated effector T cells, and upon cognate ligand binding, reduce 
effector functions. In addition, CTLA-4 and PD-1 (among other checkpoint receptors, 
such as lymphocyte-activation gene [LAG-3] and TIM-3) are highly expressed on Tregs 
but contrary to effector cells, ligand binding enhances Treg proliferation and function, 
promoting the suppression and attenuation of effector cells (101, 131). Predominately, 
antibody-based therapies have been used for directed blockade at these immune 
checkpoints.  
Extensively studied for the role in T cell responses, CTLA-4, as a key negative regulator 
of CD28-dependent responses, functions by binding members of the co-stimulatory B7 
family of accessory molecules on APCs required for T cell activation, and thereby 
inhibits further activation and expansion (132). Ipilimumab, a mAb to CTLA-4, as well 
as effectively blocking the negative regulation of this receptor, also down-regulates the 
immune suppressive function of Tregs, facilitating anti-tumour effects of T cells and 
limiting Treg activity in tumours (131, 133-135). In a pivotal phase III trial, 
administration of ipilumumab provided a significant improvement in overall survival 
(136) for advanced metastatic melanoma, granting its clinical approval by the Food and 
Drug Administration (FDA) in 2011  and by Health Canada in 2012, and is arguably one 
of the most important developments for cancer immunotherapy to date. In a long-term 
follow-up, ipilimumab has shown a durable complete response, and potentially curative 
tumour regression in a subset of treated melanoma patients (133, 137). Blockade of 
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CTLA-4 has since been undergoing further evaluation in numerous clinical settings, 
including mCRC (NCT02060188) (138). 
Another approach receiving some clinical validation is targeting immunosuppression at 
the tumour site in addition to immune cells (94). PD-1 is expressed predominantly on T 
cells (including Tregs) after induction, but can also be expressed on B cells, monocytes, 
natural killer T (NKT) cells, and some DCs (139, 140). Upon binding with its ligands 
PD-L1 or PD-L2, which are expressed by potential target cells and can also be 
upregulated in a variety of cancers (141, 142), the T cells are rendered unresponsive 
(140). Duly summarized in Ohaegbulam et al. (143), several mAbs to PD-1 or PD-L1 
have been clinically studied in Phase I trials and continue to be evaluated further either as 
a monotherapy or in combination. Of these trials, this strategy for immunomodulatory 
therapy has been well tolerated with impressive response rates and durability in 
melanoma, non-small-cell lung carcinoma (NSCLC), and renal cell carcinoma (RCC) 
(143). Currently, a PD-1 blocker (Nivolumab) is in clinical trials involving mCRC 
(NCT02060188) and similarly, studies are also proceeding using an anti-PD-L1 blocker 
in refractory mCRC as a single agent (NCT01375842; NCT01876511) with early 
responsive results (144) or in a multimodal approach with chemotherapy and 
bevacizumab (NCT01633970) or tremelimumab (anti-CTLA-4; NCT01975831) (Table 
4). 
1.4.4 Antibody-based therapy 
Over the past two decades, antibody-based therapy for cancer has become well 
recognized and for patients with haematological malignancies and solid tumours, one of 
the most successful treatment strategies (145).  Soon after the discovery of antibodies in 
the late nineteenth century, Paul Ehrlich described a ‘magic bullet concept,’ where drugs 
directly proceed to their intended structural targets (146). Targeted medicine, in his 
proposed theory, should efficaciously defend against invading pathogens (including 
cancerous cells) but remain harmless to healthy tissues (146). With clinical controversy 
however, this approach received little value until the ability to generate mAbs with 
advancements in hybridoma technology was described in 1975 by César Milstein and 
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Georges Köhler (147). In light of these developments, the search for cancer-specific 
antigens was initiated with efforts focused on identifying suitable surface structures, a 
challenge that still persists today (145). This family of molecules, termed tumour-
associated antigens, will be described further in Section 1.5. 
In this form of immunotherapy, antibodies can function through respective responses 
such as mediating alterations in antigen or receptor function (agonist or antagonist 
functions; e.g. anti-angiogenic effect), modulating the immune response or environment, 
or directing conjugated drugs or radiolabelled compounds that specifically target TAAs 
(148, 149). In addition, unconjugated mAb therapies may have immunological cytotoxic 
effects through opsonizing tumour cells and complement-dependent cytotoxicity (CDC), 
triggering apoptosis, or by removal through antibody-dependent cell-mediated 
cytotoxicity (ADCC) (150). All of these approaches have been successfully applied 
within the clinic, a proportion of those for the treatment of haematological malignancies 
(e.g. targeting CD20, CD30) including both as unconjugated mAbs and for the delivery 
of cytotoxic drugs or radioisotopes (145). For patients with solid tumours, the most 
successful mAb therapies to date have been targeting the ErbB family of receptors 
(including EGFR, human epidermal growth factor receptor [HER]2/neu) and VEGF, 
demonstrating improved tumour responses and survival (145). Immune regulation by 
antibodies has also has remarkable success within the clinic as described in Section 1.4.3. 
As of early 2015 there were 31 antibody treatments (or derivatives) that were approved 
by Health Canada for clinical use as monotherapy or in combination, 12 of which are 
designated for the treatment of various specified cancers (Table 5). 
In the development of antibody-based therapies, preclinical and clinical evaluations have 
revealed the importance of target antigen selection but have also highlighted the major 
considerations related to therapeutic mAbs, including 1) affinity and avidity, 2) the 
choice of antibody construct, and 3) the desired therapeutic approach (e.g. signaling 
abrogation, immune effector function). As such, antibodies have interdependent 
properties that can be used for molecular alteration to improve the clinical potential. Key 
elements may include antibody immunogenicity, size, effector function, and overall 
pharmacokinetics (145, 151).  
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Table 5. Antibody therapies approved by Health Canada for medical use in the 
treatment of cancer 
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Traditionally, murine mAbs were developed for therapeutic use and were first to be tested 
clinically; however, these mAbs are restricted by several factors (152-154). These mAbs 
are highly immunogenic, have a short-half life in humans, and as a result, are also 
inefficient at eliciting human effector functions (153). In particular, a major limiting 
factor due to the murine structure of the mAb, is the induction of human anti-mouse 
antibody (HAMA) response. After a first dose, administration can generate a strong 
response in up to 50% of patients, and >80% with repeated doses (153, 155, 156). Such 
responses can cause rapid clearance or direct neutralization of the administered mAb, 
compromise therapeutic efficacy and prevent further dosing or induction of systemic 
toxicity stemming from a requirement of high doses for effective treatment. In severe 
cases, typically associated with repeated intravenous administration, ‘serum sickness’ 
from immune complex formation can led to an anaphylactic response (155). The current 
success of therapeutic mAbs can be attributed to the development of chimeric and 
humanized mAbs by recombinant technology, and later fully human mAbs (Figure 1). 
Using these mAb strategies demonstrates reduced immunogenicity, a longer half-life, and 
can promote human effector functions (157-160) and are now the preferred technologies 
for developing antibodies as therapeutics. Chimeric antibodies are engineered by joining 
the antigen-binding variable domain (Fv) of a murine mAb to the constant domains of a 
human antibody (161, 162). Humanized antibodies are generated by grafting the antigen-
binding complementarity determining region (CDRs) from a mouse mAb within a human 
mAb (163, 164). To create a high-affinity humanized mAb however, the transfer of one 
or more additional residues from the framework regions (FRs) of the parental mouse 
mAb is generally required (165). High-affinity fully human antibodies are customarily 
derived from phage display libraries (166-168) or by hybridoma technology using 
transgenic mice that express human immunuoglobulin (Ig) genes (169-172). 
In addition to overcoming immunogeneticity and systemic clearance, to gain exposure to 
the intended target antigen, the mAb must also overcome capillary extravasation, 
movement from the capillaries into the tumour tissue (173) and high interstitial pressure 
gradients, in particular for solid tumours (174, 175). As such, distribution of mAbs within 
the tumour is commonly heterogenous, even perivascular, after intravenous
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Figure 1. Humanization of therapeutic antibodies for reduced immunogenicity  
Schematic illustration of antibodies developed from murine origin to human to reduce 
immunogenicity that is applied for use in therapies. Antibodies used include fully murine 
mAb, chimeric mAb, where the only the variable region is murine (65% human), 
humanized mAb, where only the CDR loops are murine (>90% human), and fully human 
mAb. A generic suffix designates the form of antibody as listed. Fc indicates fragment 
crystallizable region (constant domain); Fab, antigen-binding fragment; ABS, antigen 
binding site; CH, heavy chain, constant domain; CL, light chain, constant domain; VH, 
heavy chain, variable domain; VL, light chain, variable domain. Figure modified from 
Foltz et al. (176). 
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administration (177). While this distribution can arise from heterogeneous antigen 
expression and vasculature, as well as tumour necrosis, it is also in part due to mAb size 
and antigen-binding affinity, proposed in the ‘binding-site barrier’ model where there is 
an inverse relationship between affinity and penetration (177, 178). This poor penetration 
can decrease overall efficacy and partial exposure to the intended therapeutic, increasing 
the risk of acquiring resistance (177). The molecular architecture of antibodies can be 
modified however to generate formats that varies in both size and valency (the number of 
antigen binding sites) (151). The growing range of alternative antibody formats can span 
a range of molecular weight, valency, and include multiple distinct antigen-binding 
specificities (Figure 2). The antibody building block that is most frequently used as a 
base in the design of non-natural formats is the single-chain variable fragment (scFv). 
The scFv comprises of the variable domains from the heavy and light chain (VH and VL) 
joined by a peptide linker of ~15 amino acid residues (151). Although eliminated more 
rapidly through renal clearance, smaller antibody fragments, like scFv, extravasate more 
efficiently than IgG, and diffuse more readily within tumours (151), characteristics that 
may be suited in particular for clinical imaging. Antibody fragments also offer the 
potential to avoid fragment crystallizable region (Fc)-dependent effector functions, 
reducing the severity of a HAMA response and can show a range of pharmacokinetic 
properties (151). While a reduction in distribution is characteristic of a full mAb, this 
form is commonly favoured for its long half-life, clearly demonstrating that each format 
can have opposing factors limiting success and that the design consideration can be 
dependent on a number of factors, including desired biological potency, the targeted 
tumour, and overall clinical application (179).  
Similar to the choice of antibody fragment size, the effector function of the antibody can 
also be considered for alternation based on the target antigen, therapeutic strategy, and 
clinical setting (179). While increasing effector functions such as ADCC and CDC may 
increase therapeutic efficacy for some interventions, in others, prevention may be desired 
to reduce unnecessary side effects or toxicity. By mutational analysis and computational 
design methods, the interactions between IgG molecules and various Fc-gamma receptors 
(FcγR) for activation (e.g. FcγRI, FcγRIIa, FcγRIIIa and FcγRIIIb) and inhibition 
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Figure 2. Recombinant antibody formats for targeted therapy 
A selection of possible recombinant antibody formats represented as a schematic 
illustration and relative approximate size (kDa). Depicted are A) full mAb (IgG), B) 
building blocks for antigen-binding reformatting, C) possible reformatted antibodies to 
alter size and include multivalent platforms, and D) multi-specific antibody options for 
targeting multiple antigens. Fc indicates fragment crystallizable region (constant 
domain); Fab, antigen-binding fragment; ABS, antigen binding site; CH, heavy chain, 
constant domain; CL, light chain, constant domain; VH, heavy chain, variable domain; VL, 
light chain, variable domain. 
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(FcγRIIb) has enabled the engineering of the Fc region to modulate effector functions 
(180). Relatedly, the regulation of serum IgG concentration has been investigated to 
increase (or decrease) the terminal half-life of IgG through tailoring of the interaction 
with FcRn, a receptor known to protect IgG from degradation (181). Lastly, the majority 
of currently developed unconjugated mAbs are based on human IgG, nearly all 
containing the IgG1 isotype. With the intent to increase mAb diversity and to develop 
mAbs that are often inefficient at supporting effector function, the use of classes IgG2 
and IgG4 have been of interest, based on the distinct structural and functional properties 
(151, 182). 
Stemmed from the wide range of antibody formats, the repertoire of antibody-based 
therapeutics is continually being expanded and presented with novel functions by 
conjugations and genetic fusions, including enzymes, toxins, drugs, and radioisotopes 
(183). A notable contribution has been bispecific antibodies, designed to bind two 
different epitopes, invariably on two different antigens. Most widely used for delivering 
immune effector cells to tumours, the single chain bispecific T cell engaging antibody 
(BiTE) concept allows for a convenient approach that engages both the activation of the 
effector cells, most commonly the T cell receptor (TCR) (anti-CD3) and an antigen on the 
tumour cell surface, redirecting and localizing cytotoxic lymphocytes at the tumour site 
(94, 184). 
Even with optimal development strategies, antibody-based therapies are still limited by 
irregular bidistribution of the targeted antigen or receptor, accompanied by target 
heterogeneity, presence or development of mutations, or downregulation of expression 
(145). The persisting major clinical challenge is to determine therapeutic efficacy of the 
antibody or conjugate as a safe agent while ultimately minimizing toxicity of normal 
cells. 
Clinically, the most successful biologic therapies, and the only approved for mCRC to 
date, have been with the use of mAbs (114). As mentioned in the standard treatments of 
CRC (Section 1.2.2), bevacizumab, alfilbercept, cetuximab, and panitumumab have all 
been approved for medical use in mCRC, and demonstrate overall clinical benefit. 
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Bevacizumab, a humanized antagonist mAb directed against VEGF, blocks angiogenesis 
and also plays a role in immune modulation through the Fc region. Similarly, aflibercept 
is a recombinant protein made of human VEGF receptors 1 and 2 fused to the human Fc 
portion, to sequester circulating VEGF and prevent activation of receptors. Cetuximab is 
a human/mouse chimeric antibody directed at extracellular EGFR, blocking activation of 
receptor-associated kinases that result in inhibition of cell growth, apoptosis, and has 
been shown to increase the effects of chemotherapy (185, 186). Lastly, as an additional 
mAb to EGFR, panitumumab is a recombinant human mAb and has similar anti-tumour 
effects compared to cetuximab. Of important note however, EGFR-specific Abs are 
restricted to only patients that have wild-type KRAS, as those with mutations do not 
exhibit improved responses, disease control, or survival (58, 187). Currently there are 
many investigational mAbs in clinical trials, those that are expected to generate an anti-
tumour response by ADCC, augment T cell responses or further inhibit angiogenesis 
(Table 4) 
1.5 Tumour-associated antigens 
Traditionally, the development of an immunotherapy begins with the identification of a 
suitable cancer target, collectively known as tumour-associated antigens (TAAs) (188). 
TAAs are molecules that are selectively expressed and/or accumulated by tumours as a 
result of genomic instability that can generate genetic mutations, translocations, or 
misregulation as the tumour develops. As targets, ideally the TAA is displayed 
homogeneously on the surface of the tumour cells, but minimally expressed in normal 
tissues and serum (189). Although TAAs are heterologous in nature, several non-viral 
families are now characterized by their expression pattern as unique, 
overexpressed/accumulated, cancer-testis (CT), and differentiation antigens (190, 191).  
Unique antigens, also referred to as neo-antigens, arise from chromosomal aberrations 
such as mutations, splicing and/or translocation in normal genes but are often 
characteristic for an individual tumour (e.g. mutated KRAS, BRAF) (190). Antigens that 
are overexpressed or accumulated by a tumour are often also widely expressed by normal 
tissues, but at a comparatively lower level (e.g. epithelial cell adhesion molecule 
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[EpCAM], Her2/neu). CT antigens are characterized by epigenetic alterations that induce 
expression of otherwise silenced genes, of which, only cancer cells and adult 
reproductive tissues primarily testis and occasionally placenta characteristically express 
(e.g. MAGE family, NY-ESO-1). Lastly, differentiation antigens are commonly shared 
between tumours and have restricted expression on normal tissues, typically of the same 
lineage. This family includes oncofetal antigens, where normal expression is generally 
limited during fetal development but is upregulated in adult tumour cells (e.g. alpha-
fetoprotein [AFP], 5T4) (190, 191). TAAs encoded by tumourigenic transforming viruses 
(e.g. HPV E6/E7) can also be characterized by abnormal protein expression, termed 
oncoviral antigens (190, 191). Although the families of TAAs are characterized, it should 
be noted that these categories are not mutually exclusive and tumour antigens may fall 
across categories (191). 
In general, methods for TAAs identification include detection by screening expression 
cDNA libraries from human solid tumours with sera of the autologous patients (e.g. 
SEREX) (192), screening of trophoblasts and cancer cells for shared antigenic 
characteristics, though not currently frequently used (193, 194), and most common, 
reverse immunology aiming to identify TAAs that are defined by T cell specific 
recognition (195). A selection of TAAs recognized by T cells derived from CRC patients 
is summarized in Table 6. This group of TAA molecules is ever expanding and is 
commonly evaluated for use in diagnosis, to follow treatment of tumours, or as a target 
for developing immunotherapeutics.  
1.5.1 5T4 oncofetal antigen  
The 5T4 oncofetal antigen, also designated as trophoblast glycoprotein (TPBG), is a cell 
surface glycoprotein normally found on trophoblasts, the outermost interfacing cell type 
within the placenta between the fetus and mother, but has restricted expression on normal 
adult tissues (196). The protein was originally identified by Hole and Stern when 
searching for shared surface molecules of human trophoblasts and cancer cells, that, 
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Table 6. TAAs recognized by T cells derived from CRC patients 
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would reflect functional similarities concerned with growth, invasion, and 
immunosurveillance that allow for fetal or tumour survival within its host (194). As such, 
human 5T4 was first defined by mouse mAbs, raised from purified glycoproteins from 
human syncytiotrophoblast microvillous plasma membranes (STBM), the outer epithelial 
layer covering the villi of the placenta. Comparative tissue screening established that the 
5T4-targeting mAb detected antigen expression by different tumour cells but only low 
levels in normal tissue epithelia (194, 196). Subsequently, 5T4 has been identified on an 
array of carcinomas including cervix (197), colorectal (198-200), gastric (201, 202), lung 
(203, 204), oral (205), ovarian (206), prostate (207), and renal carcinomas (208). Further, 
as this protein remains membrane-bound and is not cleaved, there is no evidence of 
circulating 5T4 antigen (209). 
Moreover, 5T4 has been specifically associated with metastasis in CRC (199), and there 
is evidence of poorer clinical outcome for CRC, gastric, and ovarian cancer with a direct 
relationship between the expression of 5T4 and the stage of carcinoma (198, 201, 206). 
Acquired from Eisen et al. (209), the reactivity for 5T4 antigen revealed from collected 
immunohistochemical studies of patient samples demonstrated the high prevalence and 
distribution of this TAA across multiple cancers and stages (Table 7). 
Despite the potential therapeutic value of 5T4, the function and molecular mechanisms of 
this protein remain poorly understood. However, over the past two decades, biochemical 
and genomic studies have provided insight that this 72 kDa (420 amino acid) single-pass 
transmembrane-bound protein is heavily N-glycosylated (7 putative sites) and is a 
member of the family of proteins containing leucine rich-repeats (LRR) (210-213). 
Recent structural analysis of the extracellular domain of 5T4 confirmed that this 
transmembrane protein is constructed of a multiple LRR motif and associated flanking 
regions, clustered in two domains separated by a short, rigid, hydrophilic core (211). The 
LRR motif is known to contribute directly to protein-protein interactions and is 
associated with a functionally diverse group of molecules (210, 214). The cytoplasmic 
region has been reported to interact through a PDZ-binding motif (Ser-Asp-Val), 
commonly involved in mediating protein-protein interactions, with the PDZ domain of 
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Table 7. 5T4 expression of various tumour types and stages 
Cancer Type/Stage Reactivitya  Summary 
Breast Mixed 56/63 85-95% of patients express 5T4 
Cervix Mixed 
I 
II 
III 
IV 
5/5 
22/25 
22/26 
9/10 
5/6 
85-90% of patients express 5T4 
CRCb Mixed 
A 
B 
C 
D 
11/22 
2/8 
7/34 
13/21 
7/9 
40-50% of patients express 5T4 with > 
70% in stage D.  
NSCLC Mixed 
 
259/261 99% of patients express 5T4 
Ovarian Mixed 
I 
II 
III 
IV 
4/7  
2/10 
4/57  
21/29  
24/26 
> 70% of patients express the 5T4 
antigen with 90–95% 5T4 positive for 
stage IV patients 
Pancreatic Mixed 23/23 100% of patients express 5T4 
Prostate Mixed 26/26 100% of patients express 5T4 
Renal Clear cell 
Papillary 
Mixed 
215/222 
18/18 
36/37 
> 95% of patients express 5T4 
aReactivity of patient cancer biopsies for 5T4 expression. Extrapolated from Eisen et al. 2014 (209) 
bCRC represented in Dukes’ classification system.
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TIP-2/GIPC, a cytoplasmic interacting protein associated with the cytoskeleton (215, 
216). To date, further mechanisms of downstream signal transduction for 5T4 remain 
unknown. From studies focused on elucidating its role, 5T4 expression was involved with 
early embryonic stem (ES) cell differentiation (mouse and human) and increased cellular 
motility (217, 218). It has also been associated with the process of epithelial-
mesenchymal transition (EMT) in ES cells (219, 220), an important process during 
development but also designated as a key process involved in the metastatic spread of 
epithelial tumours (221, 222). Overexpression of 5T4 glycoprotein showed influences on 
cellular morphological changes, including disruption of cell-cell contacts, reduction in 
adherence, and actin cytoskeletal organization (223-226).  
5T4 has further been shown to modulate CXCR4 function by regulation of surface 
expression in differentiating ES cells, mouse embryonic fibroblasts (MEFs) and cancer 
cells (204, 223, 227). This facilitates an increased biological response to CXCL12-
mediated chemotaxis, signaling important for cell mobilization (204, 223, 227). Both 
CXCR4 and CXCL12 chemokines have been associated with embryogenesis as well as 
with tumourigenesis in many cancers with upregulated CXCR4 expressing tumours 
preferentially spreading to tissues that highly express CXCL12, such as the lung, liver, 
lymph nodes and bone marrow (228-230). Lastly, 5T4 has been found to inhibit the 
Wnt/β-catenin signaling pathway (231), a key pathway involved in embryonic 
development and also a major target in anticancer therapeutics (232, 233). The Wnt 
family of proteins is known to regulate fundamental developmental mechanisms directing 
cellular proliferation, cell fate determination, and tissue homeostasis (234). By acting as a 
feedback inhibitor of canonical Wnt signaling, 5T4 activates non-canonical, misregulated 
signaling, often associated with disease progression prominently found in cancers (231, 
235) 
Comparable to ‘normal’ cancerous tissues, similar 5T4 expression and function has been 
found in tumour progenitor cells (TPCs; also known as tumour-initiating cells [TICs], or 
cancer stem cells) of NSCLC. Specifically, 5T4 was associated with the undifferentiated 
state and the EMT of the TPCs (203, 236). From this, the therapeutic value of 5T4 is 
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enhanced by the ability to target the aggressive and tumourigenic populations within the 
tumour (TPCs) (189). 
There have been extensive studies elucidating the role of 5T4 in development, and 
recently TPCs, and though taken together, the functional biology of 5T4 is consistent 
with a role in movement of cells, as summarized in a recent comprehensive review by 
Stern et al. (189), the specific function of 5T4 remains unknown. Nonetheless, 5T4 has 
been considered an ideal candidate for cancer diagnostics and/or as a target for cancer 
immunotherapy, with widespread tumour expression and a link to a tumour progenitor 
cell phenotype (237). These characteristics have driven the development of 5T4-based 
therapeutics and indeed, there are currently three 5T4-targeting agents evaluated with 
clinical development.  
Firstly, efforts to generate a vaccine using a modified vaccinia virus Ankara (MVA) 
encoding human 5T4 (designated TroVax) has induced an anti-tumour immune response 
with 5T4 epitopes recognized by T cells in preclinical cancer models (238, 239). A 
succession of Phase I or II clinical trials in CRC, prostate, and RCC (including in 
combination with chemotherapy or cytokine treatments) has established this vaccine in 
safety, tolerability and vaccine immunogenicity, as well as for optimal dose and route of 
vaccination [reviewed in (237)]. This vaccine is presently in on-going evaluations for 
ovarian carcinoma in Phase II clinical trials (NCT01556841). A number of targeted based 
therapies have also become active in development, some of which have compelling 
representatives to support clinical advancement. These include guiding chemotherapies as 
antibody-drug conjugates (ADC) (240, 241), and activation of immune effectors as 
tumour-targeted immunotoxins (209, 242). The 5T4-targeted ADC (A1-mcmMMAF; PF-
06263507) had potent targeted anti-tumour responses in preclinical models, including 
primates, with limited non-specific exposure and low toxicity that was well tolerated 
(241). Recently terminated from Phase I clinical trials (NCT01891669), an early report 
noted that trial completion was not due to any safety concerns, but as a result of the 
program sponsor’s prioritization. Secondly, a 5T4-targeted immunotoxin (ABR-21760; 
Naptumomab estafenatox) has demonstrated preclinical therapeutic efficacy, and has 
completed Phase II/III clinical trials (NCT00420888) with early reports suggesting an 
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overall good safety profile and a clinical benefit in a subset of patients (209, 242). Thirdly, 
and most recent, with the sequence resolution of the mAb defining 5T4 (243), a pre-
clinical research program has been initiated for evaluation of re-targeting effectors using 
engineered CAR T-cell therapy (244, 245) with promising in vitro cytotoxicity directed 
specifically at 5T4 expressing tumour cells (246).  
1.6 Bacterial superantigens  
Bacterial superantigens (SAgs) are a unique class of microbial toxin that are known to be 
potent activators of T lymphocytes (247-251). The term SAg was introduced to 
emphasize the novel immune stimulatory properties and remarkable T cell expansion of 
these toxins (247, 252). Since their designation, this ‘family’ of toxins has expanded 
extensively over the last decade, heavily revealed by bacterial genome sequencing efforts 
(253). These toxins are primarily produced by Staphylococcus aureus and Streptococcus 
pyogenes (group A Streptococcus), and with more than 30 distinct SAgs currently known, 
are also the best characterized. Although SAgs are similar in function, a general feature 
of these low-molecular weight proteins (ranging from 22-29 kDa) (248) is that those that 
are genetically distinct are also antigenically distinct (253). The biological activity of 
these proteins is unusually stable, being resistant to heat (despite boiling for one hour), 
desiccation, and in general, proteolysis and acids (such as stomach acids) (254). 
Clinically, SAgs from both S. aureus and S. pyogenes have been associated with toxic 
shock syndrome (TSS), a toxin-mediated acute life-threatening illness. Albeit in different 
forms, this syndrome is a result of an elicited ‘cytokine storm’ (248, 255, 256). As noted 
above, these toxins are not limited to S. aureus and S. pyogenes and in fact recently, as 
highlighted in Spaulding et al., an increasing number of reports describe staphylococci 
strains of animal origin as well as other beta-hemolytic streptococci, namely groups B, C, 
and G as producers of SAgs (254, 257). SAgs have also been reported to occur in some 
viruses and other microorganisms, including Mycoplasma arthritidis, Yersinia 
enterocolitica, Yersinia pseudotuberculosis, Plasmodium falciparum, Clostridium 
perfringens, Candida albicans, and Toxoplasma gondii (254).  
  
42 
1.6.1 Staphylococcal superantigens  
S. aureus are bacteria that can appear as part of the human normal microbiota, but has the 
ability to become a capable pathogen, causing a wide range of host infections including 
skin and soft tissue, as well as severe invasive infections (258). SAgs produced by S. 
aureus include the staphylococcal enterotoxin (SEs), toxic shock syndrome toxin-1 
(TSST-1), and related SE-like proteins (SEl) (259). Presently classified by their SAg 
function, SEs were formerly defined by their enterotoxin properties in the pathogenesis of 
staphylococcal food poisoning (249, 260). Although SAgs from S. aureus and S. 
pyogenes share similar structure and immune-stimulating properties, this activity is 
thought to be independent of the ability to activate T cells (261) and a property not 
associated with streptococcal SAgs (262). Currently this group of SAgs includes ten SE 
serotypes: A to E, G to I, R, and T (259). Although both homologous and structurally 
similar to SEs, SEl group of SAgs, of those evaluated, lack the emetic properties of the 
bona fide SEs (259). This group of SAgs presently includes serotypes J to Q, S, U, V, and 
X (259, 263). 
A subgroup of genetically linked SEs and SEls, most commonly including SEG, SEI, 
SEl-M, SEl-N, and SEl-O and two pseudotoxins compromise an operon designated as the 
staphylococcal 'enterotoxin gene cluster' (egc) (263). Compared to classic SEs, human 
serum levels of neutralizing antibodies against the egc SEs have been shown to be lower, 
despite their broad distribution and prevalence (264). 
1.6.2 Streptococcal superantigens  
S. pyogenes (group A Streptococcus) is a prominent bacterial pathogen that can cause a 
diverse range of clinical manifestations, from common bacterial pharyngitis to severe 
complications related to invasive infections (265). To date, eleven genetically distinct 
SAgs are known to be produced by S. pyogenes. Commonly referred to as erythrogenic 
toxins, these virulence factors currently include streptococcal pyrogenic exotoxin (Spe) 
serotypes A, C, and G to M, as well as streptococcal mitogenic exotoxin Z (SmeZ), and 
streptococcal superantigen (SSA) (257). Historically defined as scarlet fever toxins, 
streptococcal SAgs are also associated in the pathogenesis of this illness (266). Widely 
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recognized in clinical implications, the contribution of SAgs for bacterial welfare is 
largely unknown; however recent work highlights that the biological function of 
streptococcal SAgs may promote the initial establishment of infection in humans, as 
evaluated in an acute infection of the upper respiratory tract of mice expressing human 
MHC II molecules. Further, SAgs may exist in redundancy to avoid host anti-SAg 
humoral immune responses and overcome polymorphisms of host MHC II (267). 
1.6.3 Superantigen structure and mechanism of action 
SAg structures and host cell interactions have been extensively reported from numerous 
structural and mutational analyses extensively reviewed by Fraser and Proft (268). 
Though SAg molecules generally share low amino acid sequence homology, the overall 
protein structure is conserved among protein family members, consisting of two major 
protein domains: an N-terminal oligonucleotide/oligosaccharide-binding (OB) domain, 
and a C-terminal β-grasp motif connected through a central α-helix (269). With similar 
structures, SAgs also share potent immnuomodulatory properties, remarkably detected 
with picogram (10-12 g) quantities (248).  
SAg-mediated activation of T cells mechanistically differs from conventional T cell 
activation as a processed peptide presented in the context of MHC (pMHC) on APCs 
(Figure 3A), as well as from non-specific T cell mitogens (e.g. phytohaemagglutinin 
[PHA], concanavalin A [ConA]). Instead, SAgs function by engaging lateral surfaces of 
pMHC as unprocessed proteins (270-273), while simultaneously engaging germline-
encoded regions within the variable region of the TCR β-chain (Vβ) (Figure 3B) (274-
278). MHC II molecules possess two independent binding sites for bacterial SAgs: a low-
affinity site on the conserved α-chain and a zinc-dependent, high-affinity site on the 
polymorphic β-chain (279, 280). SAg-mediated crosslinking of these adaptive immune 
receptors generates a ‘wedge’ that allows for the large-scale activation of T cells that is 
independent of the peptide antigen presented within MHC II. As there are ~50 functional 
Vβ genes in humans (281, 282), and because different SAgs can often target multiple Vβs, 
though preferential Vβ binding is displayed (280, 283), these toxins stimulate a very large 
percentage of exposed T cells and the subsequent release of pro-inflammatory cytokines, 
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Figure 3. Structural overview of a representative SAg-mediated T cell activation 
complex  
Cartoon representations of A) conventional T cell activation in complex with pMHC II 
(284) and B) representative Group IV SAg (SpeC) in complex with TCR and pMHC II 
cross-linked by SpeC through zinc-mediated, high affinity binding site and a low affinity 
binding site (272, 285, 286). The ternary model of TCR-SpeC-(MHC)2 was produced as 
previously described (277). In brief, the cartoon was generated by superimposing the co-
crystal structures of SpeC-TCR  (PDB code 1KTK) (285), high affinity binding site 
SpeC-MHC II (PDB code 1HQR) (272) and low affinity binding site as predicted from 
SEC-MHC II (PDB code 1JWM) (287). Colours are as follows: MHCII-α-chains, red; 
MHCII-β-chains, green; antigenic peptides, black; zinc atom, magenta; TCR Vα chain, 
yellow; TCR Vβ chain, grey; SpeC SAg, blue. 
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often referred to as a ‘cytokine storm’ (e.g. IL-2, IFN-γ, and tumour necrosis factor 
[TNF]-α) (248). This leads to the polyclonal expansion of particular Vβ subsets of T cells 
or T cell subsets, a process known as Vβ skewing. Typically, in conventional T cell 
activation, antigens stimulate ~0.01% of naïve T cells through specific interactions as 
processed peptides displayed in the context of MHC II on APCs. In contrast, the 
aforementioned mechanism demonstrated by SAgs can stimulate >20% of all exposed T 
cells (248). Although SAgs do not engage MHC I molecules, these toxins do activate 
both CD4+ and CD8+ T cells (288), as well as in specific cases, unconventional T cell 
subsets such as invariant NKT cells (289) and γδ T cells (290). Collectively, this 
activation will further lead to bystander activation of accessory cells such as NK cells 
(291), and the recruitment of monocytes, Mϕ, neutrophils, and DCs (248, 251, 280). 
Reports have also demonstrated that stimulation from evaluated SAgs can result in a 
dose-dependent TCR Vβ-specific expansion of activation-induced CD25+ FoxP3+ cells, 
indicative of a Treg phenotype. Though these cells express IL-10, their suppressive 
function remained highly cell-cell contact dependent (292, 293).  
Although SAg toxins have long been recognized to induce Vβ-specific T cell anergy, a 
state of unresponsiveness to stimulation and/or deletion following activation (294-296), 
evidence suggests that the fate of the T cell population may be influenced by both SAg 
concentration and duration of exposure, and that with addition of IL-2, the anergic cells 
may be indeed rescued (297). 
1.6.4 Superantigen classification 
A phylogenetic classification scheme of the SAg exotoxins has recently been updated 
where SAgs from staphylococci and streptococci are placed into five evolutionary groups 
based on amino acid alignments (253). Within this classification, the Group I SAgs 
contain only one member, the evolutionary distinct TSST-1. This group contains only one 
MHC II binding site in the OB-fold; a low-affinity site that interacts with the α-chain of 
MHC II molecules (271). Lacking the proposed emetic cystine loop of SEs, this SAg 
indeed does not induce emesis (262), though is considered the major cause of the 
menstrual form of TSS (298, 299).  
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The Group II SAgs contain both staphylococcal and streptococcal SAgs with members 
commonly linked with both non-menstrual-associated cases of staphylococcal TSS [SEB; 
(300)] and streptococcal TSS [SpeA; (256)]. Similar to Group I, Group II SAgs contain 
only one low-affinity α-chain MHC II binding site as highlighted in Spaulding et al. 
(254). 
The Group III SAgs are only populated by staphylococcal SAgs and although the Group 
II SE SAgs are often implicated as well, this Group generally contains those most 
commonly associated with staphylococcal food poisoning (e.g. SEA, SEE) (301). Unique 
to the Group II and III SAgs is a “cystine-loop structure” that is thought to be important 
for emetic activity (302), though its presence does not assure emesis, demonstrated by a 
lack of this activity by SpeA (262). Group III SAgs contain a low-affinity α-chain MHC 
II binding site as in previous groups, but also contain a second, zinc-mediated high-
affinity MHC II β-chain binding site within the SAg β-grasp domain (248, 303). 
The Group IV SAgs are restricted to only streptococcal members, and are characterized 
as having the high-affinity binding sites for MHC II molecules, as in Group III but lack 
the designated cystine loop and therefore are known for lack of emesis (248). Although 
the low-affinity MHC II α-chain interaction has not been characterized structurally, 
considerable evidence has indicated its presence (286, 304). 
The Group V SAgs, with the exception of SpeI (and related orthologues) contain mostly 
staphylococcal SAgs, and are the most recent to be described and highlighted in 
Spaulding et al. (254). Further, this Group includes only SEl toxins, other than SEI. 
Members of Group V are predicted to contain both the high- (305) and low-affinity MHC 
II binding sites and lack the emetic cysteine loop (254). Interestingly, SEI is the only SAg 
outside of the Group II and III SAgs reported to have emetic activity, albeit comparably 
weak (306). Lastly, Group V SAgs are characterized by a unique, relatively conserved ∼15 amino acid extension referred to as the α3–β8 loop (307). The evolutionary SAg 
Groups are summarized in Table 8, highlighting key structural features discussed.  
Regardless of the subtle or dramatic differences within the SAg-mediated T cell 
activation complexes, each member within the SAg family of toxins, despite its group  
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Table 8. Structural features of known staphylococcal and group A streptococcal 
SAgs 
Group SAgsa MHC II interactions Cystine loopb  
I TSST-1 low-affinity site α-chain No 
II SEB, SEC, SEG, SER, SEl-U, SpeA,  
SpeH, SSA, 
low-affinity site α-chain Yes 
III SEA, SED, SEE, SEH, SEl-J, SEl-N, 
SEl-O, SEl-P, SEl-S 
low-affinity site α-chain, 
high-affinity site β-chain 
Yes 
IV SpeC, SpeG, SpeJ, SpeK, SpeL, SpeM, 
SmeZ 
low-affinity site α-chain, 
high-affinity site β-chain 
No 
V SEI, SEl-K, SEl-L, SEl-M, SEl-Q, SEl-
V, SpeI 
low-affinity site α-chain, 
high-affinity site β-chain 
No 
Modified from Spaulding et al. 2013 (254) based on current phylogenetic classification scheme (253). a SAgs SET and 
SEl-X are currently not aligned amongst established evolutionally groups. b Presence of cystine loop, although related, 
is not fully predictive of emetic activity.
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classification, is able to efficiently activate large numbers of T cells. Notably, the one 
common structural feature of all characterized SAgs, with the exception of the Vα- 
specific SEH, is the engagement of the Vβ CDR2 loop, which appears to be the critical 
determinant for Vβ-specificity (277). 
1.6.5 Superantigens and cancer therapy 
There have been significant efforts to design SAg-based immunotoxins, collectively 
known as tumour-targeted superantigens (TTSs), in order to artificially ‘force’ T cells to 
recognize TAAs in a non-MHC-restricted manner. TTSs are recombinant fusion proteins 
that consist of an anti-tumour antibody moiety genetically fused to a SAg (308, 309). The 
intent of TTSs is to treat tumours through localization and activation of the patient’s 
immune system at the tumour site, with particular aims to augment a cytotoxic T 
lymphocyte (CTL) response. Presented in Figure 4 are the highlights from TTS 
preclinical and clinical developmental. 
1.6.5.1 Developmental concept of ‘first-generation’ TTSs  
The concept of using SAgs as a targeting moiety for human CTLs was initially developed 
based on early studies by Dohlsten et al. and Hedlund et al. (310, 311). In these studies, 
MHC II+ tumour cells function as a receptor for members of SE SAgs, wherein at pM 
concentrations, this complex specifically lead to subsequent triggering and lysis by CTLs; 
a mechanism coined SAg-dependent cellular cytotoxicity (SDCC) (310-313). As MHC 
II+ tumour cells are of minority in malignant disease and systemic T-cell activation would 
be expected, the general application of this treatment was limited (308).  
From this concept, tumour-specific SAgs emerged, originally created by coupling wild-
type SEA SAg to tumour-reactive mAbs (C215 or C242) to ‘coat’ the tumour cells with 
TTS (mAb::SEA) (308, 314). C215 (IgG2a) and C242 (IgG1) are mouse mAbs obtained 
after immunization with human colon carcinoma cell line (Colo205) and are known to 
recognize tumour-related epitopes associated with human colon and pancreatic 
carcinomas, respectively (315-317). In this pioneering work, the TTSs presented as 
cytotoxic mediators, selectively targeting SEA-responsive CTLs, in vitro and in vivo, for
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Figure 4. Developmental timeline of TTSs in preclinical and clinical evaluation.  
Schematic illustration of the developmental timeline of TTSs over nearly three decades. 
Highlights for preclinical and clinical arms of evaluation are represented by year of 
publication, TTS involved, and if applicable, key facts of model or phase trial. All 
combinational TTS preclinical work was completed in a murine C215-B16 tumour model. 
References are listed within Appendix 5. 
 
  
51 
  
52 
localization against tumour cells in a MHC II independent manner. Progression of the 
TTS concept lead to the assembly of genetic fusions containing wild-type SEA SAg and 
the antigen-binding fragment (Fab) region of the tumour-reactive mAbs, producing a 
recombinant protein (Fab::SEA) (309). These TTSs maintained efficient tumour targeting 
and T cell stimulatory properties but resulted in an overall reduction of MHC II binding 
(compared to native SEA) (309). Designated as SAg-mediated antibody-dependent cell 
cytotoxicity (SADCC), the Fab-SEA demonstrated a substantial reduction in tumour 
burden and improved the rate of mortality in a C215-expressing B16 syngeneic 
melanoma metastasis model (309, 318-322). Most notable, four daily injections of Fab-
SEA resulted in 90–95% reduction in the number of metastases (321). The potential to 
render the immune system in a hyporesponsive state was noted with this regime (321); 
however, the inability to eradicate residual tumours was recovered with two repeated 
cycles of TTS amongst a resting period, successfully eliciting a secondary anti-tumour 
response and significantly prolonging survival (322). Furthermore, in a humanized severe 
combined immunodeficient (SCID) mouse model, reconstituted with human PBMCs and 
disseminated human Colo205, C242Fab-SEA treatment resulted in strong inhibition of 
tumour growth, reduction in overall burden, and full resolution of carcinoma in a 
proportion of animals (318, 319).  
1.6.5.2 ‘First generation’ TTSs in clinical trials 
In Phase I clinical trials for the treatment of advanced CRC and pancreatic cancer, safety 
was established in single dose infusion (323, 324) and escalating repeated dose regimens 
(325) of the Fab moiety of mAbC242 fused to SEA (PNU-214565; nacolomab tafenatox). 
Although transient and manageable, toxicities occurred among patients; of these adverse 
events, fever and hypotension were the most common and correlated with a high 
induction of circulating IL-2 and TNF-α (324). Rapid systemic immune activation and 
associated toxicities presumed to be a result of TTS interaction with MHC II containing 
tissues, followed by engagement of appropriate Vβ subsets of T cells (323-325). To avoid 
severe systemic toxicity, the treatment could only be given in very low amounts, limiting 
the initial dose range (0.01 ng kg-1-4 ng kg-1) and ultimately, illustrated the considerable 
biological activity of the TTS (323, 324).  
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In an accompanying repeated-dose trial, the TTS treatment was safely administered in the 
program (one cycle of 4 consecutive daily infusions), and though not cumulative, parallel 
toxicities among patients remained (325). Once more, toxicity preceded with systemic 
cytokine induction and adverse events further correlated with transient losses in 
lymphocyte subsets (323, 325). In addition to cytokine induction, the required dose for 
half maximal effective concentration (EC50) correlated highly with the ratio of baseline 
circulating anti-SEA antibodies (pre-existing) and necessitated unanticipated 
individualized dosing (325). Laboratory and clinical findings showed no detectable 
HAMA responses to TTS infusions and despite the ability to bind to normal colon tissue, 
the TTS demonstrated no obvious organ-related side effects (324, 325).   
1.6.5.3 Development of ‘second-generation’ TTSs 
The first generation Fab::SEA TTSs, through the SAg moiety, still retained a 
considerable affinity for MHC II molecules (326), resulting in systemic T cell activation 
and cytokine toxicity from accumulation in MHC II positive tissues (324, 326, 327), a 
reported source of dose limiting toxicities (DLTs). To circumvent this response and allow 
for successive administration regimes, ‘second generation’ TTSs were introduced with a 
mutated version of SEA. Resembling other class III (SE) and IV (Spe) SAgs (253), SEA 
has two distinct MHC II binding sites (328, 329); one of which is low affinity and the 
other contains residues that co-ordinate a Zn2+ ion to form a high affinity binding site to 
the β-chain of MHC II (328, 330). Designed with a substitution at a key amino acid 
involved at this interface, Asp227 (328, 330), the altered SEA maintained T cell 
stimulatory properties and cytokine release in the presence of MHC II, albeit at a much 
reduced activity (>100-fold compared to wild type SEA) (328, 331). Administered at 
high doses in vivo, the tailored TTS (Fab::SEAD227A) eliminated systemic immune 
activation and toxicity but maintained a strong T cell-dependent antitumour response in 
both a C215-B16 model of mice transgenic for TCR Vβ3 (332), a preferential Vβ binding 
for SEA (332, 333), as well as in an anti-CD19 humanized mouse model carrying B 
lymphoma cells (Daudi) (334). Overall, the Fab tumour specificity replaced the initially 
required MHC II reactivity properties of the SAg, allowing targeting and activation of 
cytotoxic T cells (326, 334).  
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Later studies utilized a recombinant fusion of the modified SEA (Asp227) with a mouse 
Fab to target the oncofetal antigen, 5T4 (335, 336). While maintaining a reduced binding 
for MHC II through the modified SEA, this 5T4-targeting moiety had a high affinity for 
this tumour-restricted antigen (nM; mean Kd of 10-9 M) (335). This TTS resulted in ~95% 
reduction of tumour mass in a NSCLC model (335). 
1.6.5.4 ‘Second generation’ TTSs in clinical trials 
Using the treatment anatumomab mafenatox (5T4Fab::SEAD227A; PNU/ABR-214936) in 
a Phase I clinical trial, safety and maximum tolerated dose (MTD) was established in 
NSCLC patients as the primary objective (337). The treatment, received as single 
infusions on four consecutive days, had minor tumour responses in assessable patients 
(66/78), defined as greater than 25% tumour regression (12% [8/66] of patients) (337).  
Among certain patients, DLTs were reported and fever, hypotension, and nausea 
remained common adverse events overall (337). The MTD ranged from 103 ng kg-1 to 
601 ng kg-1, a relatively low dose, although a marked improvement from the TTS 
predecessor (337). Encouragingly from Phase II studies in RCC patients, a prolonged 
survival was observed compared to expected survival rates, and in particular, patients 
receiving the highest dose of treatment within this study lived almost double the amount 
of time than expected (338). The largest proportion of patients (27/43) showed stable 
disease and one patient (1/43) showed a partial response (PR). Notably, a large increase in 
patient IL-2 serum levels observed on the second day of treatment correlated postitively 
with overall prognosis and importantly, a significantly longer survival time. From this, 
circulating IL-2 levels may provide a useful pharmacodynamic marker for clinical effect 
of this TTS (338). 
Although with promising clinical trial results, many patients had pre-existing antibodies 
to SEA which required individualized dose-escalation TTS treatment regimens to 
overcome neutralizing effects of these antibodies (337). Consequently, patients with high 
anti-SEA antibody values were not recommended for treatment with anatumomab 
mafenatox in subsequent studies (337). This response remained within Phase II as an 
increase in titers following the first cycle were reported in a majority of patients, but this 
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was not further boosted by further exposure (338). Further, the murine Fab led to 
elevations in HAMA levels following multiple cycles of treatment (337, 338). Together, 
these effects lead to the requirement of relatively high doses for a measurable anti-cancer 
treatment. 
1.6.5.5 Development of ‘third-generation’ TTSs 
In parallel the initial clinical evaluation of anatumomab mafenatox, a ‘third-generation’ 
TTS was developed to advance the concept. The main intention was to reduce the overall 
immunogenicity demonstrated by the SAg moiety in predecessors and reduce the 
neutralizing effects of preformed antibodies in patients. Previously reported, SEA 
specifically had pre-existing anti-SEA antibodies in a proportion of patients (337). 
Additionally, as TTS treatment is most effective when given in repeated cycles (321, 322), 
high titers of antibodies against SEA can be developed (339). 
In order to reduce antigenicity, the succeeding generation of this TTS therapeutic, 
naptumomab estafenatox (ABR-217620; ANYARA) was established. This TTS, like the 
predecessor, consists of the murine anti-5T4 Fab, but is linked to the chimeric SAg 
moiety, SEA/E-120, engineered in a multi-step process by Erlandsson et al., resulting in a 
TTS with a distinct pharmacological prolife (339). In addition to reduced MHC class II 
binding (Asp227), SEA/E-120 has structural modifications to reduce immunogenicity and 
decrease binding by human antibodies (339). Designed with the premise that individuals 
in general are reported to have lower pre-existing antibodies to SEE compared to SEA, 
and that SEE demonstrated low anti-tumour properties, the chimeric SAg demonstrated 
that ~85% of the antibodies binding the previous SEA no longer affected SEA/E-120 in 
preclinical studies (339). Further, this TTS formulation demonstrated a higher efficiency 
compared to its predecessors of inducing T cell-mediated cytotoxicity of tumour cells in 
vitro, a superior binding affinity for the target antigen 5T4, and a dramatic reduction in 
tumour mass with repeated administrated in a humanized murine model (intraperitoneal 
[ip]) of human lung metastases (Calu-1) (242).  
Later studies reported that multimeric naptumomab estafenatox selectively binds to, 
activates, and expands T cells expressing Vβ7-9, including CD4+ and CD8+ subsets and 
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directs CTL cytotoxicity to 5T4-expressing cells despite the diminished MHC II binding 
and structural epitope alterations (340). Based on the succession of TTS generations and 
balancing the binding relationships of the TTS, it is currently hypothesized that for an 
optimal formulation to maximize anti-tumour effects, the immunotoxin ideally has a high 
affinity for the tumour antigen, low affinity for the TCR, and very low affinity for MHC 
II proteins; a formulation exhibited by the current TTS, naptumomab estafenatox (209). 
1.6.5.6 ‘Third generation’ TTSs in clinical trials 
The latest TTS, naptumomab estafenatox, has undergone two prospective Phase I clinical 
trials as a monotherapy in patients with advanced NSCLC, pancreatic cancer, and RCC, 
and as a combination therapy [based on (341)] with docetaxel, a cytostatic 
chemotherapeutic drug, in patients with NSCLC (342). With the primary aim to establish 
the MTD, the secondary objectives were to evaluate safety profile, immunological 
response, pharmacokinetic parameters, and effects on disease. Within the monotherapy 
evaluation, naptumomab estafenatox was administered daily (0.5 µg kg-1 – 27.4 µg kg-1) 
for five consecutive days, based on large animal safety/toxicology (Macaca fascicularis) 
studies [unpublished data reported in (342)] and previous clinical evaluations 
(anatumomab mafenatox), acknowledging the designed insensitivity to preformed anti-
SAg antibodies, with select patients receiving a second or third treatment cycle. Within 
the combination arm, TTS doses were obtained from the monotherapy information, and 
docetaxel was administered as a fixed standard dose (75 mg m-2) (342). 
In both arms of evaluation, naptumomab estafenatox was well tolerated, with manageable 
treatment-related adverse events of fever, nausea, hypotension, and rigors, all pronounced 
during the first treatment cycle (342). Recorded DLTs associated with this TTS consisted 
of fever, hypotension, liver toxicity, and acute vascular leak syndrome; all patients whom 
had received >20 µg kg-1 dose but unlike its predecessors, independent of preformed 
patient anti-SAg antibodies (342, 343). An immediate (3 hour) dose-dependent increase 
in systemic immune activation of IL-2, IFN-γ, and IL-10 plasma levels was observed 
with some evidence of anti-tumour activity. This included stabilization of disease in 36% 
(14/39) and 38% (5/13) of patients receiving monotherapy (NSCLC and RCC) and 
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combination therapy (NSCLC), respectively, and partial responses in 15% (2/13) of 
patients within the combination arm (342). Among these patients, the SAg reactive 
population of T cells were selectively expanded after TTS infusions, and returned to 
normal levels one month post-treatment, with enhancement of tumour infiltration of T 
cells after treatment in tumour biopsied NSCLC patients (343). Anti-SAg antibodies were 
increased in approximately 50% of patients after one cycle, and although low, levels of 
HAMA were detected but were reported not to effect the overall pharmacokinetics of 
naptumomab estafenatox (mean plasma concentration half-life of ~1 h over all cycles), 
presumed due to exceedingly small doses compared to non-conjugated mAb-based 
therapies (343). Based on the IL-2 level post-administration of the TTS, unlike previous 
trials, sufficient drug access could be monitored and dosing for patients adjusted within 
this evaluation (343). Overall, naptumomab estafenatox was concluded to be safe for 
administration to patients with advanced malignant disease and pharmacological proof-
of-principle obtained for the TTS concept (342, 343). 
Based on preclinical models with TTSs and IFN-α (344), a randomized Phase II/III trial 
in patients with advanced RCC was conducted with naptumomab estafenatox, comparing 
the TTS (15 µg kg-1 given 3 cycles of 4 daily intravenous [iv] infusions; MTD for RCC in 
Phase I trials) plus interferon-α (9×106 U given subcutaneous 3× weekly), to interferon-α 
alone (same dosing). Although well-tolerated and comparable to Phase I trials, early 
information revealed that the study did not reach the primary endpoint of OS; however, 
an unexpected majority of patients had high levels of pre-formed anti-SEA/E-120 
antibodies, which may have contributed to suboptimal therapy (209, 345, 346). Notably, a 
subgroup analysis of those patients with normal anti-SEA/E-120 neutralizing antibodies 
and low basal IL-6, a current biomarker for immune status of the tumour 
microenvironment (347), demonstrated that the combinational therapy with IFN-γ may 
improve and did demonstrate treatment advantages in both OS and PFS (346, 348). 
Furthermore, preliminary assessment of the immunological responses revealed patients 
with pronounced IL-2 induction and T cell expansion after treatment correlated with 
longer OS (348). After three days of initial treatment, the total T cell population, 
including TTS-specific T cells, was reduced in the peripheral blood of assessed patients. 
However, the expansion level of TTS-specific CD8+ and predominately CD4+ T cells was 
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significantly higher eight days after the first treatment cycle (4 days post-last TTS 
infusion) (348). Preliminary reports noted a large proportion of the expanded TTS-
specific CD4+ T cells displayed a memory phenotype (CD45RO) and were also detected 
in FoxP3- and not FoxP3+ cells, suggesting that the TTS expanded T effectors cells rather 
than Tregs. This response was preceded with an increase of serum levels of IL-6, IL-10, 
and TNF-α, particularly after the first treatment cycle (4 days post-last TTS infusion) 
(348). Although this form of therapy may need to be patient specific (209, 346), the 
human data for TTS remains promising, and studies have clearly demonstrated the 
potential of TTSs for cancer immunotherapy. Presently, future development strategies are 
aimed at starting a Phase II/III with a novel combination of naptumomab estafenatox with 
a tyrosine kinase inhibitor (209). 
1.6.5.7 Directed-cytotoxic mechanisms of preclinical TTSs 
Although specific mechanisms of TTS-induced anticancer immunotherapy have not been 
fully elucidated, it can be speculated that the therapeutic efficacy is attributed collectively 
from several combination of mechanisms: 1) activation and direct lysis by T cells of 
TAA-expressing tumour cells, 2) suppression of tumour cell growth by secretion of 
cytokines and 3) recruitment of immune cells and cytokine secretion that eliminates 
TAA-negative tumour cell variants (Figure 5) (209, 349, 350). 
SAgs are able to induce cytotoxicity by direct activation of CTLs (310) and induction of 
activated T cell cytokine release, primarily IL-2, TNF-α, and IFN-γ with subsequent 
activation of accessory cells such as NK cells (349, 351, 352). Consistently, initial 
preclinical studies report that therapeutic effects of TTS were largely associated with 
immune infiltration, inflammation, and activation localized to the tumour (318, 320, 322, 
350, 353, 354). Predominantly present were CD4+ and CD8+ T cells, as well as a large 
fraction of Mϕ (354). The overall response resulted in a strong T cell-dependent direct 
cell-mediated cytotoxicity through apoptosis (312, 332) and a release of pro-
inflammatory cytokines, predominantly TNF-α and IFN-γ (312, 313, 353, 354). 
Specifically reported, in a single-cell based study with SEA, the cytokines IL-2, IL-4, IL-
5, IL-10, IL-12, TNF-α, IFN-γ, GM-CSF, and TGF-β were foremost produced; the 
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Figure 5. TTS proposed mechanism of action 
TTS proposed mechanisms leading to anti-tumour effects represented as schematic 
illustrations. Images were modified from Eisen et al. (209), targeting the TAA 5T4 and 
based on A) preclinical investigations with TTSs and B) immunological responses 
observed from early analysis of clinical treatment cycles of naptumomab estafenatox 
(348).  
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majority of the TNF-α, IL-2, IL-12, and IFN-γ were made by the infiltrating human 
leukocytes, while the tumour cells were induced to produce IL-4, IL-10, and TNF-α 
(353), ultimately leading to SAg-mediated cytotoxicity. Derived primarily from CTLs, 
perforin-mediated lysis largely contributed to the eradication of local TAA positive cells 
(354, 355) and concomitantly, CD95 Fas receptor expression occurred to induce 
programmed cell death in the tumour cells (353).  
A synergistic effect of these cytokines resulted in growth inhibition of cells (tumour 
suppressive), including those lacking the targeted TAA, and overall increased 
inflammation in the tumour area (314, 350, 353, 355, 356). IFN-γ production through 
CD4+ T cells was classified an important mediator for the overall cytostatic response, and 
was found to exert both direct and indirect anti-tumour effects (354). From knock-out in 
vivo studies, recruitment of cytotoxic cells and Mϕ depended on this cytokine to mediate 
strong tumouricial effects (354) and effective therapy was influenced by the overall 
release of IFN-γ (354, 355). Preclinical work implied that both CD4+, as well as CD8+ T 
cells were necessary to collaborate for optimal anti-tumour effects of TTS (354). 
Repeated injections augmented these effects (320, 321, 350) with a strong SEAD227A-
induced production of IL-2, INF-γ, TNF-α, and IL-6 (326) and also resulted in more 
pronounced primary synthesis of macrophage inflammatory protein (MIP)-1α (CCL3) 
and MIP-1β (CCL4) at the local tumour site for immune cell recruitment (354). SAg-
reactive T cells simultaneously produced high levels of IL-2 inducing expansion and 
sustained T cell proliferation, with accumulation within the tumour area (354). These 
secondary events were important for anti-tumour effects against sub-populations of 
cancer cells not expressing the targeted TAA (335, 354). 
Mechanistically, SAgs have the potential to induce T cell anergy and deletion, 
predominately after a period of strong T cell activation (295); however experimental 
studies in vivo with repeated exposure of TTSs have demonstrated that the T cell effector 
functions were recovered after eight weeks (321, 322). Further, the potential induction of 
dose-dependent T cell unresponsiveness may be resolved with combination of IL-2 (357, 
358) and remains, among other immune modulators, an area of study for potential 
combinational therapies. 
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Recently, clinical applications of repeated cycles of TTSs have described immunological 
responses, proposing a sequence of events that may lead to therapeutic efficacy (209, 
348). Initial mobilization of T cells occurs immediately after administration, signified by 
T cell activation and increase in cytokine production (e.g. IL-2, TNF-α, IFN-γ) and 
expansion (Days 1-2). Throughout the treatment cycle on Days 3-4, full localization of 
the TTS occurs, encouraging further T cell infiltration, activation, cytokine production, 
and immune elimination (e.g. CTLs) of the targeted tumour cells with the elicited 
secondary events destroying TAA-negative bystander cells (Figure 5B) (209, 348). 
1.6.5.8 Combinational therapies of TTSs 
Clinically, TTSs have the compelling ability to also be used in combinational therapies. 
Early preclinical studies exhibited sustained T cell activation (CD4+ and CD8+) and an 
increase in IFN-γ and TNF-α production when the first generation TTS (C215Fab-SEA) 
was co-administered with a tumour targeted IL-2 fusion protein (357, 359). Improved 
therapeutic efficacy and long-term survival of the combination treatment correlated with 
tumour infiltration and prolonged immune response compared to either treatment alone in 
an established murine C215-B16 melanoma model (357, 359).  
Later studies demonstrated a synergistic anti-tumour response in the C215-B16 model 
when the TTS C215Fab-SEA was administered in a combined treatment with IFN-α 
(344). This response was accompanied with heightened CD8+ T cell infiltration into the 
tumour area, enhanced induction of perforin-dependent cytotoxicity, and prolonged 
survival time (344). Further, when combined in a multi-cycle regimen with the cytostatic 
drug docetaxel, a member of the widely used conventional cancer chemotherapies, 
pretreatment did not interfere with T cell responses but enhanced cytotoxicity and the 
overall tumour therapy was significantly improved (341). When compared to 
monotherapies, prolonged long-term survival was synergistic and administration of 
docetaxel reduced the development of anti-SEA response after repeated TTS treatment 
(341). This preclinical work was subsequently applied to an ongoing Phase I clinical trial 
with naptumomab estafenatox as a combination evaluation with docetaxel with 
encouraging synergistic effects (342).  
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Immunotherapeutic modalities, such as TTS, may expand tumour antigen-specific Tregs 
as well as T effector cells, inducing immune suppression and diminishing expansion of 
effector cells (360). Increased levels of Tregs (Foxp3+) were reported in recent Phase 
II/III clinical trials after treatment cycles with naptumomab estasfenatox but interestingly 
were not within the TTS-specific CD4+ subpopulations (348). Preclinical models of this 
TTS in conjunction with blockade of CTLA-4, a key negative regulator of immune 
responses, induced a favorable shift in the ratio between T effector and Tregs infiltrating 
the tumour and significantly prolonged the overall CTL response and sustained 
augmented responses in repeated TTS cycles (361). Monotherapy of an antagonistic 
CTLA-4 mAb was ineffective against tumours but enhanced anti-tumour effects in 
tumour-bearing animals and improved overall long-term survival (361).  
1.6.6 Streptococcal pyrogenic exotoxin C and immune mediator interactions  
Streptococcal pyrogenic exotoxin C (SpeC) is a 24 kDa, 235 amino acid protein (362) 
produced by S. pyogenes that was first characterized in 1977 by Schlievert et al. (363). 
Clinically, SpeC has been generally associated with streptococcal TSS, a toxin-mediated 
acute life-threatening illness, which results from a ‘cytokine storm’ elicited by the 
polyclonal T-cell expansion properties of SAgs (248). SpeC has also been implicated in 
other toxin-mediation ailments, such as scarlet fever, but a strict association is not always 
detected (364).  
Since its initial description, this Group IV SAg has been well-studied in terms of both 
structure (272, 285, 365) and functional engagement of host receptors (277, 286, 366-
368). As distinct SAgs typically display unique Vβ T cell activation profiles (283), it was 
determined that SpeC preferentially binds and activates human Vβ2+ T cells, although it 
is also capable of binding to Vβ3, 4, 12, and 15 T cell subsets (283, 366). Indeed, a co-
crystal structure of SpeC bound to human Vβ2.1 chain identified extensive binding 
interactions of SpeC with CDR1, CDR2, hypervariable region 4 (HV4), FR3, and CDR3 
of the TCR (285), and further work has elucidated its important interactions in a 
functional-map analysis specifically with CDR2 (277). Extensive work with SpeC has 
revealed that the TCR and pMHC II are cross-linked by SpeC through a zinc-mediated, 
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high-affinity binding site, ‘docking’ the SAg within the complex, and a predicted low-
affinity binding site, two distinct interfaces interacting with MHC II molecules (272, 286, 
369). The high-affinity interaction is between the C-terminal domain of SpeC and the β-
chain of MHC II (272), while the low affinity interaction occurs between the N-terminal 
domain of SpeC and the α-chain of MHC II (286) (Figure 6).  
Comprehensive mutational analysis has generated ‘functional’ maps that have designated 
critical amino acid residues of SpeC involved at each binding interface (286, 367, 368, 
370). Such analysis has allowed for the development of a non-mitogenic and non-lethal 
SpeC molecule, that when used as a vaccine, was able to protect against a rabbit model of 
TSS (367). Indeed, the single Asp203 to Ala mutation in SpeC, a critical amino acid in the 
zinc-mediated, high affinity MHC II interaction, has also been demonstrated to 
dramatically reduce toxicity in a lethal model of TSS (369). A representative structural 
overview of the SpeC-mediated T cell activation complex, along with highlighted critical 
residue mutations, Tyr15 (368) and Asp203 (272, 286, 369) is presented in Figure 6B. This 
knowledge may also allow for SpeC to be engineered as a prototype SAg for future use in 
immunotherapy treatments of human disease, such as those directed at cancer.  
1.7 Rationale and Hypothesis 
In recent years it is clearly evident that giant strides have been made in the development 
of cancer immunotherapeutics and that it will be vital for research to continue to provide 
alternative treatments for such a worldwide devastating disease. In the work to be 
described, it was sought to expand the repertoire of TTSs to include the first streptococcal 
SAg, using SpeC as the prototype. Bacterial genomic sequencing efforts over the last 
decade have now revealed an extensive ‘family’ of SAg exotoxins in both S. 
aureus and S. pyogenes. A general feature of these toxins is that genetically distinct SAgs 
are also antigenically distinct, and furthermore, distinct SAgs also typically display 
unique Vβ activation profiles (283). Thus, S. aureus and S. pyogenes have provided an 
abundance of T cell mitogens that could potentially be engineered as TTSs for cancer 
therapy. Prior to this work, TTSs had been built exclusively using members of the SE 
class of SAg, and SEs are also agents of staphylococcal food-borne illness, an activity 
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Figure 6. Structural overview of the SpeC-mediated T cell activation complex and 
important residues involved at binding interfaces 
Cartoon representations of A) SpeC in complex with TCR and pMHC II cross-linked by 
SpeC through zinc-mediated, high affinity binding site and a low affinity binding site 
(272, 285, 286). B) Close up view showing two important SpeC residues involved in the 
interaction at the TCR interface (Y15) and the high-affinity binding MHC II binding 
interface (D203). The ternary model of TCR-SpeC-(MHC)2 was produced as previously 
described (277). In brief, the cartoon was generated by superimposing SpeC-TCR  (PDB 
code 1KTK) (285), high affinity binding site SpeC-MHC II (PDB code 1HQR) (272) and 
low affinity site as predicted from SEC-MHC II (PDB code 1JWM) (287). Colours are as 
follows: MHCα-chains, red; MHCβ-chains, green; antigenic peptides, black; zinc atom, 
magenta; TCR Vα chain, yellow; TCR Vβ chain, grey; SpeC, blue with important 
interface residues highlighted in orange. 
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that is thought to be independent of the ability to activate T cells (261). Although 
manageable, some of the side effects seen in TTS Phase I and Phase II clinical trials 
included nausea, vomiting, and diarrhea (323, 338, 342), and may have been related to 
the emetic properties of SEA (371). A potential advantage of engineering a streptococcal 
SAg as a TTS is that these toxins naturally lack bona fide emetic activity (262), which 
may result in fewer side effects. Also, SpeC is very well studied in terms of both structure 
(272, 285, 365) and function for host receptor engagement (277, 286, 366-368), providing 
a platform for tailoring activity. Herein, it is hypothesized that SpeC mutagenized within 
the zinc-dependent, high-affinity MHC II binding domain (SpeCD203A) will have reduced 
superantigenicity while retaining tumouricidal properties and a SpeCD203A-based TTS 
fusion protein using an engineered scFv that specifically targets human 5T4 (scFv5T4) 
can be generated (scFv5T4::SpeCD203A). Finally, it is speculated that in a humanized 
mouse model of colon cancer, the scFv5T4::SpeCD203A TTS will control the growth 
potential of an established colon cancer tumour, and that this anti-tumour activity requires 
both specific targeting by the scFv5T4 moiety, as well as SAg function.  
This dissertation is based, in part, on the publication “Control of established colon cancer 
xenografts using a novel humanized single chain antibody-streptococcal superantigen 
fusion targeting the 5T4 oncofetal antigen” Patterson KG, Dixon Pittaro JL, Bastedo PS, 
Hess DA, Haeryfar SMM, McCormick JK (2014) PLoS ONE 9(4): e95200) and has been 
reformatted to departmental guidelines. 
 CHAPTER 2: METHODS AND MATERIALS
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2.1 Ethics statements 
Experiments using primary human lymphocytes were reviewed and approved by Western 
University’s Research Ethics Board (REB) for Health Sciences Research Involving 
Human Subjects (Appendix 1). Informed written consent was obtained from all blood 
donors were performed under REB 09911E. All animal experiments were performed by 
Animal Use Protocol (AUP) Number: 2012-026 in accordance with the Canadian Council 
on Animal Care Guide to the Care and Use of Experimental Animals, and was approved 
by the Animal Use Subcommittee at Western University (London, ON, Canada) 
(Appendix 2) 
2.2 Cell culture growth conditions  
2.2.1 Bacterial cell growth conditions  
E. coli strains were grown aerobically at 37°C or room temperature (RT) in Difco™ 
Luria-Bertani (LB) broth with shaking (BD Biosciences, Franklin Lakes, NJ, USA) or on 
LB with 1.5% Difo™ Agar (BD Biosciences, Franklin Lakes, NJ, USA), and if required, 
the following antibiotics to maintain target plasmids or endogenous mutations: 
kanamycin (50 µg mL-1 for BL21 [DE3] and 15 µg mL-1 for Origami B [DE3]), 
chloramphenicol (10 µg mL-1), ampicillin (100-200 µg mL-1), and/or tetracycline (12.5 µg 
mL-1) (all from Sigma-Aldrich, St. Louis, MO, USA). For storage, bacterial strains were 
frozen in LB with 20% glycerol and maintained at -80°C. All bacterial strains used within 
this study are listed in Table 9. 
2.2.2 Tissue culture media, growth conditions, and propagation  
All tissue culture basal media (Gibco®, Life Technologies Inc, Carlsbad, CA, USA) was 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, St. 
Louis, MO, USA) and the following supplements, all supplied from Gibco®: 10 mM N-
2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES), 2 mM L-Glutamine, 1 mM 
sodium pyruvate, 100 µM non-essential amino acids, 100 µg mL-1 streptomycin, and 100 
U mL-1 penicillin (Gibco®, Life Technologies Inc, Carlsbad, CA, USA) all filtered 
through 0.2 µm PES filter (Nalgene™, Thermo Scientific, Waltham, MA, USA). 
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Table 9. Bacterial strains used within this study 
Cell Description Purpose Source 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1 
Cloning Invitrogen 
XL1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F  ́proAB lacIqZ∆M15 Tn10 (TetR)] 
Cloning Stratagene 
SCS110 rpsL (Strr) thr leu endA thi-1 lacY galK galT ara 
tonA tsx dam dcm supE44 ∆(lac-proAB) [F  ́traD36 
proAB lacIqZ∆M15] 
Cloning Stratagene 
BL21 (DE3) F- ompT hsdSB(rB-, mB-) gal dcm (DE3) Protein 
expression 
Novagen 
Origami B (DE3) F- ompT hsdSB(rB-, mB-) gal dcm lacY1 aphC (DE3) 
gor522::Tn10 trxB (KanR, TetR) 
Protein 
expression 
Novagen 
BL21 (DE3) 
pBirAcm 
BL21 (DE3) containing pBirAcm Protein 
biotinylation 
This study 
Origami B (DE3) 
pBirAcm 
Origami B (DE3) containing pBirAcm Protein 
biotinylation 
This study 
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All cells used within this study and respective complete supplemented medias for each 
cell line are listed in Table 10.  
To prepare cultures from cryopreservation, cells were thawed quickly within a 37°C 
water bath and diluted 1:10 in pre-warmed media with no antibiotics. Cells were pelleted 
by centrifugation at 330 × g (Allegra 6, Beckman Coulter, Brea, CA, USA) for 5 min at 
RT, and the supernatant removed. The pellet was gently washed 3× following the same 
centrifugation, and after the final wash, the cells were seeded onto a 25 cm2 or 75 cm2 
tissue culture flask, dependent on cellular concentration of adherent cells. All tissue 
culture cells were maintained at 37°C with 5% CO2 in FBS supplemented complete 
media. At 70-80% confluence, the cells were harvested for subculturing by removal of 
the media, and gently rinsing the cells with 1× phosphate buffered saline (PBS) (Gibco®, 
Life Technologies Inc, Carlsbad, CA, USA). The cells were incubated with cold 0.05% 
Trypsin-0.53 mM ethylenediaminetetraacetic acid (EDTA) (Gibco®, Life Technologies 
Inc, Carlsbad, CA, USA) for 5 min at 37°C with 5% CO2 and gently rocked to detach the 
cells. Pre-warmed complete culture media with FBS was added immediately to the flask 
(1:1) to neutralize the trypsin and collect detached cells. The cells were collected by 
centrifugation at 330 × g, for 5 min at RT and resuspended in completed media with FBS 
and reseeded based on subculture ratio (Table 10).  
For cryopreservation, cell cultures with no exposure to antibiotics, were harvested as 
above and prior to reseeding, an aliquot stained with trypan blue exclusion dye (1:1) 
(Gibco®, Life Technologies Inc, Carlsbad, CA, USA) was counted using a 
haemocytometer. Cells were pelleted as above and resuspended in cold FBS with 10% 
dimethyl sulfoxide (DMSO). Cells were quickly transferred to cryopreservation vials and 
placed at -20°C for 2-3 h (or until frozen) and subsequently stored at -80°C for overnight 
(O/N) or until relocated to liquid nitrogen vapor cryotank for long-term storage.  
The HT-29 cells tested negative for murine pathogens and Mycoplasma spp. using 
Infectious Microbe PCR Amplification Test III (IMPACT III) profiling prior to use in 
animal models (IDEXX BioResearch Laboratories, Westbrook, ME, USA). 
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Table 10. Cell lines and primary cells used within the study 
Cell Description Medium Subculture 
ratio 
Source ATCC No. 
HEK293 Homo sapiens 
(human); Organ: 
embryonic kidney  
cMEM +  
10% FBS 
1:10 J. Madrenas, 
McGill 
University, 
Montreal, QC 
CRL-1573 
HT-29 Homo sapiens 
(human); Organ: 
colon; Disease: 
colorectal 
adenocarcinoma 
cDMEM + 10% 
FBS 
1:5 J. Koropatnick, 
Western 
University, 
London, ON 
HTB-38 
WiDr Homo sapiens 
(human); Organ: 
colon; Disease: 
colorectal 
adenocarcinoma 
cDMEM + 10% 
FBS 
1:5 J. Madrenas, 
McGill 
University, 
Montreal, QC 
CCL-218 
PBMCs Homo sapiens 
(human); Source: 
whole blood 
cRPMI-1640 + 
10% FBS 
N/A Various donors N/A 
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Human peripheral blood mononuclear cells (PBMCs) were prepared from the whole 
blood of healthy donors and isolated by density centrifugation over Ficoll-Paque Plus 
(GE Healthcare Life Sciences, Piscataway, NJ, USA). In brief, heparinized whole blood 
was diluted 1:1 with RPMI-1640 (Gibco®, Life Technologies Inc, Carlsbad, CA, USA), 
layered on top of Ficoll-Paque Plus, and components separated by centrifugation at 910 × 
g (Allegra 6, Beckman Coulter, Brea, CA, USA) for 1 h, with no applied brake for 
deceleration. The buffy coat layer containing the PBMCs was collected and washed 2× 
20 min with RPMI-1640 by centrifugation at 510 × g. PBMCs were diluted in cRPMI-
1640 with 10% heat-inactivated FBS for experimental use and an aliquot stained with 
trypan blue exclusion dye (Gibco®, Life Technologies Inc, Carlsbad, CA, USA) was 
used to quantify cell concentration with a haemocytometer. Reagents and media used for 
isolation were pre-warmed prior to use. PBMCs were cultured within a tissue culture 
flask and maintained at 37°C with 5% CO2. 
2.3 Plasmid isolation 
Plasmid DNA was isolated and purified from 1-2 mL of pelleted E. coli in stationary 
phase (O/N aerobic growth at 37°C) with QIAprep Spin Miniprep Kit (Qiagen, Venlo, 
Limburg, Netherlands) as per manufacturer’s protocol. Plasmid DNA was eluted in 10 
mM Tris·Cl, pH 8.5 and stored at -20°C. For preparation and concentration of plasmids 
for transfection, 6-10 mL of pelleted E. coli in stationary phase was processed for 
purification over a single column and eluted in 20-30 µl 10 mM Tris·Cl, pH 8.5. All 
plasmids generated within this study are listed in Table 11. 
2.4 DNA visualization and quantification 
DNA was visualized on 0.8%, 1%, or 1.2% UltraPure™ Agarose (Invitrogen, Life 
Technologies Inc, Carlsbad, CA, USA) in 1×TAE dependent on desired resolution. 
Electrophoresis was performed for 1 h at 100 V (Bio-Rad Laboratories Inc, Hercules, CA, 
USA) of DNA samples, containing loading dye, followed by staining with ethidium 
bromide (EtBr) solution for visualization under ultraviolet light (Gel Doc™, Bio-Rad 
Laboratories Inc, Hercules, CA, USA). For size determination, experimental DNA was 
compared to 1 Kb Plus DNA Ladder (Invitrogen, Life Technologies Inc, Carlsbad, CA, 
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Table 11. Plasmid DNA constructs used within this study 
Plasmid name Relevant characteristicsa Source 
pCMV6-XL5  Mammalian expression vector; engineered from pCMV6-
XL5::5t4 by removal of 5t4 with NotI sites; Apr 
This study 
pCMV6-XL5::egfp egfp from pEGFP-N1 inserted into SacI and XbaI sites of 
pCMV6-XL5::5t4 replacing 5t4 gene; Apr 
This study 
pCMV6-XL5::5t4 5t4, human trophoblast glycoprotein (TPBG), transcript variant 
1 inserted into EcoRI and SalI sites of pCMV6-XL5; Apr 
Origene 
Technologies 
pEGFP-N1 Mammalian expression vector with N-terminal egfp tag; Kmr Clontech 
Technologies 
pEGFP-N1::5t4 5t4 from pCMV6-XL5::5t4 inserted into EcoRI and BamHI 
sites of pEGFP-N1; Kmr 
Dixon (372) 
pET-41a(+)::TEV  Protein expression vector with modified protease cleavage site; 
Kmr  
Rahman et al. (368) 
pET-32a(+)  Protein expression vector; N-terminal TrxA and His6 tags; Apr  Novagen 
pET-32a(+)::TEV  Protein expression vector with modified protease cleavage site; 
Apr  
This study 
pBirAcm pACYC184 with inducible biotin ligase; Cmr Avidity 
pET-41a(+)::TEV:: 
speCWT 
speC inserted into NcoI and BamHI of pET-41a; Kmr Dixon (372) 
pET-41a(+)::TEV:: 
speCWT::biotin 
speC inserted into NcoI and BamHI of pET-41a with a C-
terminal biotin tag; Kmr 
C Herfst 
(unpublished) 
pET-41a(+)::TEV:: 
speCY15A 
speCY15A inserted into NcoI and BamHI of pET-41a; Kmr Rahman et al. (368) 
pET-41a(+)::TEV:: 
speCD203A 
speCD203A inserted into NcoI and BamHI of pET-41a; Kmr Kasper et al. (286) 
pET-41a(+)::TEV:: 
speCD203A::biotin 
speCD203A inserted into NcoI and BamHI of pET-41a with a C-
terminal biotin tag; Kmr 
This study 
pET-41a(+)::TEV:: 
speCY15A/D203A 
speCY15A/D203A inserted into NcoI and BamHI of pET-41a; Kmr This study 
pET-41a(+)::TEV:: 
speCY15A/D203A::biotin 
speCY15A/D203A inserted into NcoI and BamHI of pET-41a with a 
C-terminal biotin tag; Kmr 
This study 
pET-28a(+)::scFv5T4 scFv5T4 inserted into BamHI and EcoRI sites of pET-28a; 
Kmr 
Dixon (372) 
pET-28a(+)::scFv5T4:: 
speCD203A 
scFv5T4 translationally fused with speCD203A with an 
engineered GGP-EcoRI linker; inserted into BamHI and 
HindIII sites of pET-28a; Kmr 
Bastedo (373) 
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pET-28a(+)::scFv5T4:: 
speCY15A/D203A 
scFv5T4 translationally fused with speCY15A/D203A with an 
engineered GGP-EcoRI linker; inserted into BamHI and 
HindIII sites of pET-28a; Kmr 
Bastedo (373) 
pBluescript II SK(+) Standard cloning vector; MCS within lacZ for colorimetric 
screening of insertions; Apr 
Stratagene 
pBluescript::scFv5T4:: 
speCD203A::TEV::biotin 
scFv5T4::speCD203A::TEV::biotin inserted into EcoRV site; Apr This study 
pBluescript::scFv5T4:: 
speCY15A/D203A::TEV::biotin 
scFv5T4::speCY15A/D203A::TEV::biotin inserted into EcoRV site; 
Apr 
This study 
pET-28a(+)::scFv5T4:: 
speCD203A::TEV::biotin 
scFv5T4 translationally fused with speCD203A with an 
engineered GGP-EcoRI linker; inserted into NcoI and HindIII 
sites of pET-28a; C-terminal biotin tag; Kmr 
This study 
pET-28a(+)::scFv5T4:: 
speCY15A/D203A::TEV::biotin 
scFv5T4 translationally fused with speCY15A/D203A with an 
engineered GGP-EcoRI linker; inserted into NcoI and HindIII 
sites of pET-28a; C-terminal biotin tag; Kmr 
This study 
pUC57::scFv5T4:: 
TEV::biotin 
Murine codon optimized scFv5T4 sequence with NcoI and 
HindIII sites; C-terminal biotin tag; Apr 
GenScript Corp  
pET-28a(+)::scFv5T4:: 
TEV::biotin 
Murine scFv5T4 inserted into NcoI and EcoRI sites of pET-
28a; C-terminal biotin tag; Kmr 
This study 
pET-28a(+)::scFv5T4:: 
speCD203A::TEV::biotin 
Murine scFv5T4 translationally fused with speCD203A with an 
engineered GGP-EcoRI linker; inserted into NcoI and HindIII 
sites of pET-28a; C-terminal biotin tag; Kmr 
This study 
pET-28a(+)::scFv5T4:: 
speCY15A/D203A::TEV::biotin 
Murine scFv5T4 translationally fused with speCY15A/D203A with 
an engineered GGP-EcoRI linker; inserted into NcoI and 
HindIII sites of pET-28a; C-terminal biotin tag; Kmr 
This study 
pET-32a(+)::scFv5T4:: 
TEV::biotin 
Murine scFv5T4 inserted into NcoI and EcoRI sites of pET-
32a; C-terminal biotin tag; Apr 
This study 
pET-32a(+)::scFv5T4:: 
speCD203A::TEV::biotin 
Murine scFv5T4 translationally fused with speCD203A with an 
engineered GGP-EcoRI linker; inserted into NcoI and HindIII 
sites of pET-32a; C-terminal biotin tag; Apr 
This study 
pET-32a(+)::scFv5T4:: 
speCY15A/D203A::TEV::biotin 
Murine scFv5T4 translationally fused with speCY15A/D203A with 
an engineered GGP-EcoRI linker; inserted into NcoI and 
HindIII sites of pET-32a; C-terminal biotin tag; Apr 
This study 
pUC57::scFv5T4H:: 
TEV::biotin 
Humanized, codon optimized scFv5T4 sequence with NcoI and 
HindIII sites; C-terminal biotin tag; Apr 
GenScript Corp  
pMSP3535::mRFP1 mRFP1 inserted into BamHI and SpeI sites of pMSP3535 
shuttle vector; Ermr 
McCormick 
(unpublished) 
pET-32a(+)::scFv5T4H:: 
mRFP1 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; mRFP1 from 
pMSP3535::mRFP1 inserted into EcoRI and HindIII sites 
replacing biotin tag and fused to scFv5T4 with GGP linker; 
Apr 
This study 
  
76 
pET-32a(+)::scFv5T4H:: 
TEV::biotin 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; C-terminal biotin tag; 
Apr 
This study 
pET-32a(+)::scFv5T4H:: 
speCD203A::TEV::biotin 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; translationally fused 
with speCD203A with an engineered GGP-EcoRI linker; C-
terminal biotin tag; Apr 
This study 
pET-32a(+)::scFv5T4H:: 
speCY15A/D203A::TEV::biotin 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; translationally fused 
with speCY15A/D203A with an engineered gly-gly-pro 
(GGP)/EcoRI linker; C-terminal biotin tag; Apr 
This study 
pET-32a(+)::TEV:: 
scFv5T4H::EK::biotin 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; C-terminal EK 
protease site modified site Apr 
This study 
pET-32a(+)::TEV:: 
scFv5T4H::speCD203A:: 
EK::biotin 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; translationally fused 
with speCD203A with an engineered GGP-EcoRI linker; C-
terminal biotin tag with modified EK protease cleavage site; 
Apr 
This study 
pET-32a(+)::TEV:: 
scFv5T4H::speCY15A/D203A::EK
::biotin 
Humanized scFv5T4 from pUC57::scFv5T4::biotin inserted 
into NcoI and HindIII sites of pET-32a; translationally fused 
with speCY15A/D203A with an engineered GGP-EcoRI linker; C-
terminal biotin tag with modified EK protease cleavage site; 
Apr 
This study 
a Abbreviations: Apr, ampicillin resistance; Cmr, chloramphenicol; Ermr, erythromycin resistance; Kmr, kanamycin 
resistance; GGP, gly-gly-pro; scFv5T4H, humanized scFv5T4
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USA). Buffer and reagent composition is in Table 12. All DNA was quantified, using a 
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific Inc, Waltham, MA USA). 
2.5 DNA gel extraction 
To isolate and purify DNA fragments by gel extraction, digested DNA was separated by 
gel electrophoresis on 0.6% agarose UltraPure™ Agarose (Invitrogen, Life Technologies 
Inc, Carlsbad, CA, USA) in 1×TAE for 1 h at 100 V (Bio-Rad Laboratories Inc, Hercules, 
CA, USA) and stained with EtBr solution. Desired fragments were excised under 
ultraviolet light and purified using QIAquick Gel Extraction Kit (Qiagen, Venlo, Limburg, 
Netherlands) as per manufacturer’s protocol and eluted in 10 mM Tris·Cl, pH 8.5. 
2.6 Ethanol precipitation 
Concentration of plasmid DNA for transfection purposes was performed by adding 1/10 
volume of cold (4°C) 3 M sodium acetate to the DNA sample followed by 2× volume of 
cold (-20°C) 95% EtOH. The DNA was incubated at -20°C for 25 min and pelleted by 
centrifugation at 21 000 × g for 10 min at 4°C. The pellet was washed by inversion with 
0.75 mL cold (-20°C) 70% EtOH and centrifugation repeated for 5 min. EtOH was 
decanted and remaining evaporated for ~25 min prior to pellet resuspension in a low 
volume (10-15 µl) of 10 mM Tris·Cl, pH 8.5.  
2.7 Primer generation 
Primers were designed using the software Primer3Plus Version: 2.3.6 (374) and 
synthesized by Sigma Life Sciences (St. Louis, MO, USA). Primers were rehydrated as 
master stocks as 100 µM and diluted 1:10 for working stocks, both in sterile Milli-Q 
water (Millipore, Bedford, MA, USA).  Primers used within the study listed in Table 13. 
2.8 Polymerase chain reaction 
Polymerase chain reaction (PCR) products were amplified (Peltier Thermocycler PTC-
200, MJ Research, Waltham, MA, USA) with reactions containing 0.3 mM 
deoxyribonucleotide triphosphates (dNTPs; Roche Diagnostics, Basel, Switzerland), 
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Table 12. Buffer composition and reagents used within the study 
Reagent Composition  Application 
Coomassie Blue 
staining solution  
45% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.1% 
(w/v) Coomassie Brilliant Blue R-250 
Protein visualization 
Destain solution 45% (v/v) methanol, 10% (v/v) glacial acetic acid Protein visualization 
DNA loading dye 
(6×) 
40% (v/v) glycerol, 0.25% (w/v) bromophenol blue DNA visualization 
FACS Buffer 2% FBS, 0.01% sodium azide in 1×PBS FACS 
HEPES Buffer (1×) 150 mM NaCl, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.4 
Protein purification 
Laemmeli buffer 
(4×) 
240 mM Tris pH 6.8, 8% (w/v) SDS, 40% (v/v) 
glycerol, 0.01% (w/v) bromophenol blue, 1% (v/v) β-
mercaptoethanol 
Protein visualization 
PBS (1×) 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM 
KH2PO4, pH 7.4 
Various 
PBST (1×) 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM 
KH2PO4, 0.1% (v/v) Tween-20 
Various 
PFU Buffer (1×) 20 mM Tris-HCl (pH 8.8), 10 mM (NH4)2SO4, 10 mM 
KCl, 0.1% (v/v) Triton X-100, 0.1 mg mL-1 BSA, 2 mM 
MgSO4 
Molecular cloning: PCR 
Polyacrylamide 
resolving gel (12%) 
12% (v/v) acrylamide/bisacrylamide (37.5:1) aqueous 
solution, 0.25% (v/v) 1.5 M Tris-HCl pH 8.8, 0.1% 
(w/v) SDS, 0.1% (w/v) APS, 0.15% (v/v) TEMED 
Protein visualization 
Polyacrylamide 
stacking gel (5%) 
1.3% SDS, 25% v/v 0.5 M Tris-HCl pH 6.8, 5% v/v 
acrylamide/bisacrylamide (37.5:1) aqueous solution, 
0.1% (w/v) APS, 0.2% (v/v) TEMED 
Protein visualization 
PSI broth 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% 
(w/v) MgSO4, pH 7.6 
Chemical competent cells 
TAE (1×) 40 mM Tris-acetate, 1 mM EDTA, pH 8.0 DNA visualization 
TBS  50 mM Tris-HCl pH 7.6, 150 mM NaCl  Histology 
TBST (1×) 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 2.5% Tween-
20 
Histology 
TfbI solution 100 mM RbCl2, 50 mM MnCl2·4H2O, 30 mM 
CH3COOK, 10 mM CaCl2, 15% (v/v) glycerol, pH 5.8 
Chemical competent cells 
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TfbII solution 75 mM CaCl2, 10 mM C7H15NO4S (MOPS), 10 mM 
RbCl2, 15% (v/v) glycerol, pH 6.5 
Chemical competent cells 
Tris-Glycine 
Running buffer 
(1×) 
192 mM glycine, 25 mM Tris, 0.1% (w/v) SDS, pH 8.3-
8.6 
Protein visualization 
Western Blot 
Transfer Buffer 
20% methanol, 48 mM Tris base, 39 mM glycine, 
0.037% (w/v) SDS 
Protein visualization 
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Table 13. Primer oligonucleotides used for molecular cloning procedures and 
sequencing 
Primer name Sequence (5’ - 3’)a Restriction enzyme site 
T7 promoter TAA TAC GAC TCA CTA TAG GG n/a 
T7 terminator  GCT AGT TAT TGC TCA GCG G n/a 
M13/pUC Forward  CGC CAG GGT TTT CCC AGT CAC GAC n/a 
M13/pUC Reverse  TCA CAC AGG AAA CAG CTA TGA C n/a 
SpeC For NcoI GCG CCC ATG GGA GGA GGG CCG GAC TCT AAG 
AAA GAC ATT TCG 
NcoI 
SpeC D203A Rev 
BamHI 
GCG CGG ATC CTT ATT TTT CAA GAT AAA TAG CGA 
AAT G 
BamHI 
scFv5T4 For BspHI CCC TCA TGA TAG AGG TCC AGC TTC AGC AGT C BspHI 
SpeC D203A Rev 
HindIII Biotin 
CCC AAG CTT TTA TTC GTG CCA TTC GAT TTT CTG 
AGC CCT CGA AGA TGT CGT TCA GAC GCG CAC 
CAC TTT TGG AAA TAC AAG TTT TCT TTT TCA AAG 
ATA AAT AGC GAA ATG 
HindIII 
mRFP1-GGP For 
EcoRI 
CCC GAA TTC GGA GGC CCG ATG GCC TCC TCC 
GAG G  
EcoRI 
mRFP1 Rev HindIII CCC AAG CTT TTA GGC GCC GGT GGA GT HindIII 
scFv5T4 TEV For CGC AGA TCT GGA AAA CTT GTA TTT CCA AAG TGC 
CAT GGA AGT GCA GCT GGT 
BglII 
scFv5T4 EK Biotin 
Rev 
CGC AAG CTT TTA TTC GTG CCA TTC GAT TTT CTG 
AGC CTC GAA GAT GTC GTT CAG ACC GCC ACC CTT 
GTC GTC GTC GTC GAA TTC TTT GAT TTC CAG TTT 
CG 
HindIII 
SpeC D203A EK 
Biotin Rev 
CGC AAG CTT TTA TTC GTG CCA TTC GAT TTT CTG 
AGC CTC GAA GAT GTC GTT CAG ACC GCC ACC CTT 
GTC GTC GTC GTC TTT TTC AAG ATA AAT AGC GAA 
ATG A 
HindIII 
a Underlined nucleotides represent restriction enzyme recognition site
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5 mM MgSO4, 1 µM oligonucleotide primers, 1×PFU buffer, 1 µl template DNA and 
1:100 Pfu polymerase (generated internally, unpublished). Oligonucleotides (Sigma 
Genosys, St. Louis, MO, USA) are listed in Table 13. Amplification was performed with 
the following standard conditions: initial denature at 95°C for 5 min followed by repeated 
cycles (36×) of denaturing at 95°C for 1 min, annealing with primer-specific temperature 
for 30 sec [as designed with Primer3.0 Plus software (374)], and extension at 74°C at 1 
kb min-1, with final extension at 74°C for 5 min and maintained at 4°C until further 
processing. PCR products were purified with QIAquick PCR Purification kit (Qiagen, 
Venlo, Limburg, Netherlands) as per manufacturer’s protocol and eluted in 10 mM 
Tris·Cl, pH 8.5. 
2.9 Sequencing 
All plasmid DNA inserts were sequenced at the DNA Sequencing Facility at Robarts 
Research Institute (Western University, London, ON, Canada) using standard T7 
promoter and T7 terminator primers, or specifically designed primers, all listed in Table 
13. DNA concentrations and primers were prepared as per requirements of the DNA 
Sequencing Facility.  
2.10 Molecular cloning  
2.10.1 Restriction digestions 
Restriction enzyme digestion of DNA was performed as per manufacturer’s 
specifications (New England BioLabs Inc, Ipswich, MA, USA or Roche Diagnostics, 
Basel, Switzerland). In brief, for the specific restriction enzymes used within this study, a 
digestion reaction containing target DNA, 1 U enzyme µg-1 DNA, 1× enzyme-specific 
buffer and if required, 1× bovine serum albumin (BSA) (New England BioLabs Inc, 
Ipswich, MA, USA), was incubated for 1-2 h in a 37°C water bath. Double digestion 
completion was compared to single digestion controls by visualization on a 1% agarose 
gel as above and subsequently purified with QIAquick PCR Purification kit (Qiagen, 
Venlo, Limburg, Netherlands) as per manufacturer’s protocol with final elution in 10 mM 
Tris·Cl, pH 8.5. 
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2.10.2 DNA ligations 
Ligations of DNA were performed for 1 h in a water bath at 16°C with reactions 
containing 40 U T4 DNA Ligase (New England BioLabs Inc, Ipswich, MA, USA), 1× T4 
Ligase Buffer (New England BioLabs Inc, Ipswich, MA, USA), and appropriate 
concentrations of digested vector and insert. A standard reaction had ~100 ng total vector 
DNA and ~1 µg total insert DNA, calculated from a molar ratio of either 1:1 or 3:1 
(insert:vector), based on the size variation of the insert compared to the vector.  Blunt-end 
ligations used a molar ratio of 5:1 (insert:vector). 
2.10.3 Competent cell preparation 
2.10.3.1 Chemical competent E. coli preparation (rubidium chloride; RbCl) 
E. coli strains were inoculated 1:100 from stationary phase (O/N growth at 37°C) into 
PSI broth and grown aerobically at 37°C to optical density (OD)600 = 0.5. Cells were 
incubated on ice for 15 min prior to centrifugation at 2400 × g for 5 min at 4°C (Beckman 
Avanti® J-25 High Speed Centrifuge, Beckman Coulter, Brea, CA, USA). Cell pellets 
were gently resuspended and incubated for 15 min on ice in 0.4× original volume of TfbI 
solution. After repeated centrifugation, cells were resuspended in 0.04× original volume 
of TfbII solution and incubated 15 min on ice prior to aliquoting and immediate -80°C 
storage. Buffer and reagent composition are listed in Table 12. 
2.10.3.2 Chemical competent E. coli preparation (calcium chloride; CaCl2) 
E. coli strains were inoculated 1:100 from stationary phase (O/N growth at 37°C) into LB 
broth and grown aerobically at 37°C to OD600 = 0.5. Cells were incubated on ice for 10 
min prior to centrifugation at 4000 × g for 5 min at 4°C (Beckman Avanti® J-25 High 
Speed Centrifuge, Beckman Coulter, Brea, CA, USA). Cell pellets were gently 
resuspended in 10 mL of cold 0.1 M CaCl2 and incubated for 20 min on ice. After 
repeated centrifugation, cells were gently resuspended in 5 mL cold 0.1 M CaCl2 with 
15% (v/v) glycerol and aliquoted for immediate use or -80°C storage.  
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2.10.3.3 Electrocompetent E. coli preparation 
Electrocompetent cells were prepared with E. coli from stationary phase (O/N growth at 
37°C) by subculturing 1:500 into LB media (5 mL) with appropriate antibiotics and 
grown for 3 h at 37°C, with shaking. The cells were pelleted by centrifugation at 2100 × 
g for 5 min at 4°C and pellet resuspended in 5 mL ice cold 10% glycerol. Centrifugation 
was repeated and the pellet was resuspended in 1 mL ice cold 10% glycerol followed by a 
final centrifugation and resuspension in 0.2 mL ice cold 10% glycerol. Cells were 
aliquoted into 0.1 mL fractions and immediately used for transformation or placed          
at -80°C for storage. 
2.10.4 Transformation and transfection 
2.10.4.1 Chemical competent E. coli transformation  
To transform chemical competent E. coli, the ligation reaction (~10 µL) was added to the 
cell aliquot once thawed on ice, and incubated for 30 min remaining on ice. The cells 
were incubated at 42°C for 45 sec (RbCl2-competent cells) or 2 min (CaCl2-competent 
cells) for heat shock and subsequently placed on ice for 2 min.  LB culture media (0.9 
mL) was added to the cells prior to incubation for 1 h at 37°C with shaking. The 
transformation was cultured by spread plating (200 µL per plate) on LB Agar with 
appropriate antibiotics and grown O/N (18-24 h) at 37°C.  
2.10.4.2 Electroporation of E. coli  
Plasmid DNA (1 µL) was added to electrocompetent E. coli, prepared as described, and 
incubated on ice for 3 min. Samples were loaded into 0.2 cm electroporation cuvettes 
(VWR, Radnor, PA, USA) and pulsed at 200 Ω, 25 µF, 2.5 kV for 5 ms (Gene Pulser 
Xcell™ System, Bio-Rad Laboratories Inc, Hercules, CA, USA). The cells were 
immediately resuspended in 1 mL of LB culture media and incubated for 1 h at 37°C with 
shaking. The transformation was cultured by spread plating dilution series from 10-1-10-3 
on LB Agar with appropriate antibiotics and grown O/N (18-24 h) at 37°C. 
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2.10.4.3 Cellular transfections for gene expression 
HEK293 cells were seeded as required into multi-well tissue culture plates (Corning Inc, 
Corning, NY, USA) with cMEM + 10% FBS and allowed to grow O/N (18-24 h) at 37°C 
with 5% CO2. Liposome:DNA complexes were formed using Lipofectamine® 2000 (Life 
Technologies Inc, Carlsbad, CA, USA) and plasmid DNA of choice, as per 
manufacturer’s protocol at a ratio of 2 µl lipofectamine:0.8 µg DNA. In brief, complexes 
were formed in cMEM without FBS or antibiotics. Transfection of cells occurred in the 
same media for 4 h at 37°C with 5% CO2, after which the media was removed and 
replaced with cMEM + 10% FBS for plasmid expression over 24 h.  
2.10.5 E. coli clone selection   
Clones were screened for successful DNA ligation and transformation by selecting 
individual colonies that were subsequently grown O/N and plasmid isolation performed. 
Plasmids were visualized for band shifts on 1% agarose gels as described, as well as the 
insert size verified by restriction enzyme digestion and DNA sequencing performed for 
final sequence confirmation. Alternatively, DNA screening was performed by colony 
PCR. Individual colonies were inoculated into single PCR tubes by a sterile toothpick and 
the reaction buffer (as described) containing T7 forward and T7 terminator primers added. 
Amplification was performed with the following standard conditions: initial denaturing at 
95°C for 10 min followed by repeated cycles (36×) of denaturing at 95°C for 30 sec, 
annealing with primer-specific temperature 63°C for 30 sec, extension at 74°C at 1 kb 
min-1, and maintained at 4°C until further processing. PCR products were visualized by 
electrophoresis and staining with EtBr as described. 
2.11 Generation of protein expression vectors 
Using standard molecular cloning techniques, protein expression clones in pET-41a were 
altered such that the enterokinase (EK) cleavage site (DDDDK↓X), was replaced with a 
Tobacco Etch Virus (TEV) protease cleavage site (ENLYFQ↓S) (368). To enable biotin 
labeling of proteins, a protease cleavable C-terminal biotin ligase recognition sequence 
(biotin tag) (GLNDIFEAQKIEWHE; AviTag™, Avidity LLC, Aurora, CO, USA) 
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containing a 5’ gly-gly spacer was genetically engineered onto genetic constructs within 
the reverse cloning primers (Table 13). All constructs were transformed into both E. coli 
XL1 Blue for plasmid preservation and E. coli BL21 (DE3) or Origami B (DE3) for 
protein expression (Table 11). 
2.12 Generation of SpeC protein expression clones and variants 
Plasmid constructs containing speCWT  (372), speCY15A (368) and speCD203A (286) for 
expression within pET-41a were previously described. In this study, speCY15A/D203A for 
protein expression was generated. The 627 bp gene was amplified by standard PCR with 
an annealing temperature of 55°C from a previously generated construct containing 
speCY15A/D203A (373) using primers in Table 13. The resulting PCR product was cloned 
into pET-41a::TEV for protein expression using standard molecular cloning techniques as 
described and transformed into E. coli BL21 (DE3). 
2.13 Generation of murine scFv5T4 and linked SpeC variants for protein expression 
Expression pET-28a constructs containing murine scFv5T4 alone (372) or genetically 
linked speCD203A or speCY15A/D203A (373) were previously generated. In this study, the 
linked constructs were developed further to include a C-terminal biotin tag, as described, 
which was added by standard PCR amplification with an annealing temperature of 50°C. 
Primers used are listed in Table 13. The resulting 1443 bp product was initially generated 
within pBluescript II SK (+) as an intermediate step with blunt-end ligation and 
subsequently by standard cloning techniques, into pET-28a for protein expression. For 
further product development, the murine scFv5T4 alone was designed to contain a C-
terminal biotin tag and codon optimized for expression in E. coli. The 798 bp gene was 
manufactured by GenScript Corp (Piscataway, NJ, USA) and cloned by restriction 
enzyme digestion and standard techniques into pET-28a as well as pET-32a, an 
expression vector containing N-terminal thioredoxin (TrxA) and His6 tags. The 
synthesized scFv5T4 was genetically linked to previously constructed speCD203A or 
speCY15A/D203A with existing biotin tags by standard cloning methods and transformed into 
either E. coli BL21 (DE3) or Origami B (DE3) for co-expression with pBirAcm.  
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2.14 Design and generation of humanized scFv5T4 construct for protein expression 
The humanized scFv was designed in this study based on the predicted CDRs of the 
characterized murine scFv specific for the human 5T4 TAA (243). The cDNA sequence 
for a humanized scFv5T4 was recoded for E. coli expression and manufactured by 
GenScript Inc (Piscataway, NJ, USA). Amino acid substitutions were made in the 
backbone sequence of scFv5T4 from the original murine sequence (243), determined by 
aligning with a human consensus sequence. The consensus sequence was generated from 
10 previously sequenced human scFv fragments taken from NCBI Protein Database 
(www.ncbi.nlm.nih.gov/protein) and aligned using MacVector (MacVector Inc, Cary, NC, 
USA). The CDR loops specific for 5T4, and the immediate amino acids flanking the 
predicted loops were not altered to maintain antibody structure and specificity. Amino 
acids within the CDRs were determined based on predicted topological modeling using 
PyMol Software (Schrödinger, New York, NY, USA) of scFv5T4 with the structure 
modeled from human 80R scFv (PDB 2GHW22) (375)  with 75.9 sequence identity by 
SWISS-MODEL (www.swissmodel.expasy.org). Lastly, the gene was also designed to 
include a TEV cleavable C-terminal biotin tag as well as restriction enzyme sites for 
strategic cloning purposes. The synthesized 819 bp gene was cloned by restriction 
enzyme digestion using standard techniques into pET-32a for protein expression. The 
final construct development was to arrange the protease cleavage sites so that the TEV 
recognition site was N-terminal for TrxA and His6 removal and the EK recognition site 
was C-terminal for removal of the biotin tag. The construct was amplified by PCR, with 
an annealing temperature of 65°C. The primers used are listed in Table 13. The resulting 
product for scFv5T4 was cloned by standard molecular techniques into pET-32a for 
protein expression in either E. coli BL21 (DE3) or Origami B (DE3) for co-expression 
with pBirAcm. 
2.15 Generation of humanized scFv5T4 linked mRFP1 
mRFP1 was amplified by standard PCR with an annealing temperature of 58°C from 
previously generated shuttle vector pMSP3535::mRFP1 (Table 11). The resulting 687 bp 
product, containing a GGP linker was translationally fused to humanized scFv5T4 by 
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standard molecular cloning procedures within pET-32a vector. The final construct was 
transformed into E. coli BL21 (DE3) for protein expression. Primers are listed within 
Table 13. 
2.16 Generation of humanized scFv5T4 linked SpeC variants  
Humanized scFv5T4 from the pUC57::scFv5T4 construct was genetically linked with 
previously biotin-tagged speCD203A or speCY15A/D203A by restriction enzyme digestion and 
standard molecular cloning techniques into pET-32a to generate protein expression 
constructs. The final constructs were amplified by PCR, with an annealing temperature of 
65°C to arrange the protease cleavage sites so that the TEV recognition site was N-
terminal for TrxA and His6 removal and the EK recognition site was C-terminal for 
removal of the biotin tag. Primers used are listed in Table 13. The resulting 1443 bp 
products were cloned into pET-32a and were transformed for co-expression with 
pBirAcm in E. coli BL21 (DE3) or Origami B (DE3).  
2.17 Generation of transfection plasmids for human cell lines 
Transfection vectors pCMV6-XL5::5t4 and pEGFP-N1 were purchased from Origene 
Technologies, Inc. (Rockville, MD, USA), and Clontech Laboratories, Inc. (Mountain 
View, CA, USA), respectively. pEGFP-N1::5t4 engineered to genetically link 5t4 to 
eGFP  was previously generated (372). In this study, control vehicle pCMV6-XL5 was 
generated by removal of 5t4 from pCMV6-XL5::5t4 by restriction enzyme digestion and 
the remaining fragment purified from gel electrophoresis and ligated to complete the 
vector. Transfection control vector pCMV6-XL5::eGFP was generated by the 
replacement of 5t4 of pCMV6-XL5::5t4 with eGFP from pEGFP-N1 (replicated in E. 
coli SCS110) by restriction enzyme digestion and standard molecular techniques. The 
resulting constructs (Table 11) were transformed into E. coli XL1 Blue. 
2.18 Protein visualization 
2.18.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
To visualize proteins, 1-D vertical gel electrophoresis was performed for 50 min at 200 V 
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(Mini-PROTEAN System, Bio-Rad Laboratories Inc, Hercules, CA, USA) using 12% 
polyacrylamide resolving gels with 5% stacking gels in Tris-Glycine Running Buffer. 
Prior to electrophoresis, samples were mixed 3:1 with 4× Laemmli buffer and boiled for 
5 min. Gels were fixed and stained for 1 h with coomassie blue staining solution 
containing Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories Inc, Hercules, CA, 
USA) followed by replacing destain solution several times until background of the gel 
was resolved. For size determination, experimental proteins were compared to Prestained 
Broad Range P7708S Protein Marker (New England BioLabs Inc, Ipswich, MA, USA). 
Buffer and reagent composition are listed in Table 12. 
2.18.2 Western Blot 
To probe specific proteins, samples were separated by gel electrophoresis by SDS-PAGE 
on 12% polyacrylamide resolving gels as described, without end-stage staining. To 
immobilize proteins for detection, the samples were transferred from the gel matrix to an 
Immobilon-FL polyvinylidene difluoride (PVDF) membrane (EMD Millipore, Billerica, 
MA, USA) by electroblotting (Mini Trans-Blot® Cell, Bio-Rad Laboratories Inc, 
Hercules, CA, USA) for 1 h at 100 V (or 25 V O/N). Prior to transfer, the membrane was 
immersed for 5 min in methanol (100%) and equilibrated in Western blot transfer buffer. 
After transfer, to reduce non-specific binding, the membrane was blocked for 0.5 h with 
5% (w/v) non-fat dry milk in 1×PBS. For specific protein detection the biotinylated tag 
was probed for 1 h with conjugated streptavidin-IRDye800 (1:10 000 in 1×PBS with 1% 
[w/v] non-fat dry milk). The membrane was washed 3× 15 min with 1×PBST prior to 
viewing with LI-COR Odyssey® Infrared Imaging System (LI-COR, Lincoln, NE, USA). 
All incubations had slight agitation. Buffer and reagent composition are located in Table 
12.  
2.19 Protein expression and purification 
Recombinant proteins were produced using an E. coli BL21 (DE3) or Origami B (DE3) 
expression system. For biotinylation of proteins, the E. coli was engineered by bacterial 
transformation to contain pBirAcm, an IPTG inducible plasmid containing the birA gene 
encoding biotin ligase. Cells were grown aerobically, with shaking, at 37°C in LB 
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medium with the appropriate antibiotics to OD600 = 0.5. For the final constructs, protein 
expression was induced O/N (18-24 h) at RT with 0.2 mM IPTG (Bio Basic Inc, 
Markham, ON, Canada) and biotinylated with the addition of 50 µM D-biotin (Bio Basic 
Inc, Markham, ON, Canada). Cells were pelleted at 4°C, 7000 × g for 5 min and 
resuspended in cold 20 mM Tris-HCl, pH 7.4, 200 mM NaCl (or 1×HEPES Buffer for 
SAg alone) containing 0.25 mg mL-1 lysozyme (Sigma-Aldrich, St. Louis, MO, USA) 
and 0.02 mg mL-1 DNaseI (Sigma-Aldrich, St. Louis, MO, USA). Cells were incubated 
on ice for 1 h prior to lysis with a continuous head flow cell disruptor (Constant Systems 
Ltd, Daventry, United Kingdom) at 25 psi, followed by sonication with output 4, using 1 
pulse per mL of sample. Cellular debris was pelleted at 4°C, 10 000 × g for 10 min. 
Supernatants were applied to a charged (100 mM NiSO4) Ni-NTA affinity column 
(Novagen, EMD Millipore, Billerica, MA, USA), washed with buffer and eluted with 
increasing concentration of imidazole (5 mL each of 15 mM, 30 mM, 60 mM, and 200 
mM imidazole in 20 mM Tris-HCl, pH 7.4, 200 mM NaCl or 1×HEPES Buffer). Purified 
fractions were dialyzed 3× against the respective buffer and the N-terminal tags cleaved 
by autoinactivation-resistant His7::TEV (376) as previously described (377) with O/N  
(18-24 h) incubation at RT. Cleaved proteins were applied and eluted as described from a 
second Ni-NTA affinity column to remove TEV protease and obtain a pure protein. 
Proteins were dialyzed 3× against the respective buffer or 0.9% NaCl (saline), assessed 
for homogeneity and purity by SDS-PAGE, and quantified with Pierce™ BCA Protein 
Assay Kit (Thermo Fisher Scientific Inc, Waltham, MA, USA) using manufacturer’s 
instructions. In brief, protein aliquots were mixed with the kit formulation, based on 
bicinchoninic acid (BCA), for colorimetric detection of protein complexes at absorbance 
562 nm (Bio-Rad Microplate Reader 680, Bio-Rad Laboratories Inc, Hercules, CA, USA). 
The protein quantification was reported with reference to a common protein standard, 
BSA. 
2.20 Binding detection of humanized scFv5T4 to 5T4 antigen 
HT-29 (1.0×106) or transfected HEK293 cells (1.0×106) containing either pCMV6-XL5 
or pCMV6-XL5::5T4, were incubated for 1 h at RT with either anti-human mAb5T4 
(1:200; ab88091, Abcam, Cambridge, United Kingdom) or scFv5T4-biotin (1:100; 2 mg 
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mL-1), washed with 1×PBS followed by incubation with fluorescein isothiocyanate 
(FITC) anti-mouse IgG (1:1000; eBioscience, San Diego, CA, USA) or streptavidin-
FITC (1:1000; Rockland Immunochemiclas Inc, Pottstown, PA, USA), respectively, for 1 
h at 4°C. Cells were washed and either assessed with fluorescence-activated cell sorting 
(FACS) (BD FACSCanto II, BD Biosciences, Franklin Lakes, NJ, USA) or viewed with 
fluorescence microscopy (Olympus IX71 Inverted Micropscope, Olympus Canada Inc, 
Richmond Hill, ON, Canada). For FACS analysis, mouse IgG2bκ isotype control was 
also included (1:200, eBioscience, San Diego, CA, USA). Alternatively, transfected 
HEK293 cells were incubated with anti-human mAb5T4 (1:200, Clone EPR5529; Abcam, 
Cambridge, United Kingdom) in conjunction with scFv5T4-biotin (1:100; 2 mg mL-1), 
for 1 h at RT, followed by tetramethylrhodamine (TRITC) anti-rabbit IgG (1:1000; 
Jackson ImmunoResearch Labs, West Grove, PA, USA) and streptavidin-FITC (1:1000; 
Rockland Immunochemiclas Inc, Pottstown, PA, USA), for 1 h at 4°C, washed and 
viewed for co-staining by fluorescence microscopy (Olympus IX71 Inverted Microscope, 
Olympus Canada Inc, Richmond Hill, ON, Canada). Lastly, HEK293 cells, transfected 
for expression of either pEGFP-N1::5T4 or vehicle pEGFP-N1, were incubated with 
scFv5T4::mRFP1 (1:100; 2 mg mL-1) for 1 h at RT and subsequently washed and viewed 
with fluorescence microscopy (Olympus IX71 Inverted Microscope, Olympus Canada 
Inc, Richmond Hill, ON, Canada). All microscopy images were taken using ImagePro 
Plus Software (MediaCybernetics, Rockville, MD, USA) and FACS analysis was 
completed using FlowJo Software (FlowJo, LLC, Ashland, OR, USA). Buffer reagent 
composition is in Table 12 and antibodies and dyes are in Table 14.  
2.21 SpeC-mediated PBMC proliferation 
2.21.1 Radioactive proliferation assay 
Human PBMCs were isolated and prepared as described. PBMCs (2×105) were cultured 
in cRPMI + 10% FBS containing 2 µg mL-1 Polymyxin B (MP Biomedicals, Santa Ana, 
CA, USA) with titrating SpeC variants (10-4-100 µg mL-1), including SpeCWT, 
SpeCY15A/D203A, SpeCD203A, or titrating SpeC variants in addition to scFv5T4, 
scFv5T4::SpeCY15A/D203A or scFv5T4::SpeCD203A (2×10-2 - 2×102 nM) in U-bottom 
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Table 14. Antibodies and dyes used within the study 
Antibody or Dye Clone or Catalog No. Dilution Application Source 
7-AAD A1310 2 µl FACS Molecular Probes, 
Life Technologies 
Alexa Fluor® 488 goat anti-
rabbit IgG (H+L) 
A-11008 1:400-
1:1000 
IHC  Life Technologies 
AlexaFluor700 anti-human 
CD8 
RPA-T8 1:200 FACS BD Pharmingen 
APC anti-human CD3 UCHT1 1:200 FACS BD Pharmingen 
CFSE C34554 10 µM FACS Molecular Probes, 
Life Technologies 
DAPI nuclear stain  B2261 1:1000 IHC Sigma-Aldrich 
FITC rat anti-mouse IgG 11-4011-85 1:1000 FACS/microscopy eBioscience 
mouse anti-human 5T4 ab88091 1:200 FACS/microscopy Abcam 
mouse IgG2bκ Isotype 
Control 
eBMG2b/14-
4732-85 
1:200 FACS eBioscience 
PE anti-human CD4 RPA-T4 1:200 FACS BD Pharmingen 
rabbit anti-CD3  SP7 1:50  IHC Abcam  
rabbit anti-human 5T4 EPR5529 1:200 FACS/microscopy Abcam 
rabbit anti-Ki67  NB500-170  1:20 IHC Novus Biologicals 
rabbit anti-vWF  A0082 1:400 IHC Dako 
Rhodamine (TRITC) goat 
anti-rabbit IgG (H+L) 
111-025-003 1:1000 FACS/microscopy Jackson 
ImmunoResearch 
Labs 
streptavidin-FITC S000-02 1:1000 FACS/microscopy Rockland 
Immunochemicals 
streptavidin-IRDye800 S000-32 1:10 000 Western Blot  Rockland 
Immunochemicals 
TACS® 2 TdT In situ FITC 
Apoptosis Detection Kit 
4812-30-K As per kit IHC Trevigen 
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96-well microplates (BD Biosciences, Franklin Lakes, NJ, USA). Cells were incubated 
for 72 h and subsequently labeled with 3H-thymidine (PerkinElmer, Waltham, MA, USA) 
incorporation for 18 h at 37°C with 5% CO2. Cells were harvested to glass-fiber filters 
and DNA-incorporated 3H-thymidine was measured in a beta scintillation counter 
(Wallac 1450 MicroBeta Counter, PerkinElmer, Wallac Oy, Turku, Finland). 
2.21.2 CFSE proliferation assay 
Human PBMCs were isolated and prepared as described and labeled with CellTrace™ 
carboxyfluorescein succinimidyl ester (CFSE) Cell Proliferation Kit (carboxyfluorescein 
diacetate; Molecular Probes®, Life Technologies Inc, Carlsbad, CA, USA) as per 
manufacturer’s instructions. In brief, cells (10 × 106 mL-1) were suspended in pre-warmed 
RPMI-1640 and labeled with 10 µM CFSE for 10 min in a 37°C water bath, protected 
from light. To stop the reaction, cold cRPMI + 10% FBS was added to the cells and 
incubated on ice for 5 min. Cells were pelleted and resuspended for assay. Cells 
(0.8×106-1.0×106) were cultured in cRPMI + 10% FBS containing 2 µg mL-1 Polymyxin 
B (MP Biomedicals, Santa Ana, CA, USA) and treated with either SpeCWT or variants 
SpeCY15A, SpeCD203A or SpeCY15A/D203A (1 µg mL-1) and incubated for 5 days at 37°C with 
5% CO2 in 5 mL round-bottom polystyrene tubes (BD Falcon™, BD Biosciences, 
Franklin Lakes, NJ, USA). Cells were then washed with FACS buffer by centrifugation 
and stained in the dark with anti-human CD3 (1:200), anti-human CD4 (1:200) and anti-
human CD8 (1:200) antibodies for 30 min on ice. Cells were washed in FACS buffer, 
labeling with 7-aminoactinomycin D (7-AAD; 2 µl sample-1) and analyzed by FACS (BD 
FACSCanto II, BD Biosciences, Franklin Lakes, NJ, USA). FACS analysis was 
completed using FlowJo Software (FlowJo, LLC, Ashland, OR, USA). Buffer and 
reagent composition are listed in Table 12 and antibodies and dyes are listed in Table 14. 
2.22 SpeC-mediated PBMC cytotoxicity assays 
2.22.1 JAM-assay  
Cytotoxicity in vitro was evaluated using the just another method (JAM)-assay (378) by 
labeling WiDr cells (2.5×104) grown O/N (18-24 h) with 3H-thymidine (PerkinElmer, 
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Waltham, MA, USA) for 18 h in flat bottom 96-well microplates (BD Biosciences, 
Franklin Lakes, NJ, USA) at 37°C with 5% CO2 and incubating with isolated human 
PBMCs (as described) at an effector:target cell ratio of 10:1 with titrating SAgs (100-103 
ng mL-1) including SpeCWT, SpeCY15A, and SpeCD203A. Incubation periods in cRPMI + 
10% FBS containing 2 µg mL-1 Polymyxin B (MP Biomedicals, Santa Ana, CA, USA) 
were 24, 48, 72, 96 and 168 h to determine time-response. At each time point, 
supernatants were aspirated, removing PBMCs and any non-adherent (dead) WiDr cells. 
Remaining live cells were washed with 1×PBS and incubated with 0.05% trypsin-EDTA 
(Gibco®, Life Technologies Inc, Carlsbad, CA, USA) for 20 min at 37°C with 5% CO2 
and subsequently harvested to glass-fiber filters. Live cells containing DNA-incorporated 
3H-thymidine were measured in a beta scintillation counter (Wallac 1450 MicroBeta 
Counter, PerkinElmer, Wallac Oy, Turku, Finland). The specific apoptosis was calculated 
according to the formula with counts per minute (CPM) (spontaneous) condition 
equivalent to WiDr incubated with PBMCs alone: 
%  specific  apoptosis  =  CPM(spontaneous)  –  CPM(experimental)CPM(spontaneous)   ×  100%    
2.22.2 Flow cytometry 
Human PBMCs were co-cultured with either WiDr or HT-29 cells previously grown (24-
48 h) on flat well microplates (BD Biosciences, Franklin Lakes, NJ, USA) at a ratio of 
10:1 and titrated SpeC variants for 48 h at 37°C with 5% CO2 in cRPMI + 10% FBS 
containing 2 µg mL-1 Polymyxin B (MP Biomedicals, Santa Ana, CA, USA). Cells were 
harvested and labeled with 7-AAD following the manufacturer’s protocol and analyzed 
by FACS (BD FACSCanto II, BD Biosciences, Franklin Lakes, NJ, USA). Using FlowJo 
software, the WiDr or HT-29 populations were gated upon by comparison of human 
PBMC alone samples and subsequently assessed for presence or absence of 7-AAD. 
Additional experimentation was repeated as above to further include the cytotoxic 
potential of scFv5T4::SpeCD203A, and controls scFv5T4 and scFv5T4::SpeCY15A/D203A.  
2.22.3 51Cr-release assay 
Human PBMCs were treated with SAg, scFv5T4, or fusion proteins as in the FACS assay 
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for 48 h in U-bottom 96-well microplates (BD Biosciences, Franklin Lakes, NJ, USA) at 
37°C with 5% CO2 in cRPMI + 10% FBS containing 2 µg mL-1 Polymyxin B (MP 
Biomedicals, Santa Ana, CA, USA). Target HT-29 cells were labeled with (Na)251CrO4 
(PerkinElmer, Waltham, MA, USA) in cRPMI + 10% FBS. PBMCs were added at 
effector:target cell ratios of either 1:1, 5:1 or 10:1 against HT-29. Cytotoxicity was 
determined after 4–6 h incubation at 37°C with 5% CO2 in a standard chromium release 
assay measuring the 51Cr content of culture supernatants using a gamma-counter (Wallac 
Wizard 1470 Automatic Counter, PerkinElmer, Wallac Oy, Turku, Finland). Total release 
control was obtained by exposing target cells to 1% SDS (EMD Millipore, Billerica, MA, 
USA). The specific lysis was calculated according to the formula: 
%  specific  lysis  =   experimental  release  -­‐  spontaneous  releasetotal  release-­‐spontaneous  release   ×  100% 
2.23 Mouse housing and breeding 
Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were bred and housed in 
an animal barrier facility (Western University, London, ON, Canada) under sterile 
conditions with food and water ad libitum. 
2.24 TTS in vivo tumour-killing model 
Twenty-eight NSG mice, male and female, aged 13 weeks were used throughout the 
experimental timeline. Based on a previously developed protocol (242, 335) mice were 
injected intraperitoneally (ip) with 3×106 HT-29 cells in 0.2 mL vehicle (1×PBS). Three 
weeks later, once tumours were palpable, the mice were injected ip with either vehicle 
alone (n=3) or 1×106 human PBMCs in 0.2 mL vehicle (1×PBS). Two hours after 
receiving PBMCs, 2 µM kg-1 of treatment, controls, or vehicle alone was injected 
intravenously (iv). Mice were grouped (n=4), ensuring weight- and sex-match distrubtion 
(Appendix 6), with a random number generator to receive either scFv5T4::SpeCD203A, 
SpeCD203A, scFv5T4, scFv5T4::SpeCY15A/D203A, or vehicle alone (saline), however 
ensuring an even distribution of male and female animals. Mice with no PBMCs received 
vehicle alone. Intravenous (iv) injections were given daily for 7 additional days. Animals 
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were monitored and weighed every second day until Day 25 of the experiment (injection 
of PBMCs), and then daily until end of experiment (Day 60). Primary tumours were 
measured daily by caliper (height and width) beginning on Day 28 (treatment Day 4) 
until end of experiment (Day 60). Blood was collected prior to treatment and 
subsequently drawn once per week after treatment through the saphenous vein. In brief, 
the animal fur was removed surrounding the vein and Vaseline applied prior to venous 
puncture, and subsequently collecting drops of whole blood (200 µL total) in a microfuge 
tube. Blood was processed by centrifugation for 5 min at 3000 × g and supernatant 
collected for serum and stored at -20°C. Four weeks after the final injection, the mice 
were electively euthanized under anesthetics by exsanguination through cardiac puncture 
for a terminal blood draw and serum was processed as above. The mice were examined 
visually for overall tumour burden and macro-metastases were scored accordingly based 
on the degree of regional spread distant from the primary tumour site. All tumours were 
excised, size- and weight-measured in a blinded fashion and the total tumour volume was 
calculated. Tumour-associated organs, along with all livers and spleens were also 
harvested and all tissues were processed for histological assessment as described. All 
reagents used are listed in Table 12. 
2.25 Histology of in vivo TTS animal model 
2.25.1 Histological tissue processing, embedding, and sectioning  
Tissues were fixed in 10% neutralized formalin buffer (BDH, VWR, Radnor, PA, USA) 
for 48 h at RT, followed by 5× washes with 1×PBS every 12 h with a final wash in 70% 
ethanol. Tissues were dissected as follows: the primary tumours were dissected 
longitudinally, dividing the tumour in half, and embedded so that the internal surface was 
exposed for sectioning. The remaining tumours were dissected on an individual basis, 
with aim to section both tumour with surrounding normal tissue. Livers were dissected 
into respective lobes: median, right, left, and caudal, and embedded as separate tissues. 
Spleens were dissected longitudinally and embedded so that the internal surface was 
exposed for sectioning. Dissected tissues were placed in Fisherbrand™ TRUFLOW™ 
Tissue and Biopsy Cassettes (Fisher Scientific, Whitby, ON, Canada), processed using 
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the ‘brain and bone’ program for paraffin wax treatment in a Leica ASP300 (Leica 
Biosystems, Nussloch, Germany) at the Molecular Pathology Core Facility (Robarts 
Research Institute, Western University, London, ON, Canada) and were embedded with 
proper orientation in paraffin wax. Serial sections (5 µm) of the tissues were cut using 
MB35 Premier Blades (Thermo Scientific, Waltham, MA, USA) on a Leitz 1512 
microtome (Leica Biosystems, Nussloch, Germany) and mounted on Fisherbrand™ 
Superfrost™ Plus microscope slides  (Fisher Scientific, Whitby, ON, Canada). Slides 
were incubated at 37°C for 48 h and either stored or processed for histological staining. 
All reagents used are listed in Table 12. 
2.25.2 Histological staining and immunohistochemistry  
Prior to staining or immunohistochemistry (IHC) analysis, sections were deparaffinized 
and rehydrated using a Leica AutoStainer XL (Leica Biosystems, Concord, ON, Canada) 
at the Molecular Pathology Core Facility (Robarts Research Institute, Western University, 
London, ON, Canada). Sections were stained with hematoxylin and eosin (H&E) using a 
standard protocol within the Leica Autostainer XL (Leica Biosystems, Concord, ON, 
Canada) and sealed with a coverslip using low-viscosity Richard-Allan Scientific® 
Cytoseal™ 60 mounting medium (Thermo Scientific, Waltham, MA, USA). For 
apoptosis detection and IHC staining, all sections of the primary tumours from the TTS 
treatment group (scFv5T4::SpeCD203A) and control group (scFv5T4::SpeCY15A/D203A) were 
used. Specifically, for apoptosis detection, sections were stained with TACS® 2 TdT in 
situ Fluorescein Apoptosis Detection Kit (Trevigen, Gaithersburg, MD, USA) as per the 
manufacturer’s protocol. In brief, slides were washed for 2× 10 min in 1×PBS, followed 
by a 30 min incubation in Cytonin™ permeabilization buffer and a 2× 2 min wash in 
deionized water. Sections were incubated with 1× terminal deoxynucleotidyl transferase 
(TdT) labeling buffer for 5 min prior to addition of labeling reaction consisting of TdT 
dNTP mix, cations (Mg2+, Mn2+, or Co2+), TdT enzyme (TACS-Nuclease™) and TdT 
labeling buffer, incubated for 60 min at 37°C in a humidified chamber. The reaction was 
stopped by addition of 1×TdT stop buffer for 5 min. Slides were washed 2× 2 min in PBS 
followed by 20 min incubation in the dark with Strep-Fluorescein solution. Final washes 
were 3× 2 min in 1×PBS and slides were mounted with VECTASHIELD® Mounting 
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Medium with 4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, 
CA, USA) and sealed with a coverslip. Reagent composition is listed in Table 12. 
Prior to IHC staining, sections were pretreated with Target Retrieval Solution (Dako 
Canada Inc, Burlington, ON, Canada) for 30 min in pre-warmed solution at 95°C within a 
water bath. Slides were allowed to cool within the solution for 20 min prior to rinsing 3× 
with RT TBST buffer. Sections were blocked for 30 min at RT with 10% goat serum in 
TBST. The following primary antibodies were then incubated for 2 h at RT or O/N (18-
20 h) at 4°C on separate sections and slides including, anti-Ki67 (1:20; NB500-170, 
Novus Biologicals, Littleton, CO, USA), anti-vWF (1:400; A0082 Dako Canada Inc, 
Burlington, ON, Canada) or anti-CD3 (1:50; Clone SP7, ab16669, Abcam , Cambridge, 
United Kingdom) in tris-buffered saline (TBS) with 1% goat serum. Each slide had at 
least one negative control where the primary antibody was omitted and instead incubated 
with TBS with 1% goat serum. Sections were washed 3× with TBST for 10 min followed 
by incubation with secondary antibody, Alexa Fluor® 488 goat anti-rabbit IgG (1:1000 in 
TBST with 1% goat serum; Molecular Probes® Life Technologies Inc, Carlsbad, CA, 
USA) for 1 h at RT with further washing 3× with TBST for 10 min. Sections were 
counterstained with DAPI nuclear stain (1:1000, Sigma-Aldrich, St. Louis, MO, USA) in 
TBST for 5 min at RT. Sections were washed prior to application of anti-fade 
fluorescence mounting medium (Dako Canada Inc, Burlington, ON, Canada) and sealed 
with a coverslip. Buffer composition is listed in Table 12 and antibodies are summarized 
in Table 14. 
2.25.3 Histological imaging and evaluation 
H&E sections were imaged with an Aperio ScanScope™ (Leica Biosystems, Concord, 
ON, Canada) for full slide scanning and images taken with Aperio ImageScope Viewing 
Software (Leica Biosystems, Concord, ON, Canada). Images taken for quantification 
purposes were captured by random field of view selection in a blinded fashion of one 
serial section at 400× using an Olympus BX61 fluorescent microscope (Olympus Canada 
Inc, Richmond Hill, ON, Canada) and analyzed by Image-Pro Plus Software 
(MediaCybernetics, Rockville, MD, USA). Images for figure representative purposes 
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were taken using a Zeiss Axio Imager Z1 (Carl Zeiss Canada Ltd, Toronto, ON, Canada) 
and imaged using Zen 2012 Software (Carl Zeiss Canada Ltd, Toronto, ON, Canada). All 
images were taken in same field of view with the same exposure time for each 
fluorescence filter.  
IHC and apoptosis stains were quantified in a blinded-fasion by manually counting the 
positive fluorescence signals on each of the captured 5 high-power field of view images 
(400×) from each animal per treatment group (n=20) and subsequently averaged or index 
calculated. More specifically, von Willebrand factor (vWF)+ blood vessels were 
considered to be a single, countable microvessel when any endothelial cell or cell cluster 
demonstrated antibody staining and was clearly separated from an adjacent cluster. For 
the CD3 stain, any cell showing antibody staining was considered to be a single, 
countable CD3+ cell. For Ki67 and TUNEL, the number of positively stained cells, in 
addition to the number of DAPI positive cells, per same fields of view, were counted. 
Indexes (proliferative index and apoptotic score) were defined by dividing the positive 
stain count by the total number of nuclei in one image and indexes were subsequently 
averaged from each animal. 
2.26 Statistical analysis 
Statistical comparisons were performed using an unpaired Student t test or by 2-way 
ANOVA with Bonferroni multiple comparison test (GraphPad Prism Software, La Jolla, 
CA, USA). Differences were considered significant when p<0.05. 
 CHAPTER 3: RESULTS
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3.1 SpeC mutant generation, expression, and protein purification 
Prior work indicated that Tyr15 was a critical residue for the SpeC SAg to engage the 
TCR (368), and Asp203 was necessary to coordinate a zinc-mediated high-affinity 
interface with the β-chain of MHC II (Figure 6B) (272, 286, 369). Indeed, the single 
Asp203 to Ala mutation in SpeC has been demonstrated to dramatically reduce toxicity in 
a lethal model of toxic shock syndrome (369).  
To supplement the previously generated variants, a double mutant version of SpeC 
containing both alanine substitutions at Tyr15 and Asp203 was generated to create a SpeC 
variant that maintained overall protein structure but was anticipated to be non-functional 
in eliciting an immune response. speCY15A/D203A was amplified by PCR from a previously 
generated construct containing speCY15A/D203A (373) where the forward primer used to 
amplify speC lacked the coding region for the 27-amino acid signal peptide (362). The 
resulting PCR product was cloned into pET-41a::TEV to generate a N-terminal 
translational fusion with glutathione S-transferase (GST) and His6 purification tags, 
cleavable by TEV protease. The resulting genetic product, pET-41a::TEV::speCY15A/D203A 
followed suit with the other translational genetic constructs (Figure 7A) for SpeC protein 
expression.  
To generate and purify SAg proteins, following induced bacterial expression of either 
wild-type SpeC (SpeCWT), SpeCY15A, SpeCD203A, or SpeCY15A/D203A, the cell lysate was 
applied to a nickel resin column and eluted with increasing concentration of imidazole 
with the desired protein verified at the anticipated molecular weight of 59 kDa (Figure 
7B). The purification tags were removed with autoinactivation-resistent His7::TEV as 
described (368) (Figure 7C) and purified SpeC was eluted in low imidazole 
concentrations. Protein containing fractions were confirmed with the expected 25 kDa 
size (Figure 7D) and after buffer exchange, resulted in purified SpeC protein (Figure 
7E). 
  
101 
 
Figure 7. Overview of recombinant SpeC SAg protein expression and purification 
A) Schematic representation of a speC genetic construct contained within pET-41a for 
SAg protein expression, including TEV protease cleavable N-terminal purification tags, 
GST and His6. Representative protein electrophoresis of typical SpeC purification steps 
including B) separation from crude extract (flow) using Ni2+-affinity gravity 
chromatography and elution by increasing imidazole concentrations (mM), C) tag 
removal with autoinactivation-resistent His7::TEV cleavage (368), D) separation from 
TEV protease with Ni2+-affinity gravity chromatography and E) final purified SpeC 
protein. Representative images of coomassie blue stained protein gel electrophoresis of 
the purification of SpeCY15A/D203A. 
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3.2 SpeC-mediated T cell activation and cytotoxicity evaluation 
3.2.1 PBMC proliferation and T cell activation 
The ability of SpeCWT, SpeCY15A, SpeCD203A, and SpeCY15A/D203A to activate human 
PBMCs was evaluated. Firstly, activation of human PBMCs was assessed by induction of 
proliferation by incubation with increasing concentration of SAg. Both SpeCY15A and 
SpeCD203A were impaired for the ability to expand PBMCS by >100-fold compared with 
SpeCWT, and the SpeCY15A/D203A double mutant was unable to induce PBMC proliferation 
(Figure 8A).  
Also evaluated was the ability of the recombinant proteins (at 1 µg mL-1) to specifically 
induce proliferation by measuring generations of dividing cells of human CD3+CD4+ and 
CD3+CD8+ T cell populations using FACS. Based on the dilution of CFSE (CFSElow), 
SpeCWT and each of the single mutants were able to induce proliferation of both T cell 
subsets, as shown by the increase percent of CFSElow, while the double mutant failed to 
induce proliferation of either subset (Figure 8B). The total CD3+ CFSElow population was 
21.7% after incubation with SpeCWT, 16.0% and 18.9% with SpeCY15A and SpeCD203A 
respectively, and 1.0% with SpeCY15A/D203A, comparable to the unstimulated treatment 
group, with 1.4% CFSElow staining (Figure 8C). 
3.2.2 PBMC-induced cytotoxicity 
The ability of SpeCWT and mutant variants to mediate a cytotoxic PBMC-dependent 
killing response towards human colon cancer cell line, WiDr, was evaluated in vitro by 
two methods. Firstly, WiDr cells, radiolabeled with 3H-thymidine, were incubated over a 
7-day period with human PBMCs and increasing concentrations of SpeC variants WT, 
Y15A, or D203A. The degree of cytotoxicity against WiDr was measured with a standard 
JAM-assay (378) . Based on DNA fragmentation that occurs as of one of the hallmarks of 
apoptosis, in the JAM-assay first reported by Matzinger (378), the intact DNA of viable 
cells are trapped within the glass fiber filters during cell harvesting, while the DNA of 
apoptotic cells as fragments are easily washed through the filter. Therefore, detectable 
radioactivity reflects the amount of intact DNA and remaining viable cells and is
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Figure 8. SpeC-mediated T cell activation 
A) Proliferation of human PBMCs mediated by SpeCWT or proteins containing mutated 
residues Y15A (TCR-binding mutant), D203A (MHC II-binding mutant) or 
Y15A/D203A was determined by the uptake of 3H-thymidine after 72 h post-stimulation 
(n=4 in triplicate; data representative of one individual). B-C) Proliferation of CFSE 
labeled-human PBMCs mediated by SpeCWT or proteins containing mutated residues was 
determined by FACS five days post-stimulation, specifically measuring total CD3+ T cell 
population, CD3+CD4+ T cells and, CD3+CD8+ T cells. Data shown (mean ± SEM) is 
from four independent human donors (n=4; FACS data representative of one individual). 
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correlated to the degree of cellular death (percent apoptosis) (378, 379). Cellular death 
was demonstrated in both a time- and dose-dependent manner (Figure 9A). After 24 h 
incubation, there was an evident dose-dependent increase in percent apoptosis with 
treatment of SpeCWT, however not with the either of the mutant variants. The 
cytotoxiceffect mediated by SpeCWT was more profound after 48 h and could also begin 
to be noted with the higher concentrations of SpeCY15A and SpeCD203A, although the 
cytotoxic response appeared dampened considerably compared to SpeCWT. This trend 
was evident throughout the experimental time course and even 168 h (7 days) post-
incubation, mutant versions were revealed to display hindered PBMC cytotoxic affects 
towards WiDr cells, with the exception at the highest used concentration. Based on the 
JAM-assay results, subsequent killing assays were performed with a 48 h period of 
PBMC stimulation.  
Secondly, to assess the degree of cytotoxicity further, WiDr cancer cells were co-cultured 
with human PBMCs and increasing concentration of either SpeC variants WT, Y15A, 
D203A, or Y15A/D203A and analyzed by FACS (Figure 9B). After 48 h incubation, all 
cells were harvested and stained with 7-AAD, a dye that intercalates with DNA to form a 
fluorescent complex, however is generally excluded from the intact membrane of live 
cells in order to measure cell death. Within the WiDr cell population, SpeCY15A caused a 
significant reduction in WiDr cytotoxicity compared with SpeCWT, and both the 
SpeCD203A and SpeCY15A/D203A mutants failed to induce WiDr cytotoxicity (Figure 9B).  
These data, including proliferation and cytotoxicity, indicated that TCR and MHC II 
engagement are important for induction of immune cell-mediated killing by SpeCWT, and 
that SpeCD203A may be a suitable mutant to reduce or prevent systemic immune cell 
activation while maintaining full engagement with the TCR. 
3.3 Development of genetic constructs and expression of murine scFv5T4 proteins 
In order to develop a specific targeting mechanism for SpeCD203A, a single chain variable 
fragment (scFv) from the characterized mouse scFv (729 bp) specific for the human 5T4 
TAA (243) was generated (scFv5T4) (372). This construct, as well as the genetically
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Figure 9. Cytotoxicity potential of human PBMC mediated by SpeCWT and SpeC 
mutants 
A) Dose- and time-dependent manner of cytotoxicity directed against human colon 
cancer cell line (WiDr) elicited by SpeCWT (black), SpeCY15A (white), and SpeCD203A 
(grey). Incorporation of 3H-thymidine was used to assess the specific apoptosis (%) of 
cancer cells in JAM-assay. Data representative of one human PBMC donor. B) Dose-
dependent cytotoxicity of 7-AAD+ WiDr cells measured by FACS after 48 h incubation 
with human PBMCs and either SpeCWT, SpeCY15A, SpeCD203A, or SpeCY15A/D203A (n=3–6 
per group represented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, compared to 
SpeCWT). 
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linked (gly-gly-pro) speCD203A or speCY15A/D203A, was cloned into pET-41a and pET-28a 
(373) (Figure 10A). However, these proteins proved difficult for successful protein 
production within the E. coli BL21 (DE3) system. In this study, attempts were taken to 
improve on the overall protein yield. This involved the optimization of induction time 
and temperature throughout expression, concentration of the inducer (IPTG), and 
enhancements on the subsequent purification steps, including the analysis of a variety of 
diverse buffer compositions to increase solubility. Despite these efforts, the overall 
expression of soluble proteins containing scFv5T4 resulted in poor production with low 
protein yield. Efforts to increase purification yield from the soluble fraction, including 
use of various columns with high performance liquid chromatography (HPLC), although 
robust, did not result in an improved yield of protein product (data not shown). 
To enhance the sensitivity and protein capture within the purification methods, the high 
affinity and specific interaction between biotin and (strept)avidin molecules was applied 
to the development of the construct. This peptide tag system has been well established 
and is commonly developed for the basis of molecular biology products for detection and 
purification of proteins (380-383). As such, this technology was applied to the pET-28a 
system with aims to increase protein yield by use of this strong interaction as a 
purification tag, as well as to develop a more rigorous protein detection method. For the 
in vivo enzymatic biotinylation of the protein, the genetic constructs were designed to 
include a unique 15 amino acid peptide sequence (AviTag™ Technology, Avidity) that is 
specifically recognized by the BirA enzyme for the addition of biotin onto the specified 
peptide sequence (biotin tag). For the addition of the biotin tag to existing genetic 
constructs, a reverse primer containing the specific sequence along with a TEV protease 
cleavage sequence site was used. The resulting PCR product was cloned intermediately 
into pBluescript II SK+ and subsequently into pET-28a, creating a TEV protease 
cleavable C-terminal translational fusion of the biotinylation peptide tag with scFv5t4 
genetically linked speC variants. Similar to the previous translational protein expression 
plasmids, the resulting constructs were pET-28a::scFv5t4::speCY15A/D203A::TEV::biotin, 
and pET-28a::scFv5t4::speCD203A:TEV::biotin (Figure 10B; Table 11). The E. coli BL21 
(DE3) clones were further engineered to co-express pBirA, an IPTG inducible plasmid 
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Figure 10. Genetic construct development for expression of soluble recombinant 
fusion protein 
Schematic illustrations representing the stepwise development of constructs containing a 
murine scFv targeted toward human 5T4 (scFv5T4) (243) genetically fused to SpeCD203A 
via gly-gly-pro linker A) cloned within pET-28a protein expression vector containing N-
terminal thrombin (Thr) cleavable 6×His purification tag and B) genetically altered to 
remove 6×His and addition of C-terminal TEV cleavable biotin tag for enzymatic 
biotinylation. Codon-optimized version of murine scFv5T4 (grey bar) cloned within C) 
pET-28a construct containing the C-terminal biotin tag and D) pET-32a expression vector 
for addition of N-terminal EK cleavable TrxA and 6×His tag. 
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containing the BirA gene for protein biotinylation. Upon protein induction, similar to the 
original design, these constructs did not result in sufficient expression of soluble protein, 
however the in vivo biotinylation of the protein proved successful and aided in the 
detection sensitivity of the expressed constructs (data not shown). Conversely however, 
the attempted purification methods utilizing the biotinylated tag were not advantageous to 
the overall yield of the protein. From these results and after pellet solubilization in 8 M 
urea, it was determined with that upon targeted gene overexpression in E. coli, the 
proteins formed intracellular, insoluble protein within aggregates, termed inclusion 
bodies. While the particular optimization completed within this study for inclusion body 
isolation, purification, protein denaturation, and refolding proved successful from 
previous constructs mentioned, the concentration yield was low and the success rate for 
obtaining its native structure was particularly difficult to determine for regaining full 
biological activity. This method was overall inefficient to obtain adequate protein for 
proper therapeutic assessment.  
For further development of the immunotherapeutic, it was perceived that occasionally in 
the recombinant protein E. coli expression system, low levels of soluble protein 
expression can occur, despite the use of strong transcriptional and translational signals. It 
has been noted that this may be due to the mRNA codon usage of the heterologous 
protein (384-386). Each organism has a preference for codons that are recognized (major 
codons) whereas those not preferentially used (rare codons) and forced high-level 
expression of proteins can deplete the pool of rare tRNAs. As a result, this can stall 
translation, decrease mRNA stability, and can potentially inhibit protein synthesis by 
generating genetic frame-shifts, deletions, misincorporations, and premature termination 
of transcription or translation. Within the murine sequence of scFv5T4, 16 rare codons of 
E. coli were noted (7%) (386). The scFv5T4 containing constructs were co-expressed 
with the genes encoding for a number of the rare codon tRNAs within BL21 (DE3) 
CodonPlus-RIL cells  (Stratagene, La Jolla, California, USA) reducing the number of rare 
codons to 11 (5%), however no difference in protein expression level was noted (data not 
shown). Furthermore, the murine scFv5t4 gene sequence was codon optimized for E. coli 
and synthesized, and subsequently cloned within the pET-28a system (Figure 10C; 
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Table 11). However, the expression of soluble protein remained low from the codon 
optimized scFv5t4 gene (data not shown).  
Efforts were subsequently focused on increasing protein solubility, with results 
monitored through protein biotinylation. Firstly, a common approach to address solubility 
issues is to fuse the target protein with a highly soluble carrier protein (380). TrxA has 
been widely used as such (380, 387-389), including scFv constructs (390, 391). Secondly, 
to encourage maintenance of overall protein structure for solubility, the disulfide bridges 
contained within scFv5T4 require a proper folding environment. To generate a construct 
conducive to these considerations, the codon optimized scFv5t4 and genetically linked 
speC constructs were cloned into the pET-32a, a protein expression vector containing EK 
cleavable N-terminal TrxA and His6 tags, and transformed into both E. coli BL21 (DE3) 
as well as E. coli Origami B (DE3), an E. coli designed to improve disulfide bond-
dependent protein folding. The resulting genetic products were pET-
32a::scFv5t4::TEV::biotin, pET-32a::scFv5t4::speCY15A/D203A:TEV::biotin, and pET-
32a::scFv5t4::speCD203A:TEV::biotin (Figure 10D; Table 11). The E. coli was also 
engineered to contain pBirAcm for in vivo biotinylation of each protein construct. All 
experimental attempts to optimize and increase soluble protein yield, such as those 
previously mentioned, were assessed. Through all of the efforts, it was clear that 
sufficient protein yield of the murine scFv5T4, as a soluble product, continued and still 
remains a challenge within this field.  
3.4 Development and generation of humanized 5T4-targeting scFv  
In this work, the generated murine scFv5T4 constructs proved to be a challenge for 
purification, therefore, with aims to advance the specific targeting mechanism for 
SpeCD203A, a humanized scFv specifically targeted for human 5T4 was designed and 
generated. This construct should be beneficial as a therapeutic with a reduction in the 
overall HAMA immunological response. Based on the amino acid sequence of the 
backbone structure and from preliminary work conducted (data not shown), it was 
predicted that human recombinant scFv proteins would be readily produced in soluble 
form. The cDNA sequence was designed to incorporate a ‘humanized’ backbone 
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sequence, with the CDRs remaining specific for human 5T4. The CDRs were designed 
from the characterized mouse scFv specific for the human 5T4 TAA (243), formerly used 
within this study. Amino acid substitutions were determined by aligning the previously 
described mouse scFv5T4 with 10 human scFv sequences to generate a consensus 
sequence of the VH and VL regions of the antibody and subsequently linking the Fv with a 
general peptide linker (Figure 11). The CDR loops specific for 5T4, and the immediate 
amino acids flanking the predicted loops were not altered to maintain antibody structure 
and specificity, predicted from topological modeling. This cDNA sequence was codon 
optimized for E. coli (Figure 12A), synthesized, and was subsequently used for the 
generation of a number of recombinant proteins (Table 11). The final amino acid 
sequence for the translated protein is found in Figure 12B. All subsequent results were 
generated using the humanized scFv5T4. Based on former experience of the murine 
scFv5T4 protein expression, the humanized scFv5T4 was directly inserted into the pET-
32a protein expression system for genetic fusion with TrxA to increase protein solubility. 
The resulting genetic product was pET-32a::scFv5t4::TEV::biotin (Figure 13A), 
containing N-terminal EK cleavable TrxA and His6 tags and a C-terminal TEV cleavable 
biotin tag for in vivo enzymatic biotinylation. The humanized scFv5T4 construct was 
transformed and overexpressed as a soluble protein from BL21 (DE3) and Origami B 
(DE3), both engineered to express BirA. The final protein, cartoon depicted (Figure 13B), 
was purified with the His6 tag, and subsequently cleaved for removal of the N-terminal 
tags then dialyzed, generating a pure, biotinylated humanized scFv5T4 protein of 
anticipated 27 kDa size. A cartoon ribbon diagram depicts the predicted location and 
structure of the generated 5T4-specific CDR loops of each of the Fv regions (Figure 
13C). The humanized scFv5T4, when fused with TrxA within the E. coli recombinant 
expression system, was successfully producced and purified as a highly soluble protein.  
3.5 Engineered human scFv5T4 specifically targets the 5T4 tumour-associated 
antigen 
To examine the specificity of the humanized scFv5T4 for binding to human 5T4, the 
scFv5T4 was either engineered with a biotinylated C-terminal biotin tag, to be detected 
with streptavidin conjugated fluorescence reagents or genetically fused to monomeric red  
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Figure 11. Humanized scFv5T4 sequence generation  
Multiple sequence alignment of human scFv proteins (n=10) compared to murine anti-
human 5T4 scFv. Conserved amino acids (dark grey) generate a consensus human 
backbone sequence shown below the alignment. CDR loops and the linker are labeled 
above their predicted regions. All sequences were taken from NCBI Protein Database 
(www.ncbi.nlm.nih.gov/protein) and analyzed using MacVector.  References to human 
scFv proteins are found in the Appendix 8. 
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Figure 12. cDNA and amino acid sequence of humanized scFv5T4  
A) Generated DNA sequence of the consensus human scFv backbone with maintained 
human 5T4-targeting CDRs and B) translated amino acid sequence. scFv was constructed 
as VH-linker-VL with polylinker denoted in bold.  
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Figure 13. Humanized 5T4-targeting scFv constructs and predicted structure  
A) Schematic illustration of genetic construct for expression of humanized scFv5T4 
within pET-32a, containing an N-terminal TEV cleavable TrxA and 6×His tags and C-
terminal EK cleavable biotin tag for enzymatic biotinylation. B) Schematic representation 
of purified scFv5T4 protein (grey) containing biotinylated C-terminal tag (green) and C) 
cartoon representation of predicted humanized scFv5T4 structure (grey) containing VH 
and VL regions fused with a polylinker. Structure modeled from human 80R scFv (PDB 
2GHW22) (375) with 75.9 sequence identity using SWISS-MODEL 
(www.swissmodel.expasy.org). 5T4-targeting CDR loops of each fragment are coloured 
as follows: CDR1, red; CDR2, blue; CDR3, magenta. 
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fluorescent protein 1 (mRFP1) (392). Upon incubation with the human HT-29 colon 
cancer cells known to express 5T4 (Appendix 7) (194, 224), from which WiDr cells are 
also derived (393), scFv5T4 bound to the surface of these cells comparable to 
commercial anti-human 5T4 mAb (mAb5T4) (Figure 14A). Furthermore, both mAb5T4, 
as well as the scFv5T4 fragment, bound to HEK293 cells engineered to express the 5T4 
antigen by transfection with pCMV6-XL5::5t4 as shown by FACS and 
immunofluorescence microscopy, whereas control HEK293 cells that contain only the 
vector (pCMV6-XL5) did not stain with either antibody (Figure 14B-C).  
The scFv5T4 targeting for 5T4 was also determined by co-incubation of scFv5T4 and 
mAb5T4 with HEK293 cells engineered to express 5T4 and resulted in the same cells 
binding both antibodies (Figure 15A). Lastly, specificity for 5T4 was verified with 
HEK293 cells transfected with pEGFP-N1::5T4, or control vector pEGFP-N1. 
Microscopic analysis of GFP::5T4-expressing HEK293 cells demonstrated that scFv5T4 
bound only to those cells expressing the 5T4::GFP fusion, but not to control transfected 
cells (Figure 15B). Together, these data indicate that the humanized scFv5T4 can bind 
specifically to human 5T4. 
3.6 Generation of scFv5T4::SpeCD203A 
In order to target SpeC to 5T4, SpeC was genetically fused with a small flexible linker 
(Gly-Gly-Pro) to the humanized scFv5T4 resulting in recombinant scFv5T4::SpeCD203A. 
For soluble protein expression, similar to the scFv5T4 alone, the fusion 
scFv5T4::SpeCD203A construct was cloned into the pET-32a protein expression system 
creating an N-terminal translational fusion of TrxA and His6 purification tags with a C-
terminal translational biotin tag. For all of the final construct designs, including the 
scFv5T4 and non-functional fusion protein containing SpeCY15A/D203A, the pET-32a 
vector was altered as such that the EK cleavage site (DDDDK↓X), was replaced with a 
TEV protease cleavage site (ENLYFQ↓S) (368) and the C-terminal biotin tag (AviTag™, 
Avidity) containing a 5’ gly-gly spacer was engineered to include an EK cleavage site 
(Figure 16A-B; Table 11). Constructs were transformed into either E. coli BL21 (DE3) 
or Origami B (DE3), both engineered to co-express pBirAcm for biotinylation. No 
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Figure 14. Human 5T4-targeting of scFv5T4 
A-B) Histograms demonstrating surface binding of the indicated antibodies, either 
commercial mAb5T4 or scFv5T4 (empty curves) to A) colon cancer cell line HT-29 and 
B) HEK293 cells transfected with pCMV6-XL5 or pCMV6-XL5::5T4 measured by 
FACS. The shaded curves show the IgG2b isotype control (top panels) or streptavidin-
FITC alone (bottom panels). Inlays represent dot plots of histogram. C) Visualization of 
commercial mAb5T4, or generated scFv5T4, targeting of HEK293 cells transfected with 
vehicle control (pCMV6-XL5) or pCMV6-XL5::5T4 by fluorescence microscopy. 
Representative images taken at 400× magnification. 
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Figure 15. Specific human 5T4-targeting of scFv5T4  
Visualization of HEK293 transfected with A) vehicle control (pCMV6-XL5) or pCMV6-
XL5::5T4 co-stained with commercial mAb5T4 (red; TRITC) and scFv5T4 (green; 
FITC) and B) pEGFP-N1 or pEGFP-N1::5T4 and incubated with  recombinant 
scFv5T4::mRFP1. Same field of view photographs were taken under phase contrast, and 
green and red fluorescent filters at 100× or 400× magnification. 
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Figure 16. Schematic illustration and predicted protein structure of 
scFv5T4::SpeCD203A fusion protein and control reagent  
Schematic illustration representing the final genetic constructs for the expression of 
fusion proteins A) scFv5T4::SpeCD203A and B) control reagent, scFv5T4::SpeCY15A/D203A. 
The genetic constructs are generated within pET-32a containing N-terminal TEV 
cleavable TrxA and 6×His tags and C-terminal EK cleavable biotin tag for enzymatic 
biotinylation. Cartoon representation and illustrations of humanized scFv5T4 (grey), 
genetically fused by a gly-gly-pro linker to SpeC (blue) either containing C) an alanine 
substitution at residue D203 or D) an additional alanine substitution at residue Y15. E-F) 
Fusion structures modeled from human 80R scFv (375) (PDB 2GHW) with 75.9 
sequence identity using SWISS-MODEL (swissmodel.expasy.org) and SpeC-TCR (285) 
(PDB code 1KTK). Residues are coloured orange and 5T4-targeting CDR loops of each 
VH and VL fragments are coloured red. All constructs were generated to contain a C-
terminal biotin tag (green). 
  
127 
  
128 
difference with protein yield between strains was notable (data not shown). The final 
fusion protein design and predicted molecular structure, once expressed and purified, is 
highlighted as representative images in Figure 16C-F. 
For protein expression and purification of the fusion construct scFv5T4::SpeCD203A and 
controls, following induced bacterial expression, the cell lysate was applied to a nickel 
resin column for purification with the His6 tag and eluted with increasing concentration of 
imidazole. The expression of desired protein with TrxA was verified of the anticipated 
molecular weight of 64 kDa for fusion proteins and 39 kDa for scFv5T4 alone and 
purification tags were removed with autoinactivation-resistent His7::TEV as described 
(368). The purified proteins were eluted in low imidazole concentrations and protein 
containing fractions were confirmed with expected 52 kDa and 27 kDa for fusion protein 
and scFv5T4 alone respectively and after buffer exchange, resulted each as soluble 
purified proteins (Figure 17A). The positive probed signal for biotin signified the 
successful in vivo biotinylation of each protein, including scFv5T4::SpeCD203A and 
control reagents scFv5T4 and scFv5T4::SpeCY15A/D203A (Figure 17B). The genetic fusion 
of the humanized scFv5T4 and SpeCD203A, with use of the multi-tag system, resulted in 
successful expression and purification of the potential TTS. 
3.7 scFv5T4::SpeCD203A and recombinant protein panel for therapeutic potential 
assessment 
Purified recombinant proteins, including scFv5T4::SpeCD203A, control reagents scFv5T4 
and scFv5T4::SpeCY15A/D203A, as well as SAgs, SpeCWT, SpeCD203A and SpeCY15A/D203A 
were all biotinylated and diluted in saline (0.9%) to the same molar concentrations for 
comparative use in vitro and in vivo (Figure 18). All proteins were of predicted 25, 27, 
and 52 kDa size for SAgs, scFv5T4 and fusion constructs, respectively. The protein 
bands corresponded to relative concentrations of each dilution as well as represented the 
purity of the final product.  
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Figure 17. Purified recombinant scFv5T4::SpeCD203A fusion protein and control 
reagents 
The purified recombinant proteins shown by A) SDS-PAGE stained with coomassie blue 
and B) detected by Western blot analysis by streptavidin-IRDye800. 
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Figure 18. Recombinant protein panel for in vitro and in vivo therapeutic potential 
assessment  
Purified recombinant proteins diluted in saline (0.9%) used in vitro and in vivo are shown 
by A) SDS-PAGE stained with coomassie blue and B) detected by Western blot analysis 
by streptavidin-IRDye800. Left and right lane represents 2000 nM and 200 nM dilutions, 
respectively.  
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3.8 Human T-cell proliferation induced by scFv5T4::SpeCD203A 
Functionality of the SpeCD203A containing scFv5T4 TTS was assessed for the ability to 
induce proliferation of human PBMCs compared to control proteins. scFv5T4::SpeCD203A 
induced a dose-dependent proliferative response of human lymphocytes that was 
comparable to SpeCD203A (Figure 19). Notably however, the activation induced by 
scFv5T4::SpeCD203A remained significantly reduced compared to that of SpeCWT. 
Furthermore, and importantly, the scFv5T4 antibody fragment alone and the double 
mutant fusion (scFv5T4::SpeCY15A/D203A) did not induce significant proliferative 
responses. This result indicated that the SpeCD203A portion of the fusion is responsible for 
inducing PBMC activation. 
3.9 Human T-cell cytotoxicity of human CRC cells induced by scFv5T4::SpeCD203A 
Human SpeC-reactive PBMCs were used in two assays to evaluate the TTS 
immunotherapeutic agent for the ability to mediate tumour cell killing. First, the human 
colon cancer cell line WiDr was used as the target in a 7-AAD-based killing assay. 
Efficient cell killing was observed after human PBMCs were stimulated with 200 nM of 
the agent for 48 hours, compared to wild-type SpeC and unstimulated controls (Figure 
20A). Second, HT-29 colon cancer cells labeled with 51Cr were used as targets. Efficient 
cell killing was observed in a dose-dependent manner after human PBMCs were 
stimulated with the agent for 48 hours, and subsequently added to tumour cells with 
increasing effector to target (E:T) ratios (Figure 20B) Furthermore, the single mutant 
fusion (scFv5T4::SpeCD203A) was more efficient than that of the similar double mutant 
fusion (scFv5T4::SpeCY15A/D203A) or antibody alone, but was reduced when compared 
with SpeCWT. These data indicate that scFv5T4::SpeCD203A is functional for inducing 
immune cell-mediated cancer cell death and that SpeCD203A, scFv5T4, and 
scFv5T4::SpeCY15A/D203A proteins can function as precise controls to evaluate the 
requirement for targeting and SAg activity in vivo.  
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Figure 19. Functionality assay of recombinant protein panel for human PBMC 
proliferation in vitro 
SpeC proteins were used to compare scFv5T4 alone, scFv5T4::SpeCY15A/D203A and 
subsequently scFv5T4::SpeCD203A in the uptake of 3H-thymidine as a measure of PBMC 
proliferation after 4 day incubation. Data shown is one representative human donor  
(mean ± SEM) of five independent human donors (n=5 in triplicate). *p<0.05, **p<0.01, 
***p<0.001, compared to SpeCWT. 
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Figure 20. Cytotoxic potential of SpeC mutants and fusion proteins in vitro  
Dose-dependent, SpeC-mediated PBMC cytotoxicity of scFv5T4::SpeCD203A compared 
with SpeC controls, scFv5T4 alone and scFv5T4::SpeCY15A/D203A. A) Percent cell death 
by 7-AAD exclusion staining of human colon cancer cell line WiDr after 48 h incubation 
with stimulated human PBMCs (n=3; mean ± SEM compared to SpeCWT) and B) by 51Cr-
release from 51Cr-labeled HT-29 human colon cancer cells with increasing effector:target 
ratios using human PBMCs stimulated for 48 h. Data shown (mean ± SEM compared to 
the inactive SpeCY15A/D203A control protein) is from four independent human donors each 
completed in triplicate. ns = non-significant, *p<0.05, **p<0.01, ***p<0.001. 
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3.10 Immunotherapy of established colon cancer using scFv5T4::SpeCD203A 
SpeC is specific for human Vβ2+ T cells, but this SAg does not recognize mouse T cells 
(366). Thus, testing the SpeC-based TTS required a model utilizing human lymphocytes. 
Furthermore, the human 5T4 targeting scFv has minimal cross-reactivity with murine 
5T4 (243). Therefore, human tumour cells expressing human 5T4 were necessary for the 
experiments. Based on a previously developed model (242, 335), an animal model using 
immunodeficient NSG mice was employed for the engraftment of 5T4+ human HT-29 
colon cancer cells. NSG mice lack T, B, and NK cells (394) and represent an optimum 
mouse strain for human tumour engraftment (395, 396). Furthermore, these mice would 
permit the survival of transferred human immune cells (394, 397). HT-29 cells were 
injected ip into NSG mice and once solid tumours were palpable at 3 weeks post-
injection (Figure 21B), treatments were initiated with iv injection (2 µM kg-1 per 
injection) of scFv5T4::SpeCD203A, 2 hours post-ip injection of human PBMCs. Followed 
by 7 daily iv treatments, animals were electively euthanized 4 weeks post-treatment 
(Figure 21A). Control NSG mice did not receive PBMCs, or received PBMCs without 
additional treatments. Additional groups included the scFv5T4 alone, SpeCD203A alone, or 
inactive scFv5T4::SpeCY15A/D203A.  
Three weeks post-injection of the HT-29 cancer cells, further internal assessment 
revealed a visual mass on the mouse peritoneum of an established tumour growth at the 
site of injection (Figure 21C).  Histological evaluation by H&E stain of the tumour site 
showed distinct tissue morphology compared to the surrounding normal peritoneal tissue 
(Figure 21D).  
Change in individual animal weight was monitored throughout the experiment and results 
suggested that weight fluctuation in the animals receiving the scFv5T4::SpeCD203A TTS 
was highly reduced compared to all other groups, and in general remained relatively close 
to original baselines, in particular near the termination of the time course (Figure 22). 
The tumour surface area was monitored using caliper measurement throughout the 
experiment and demonstrated little to no growth of the tumours in the  
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Figure 21. In vivo model of SpeC-based TTS therapy of established HT-29 colon 
cancer  
A) Schematic illustration of the xenograft solid tumour model experimental timeline. 
NSG mice with established (3 week) ip human HT-29 tumours were injected once with 
human PBMC ip, followed by 8 daily intravenous injections of scFv5T4::SpeCD203A, or 
individual controls (2 µM kg-1 per injection) and sacrificed 4 weeks post-treatment. HT-
29 tumour growth after 3 weeks shows palpable and visual establishment at the site of 
injection B) externally (black circle), C) internally on the peritoneum (dashed circles), 
and D) histologically by H&E stain of tumour (T) and surrounding normal peritoneum 
tissue (P). Black bar represents 2 mm. 
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Figure 22. Weight change of NSG mice throughout tumour establishment and TTS 
therapy  
Weight of animals was measured throughout the experimental timeline (total = 60 days) 
and fluctuation evaluated from initial baseline measurement taken Day 0 and represented 
as individual animals. All groups contained n=4, with exception of saline treated, no 
PBMC control group (n=3). 
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scFv5T4::SpeCD203A treatment group, while growth was observed in all other group 
(Figure 23A). The animals were electively euthanized at week 8 of the experiment and 
tumours were evaluated in a blinded fashion. Exterior overviews demonstrated evidence 
of the outgrowth size of the primary tumour at the injection site in all treatment groups, as 
well as visual metastatic sites on the upper right side of select control treated animals 
(Figure 23B). Upon internal exposure of the tumour injection site, it was evident that the 
human HT-29 cells established a primary solid tumour from the peritoneal cavity in all 
groups, which extended and attached to the inner skin surface. Gross pathology and H&E 
histological analysis suggested that the TTS treated animals had a reduced size in primary 
tumour, compared to all other treatment groups (Figure 23C-D), but that similar 
morphology and tissue composition of all primary tumours indicated that the tumours 
were of the same origin. Upon necropsy of the animals, tumours distant from the primary 
injection site at the time of sacrifice were evident within all treatment groups, however 
from a gross pathology overview of the peritoneal cavity, the metastatic burden was 
much reduced in the TTS treated animals (Figure 24A). Furthermore, the rate of liver 
metastasis was also diminished (Figure 24B). Of note however, the TTS treatment did 
not completely eliminate all metastasis as 2 out of 4 animals had evidence of at least 2 
established metastases, albeit smaller comparable volume to control groups (Table 15). 
The degree of metastatic burden was visually characterized based on the location spread 
within the animal and also histologically analyzed by H&E stained sections to compare 
the composition of the metastases to the original solid tumour and to distinguish from 
existing healthy tissues. From this, 5 distinct locations distant from the primary tumour 
were defined (Figure 24C-D).  
Of note, two animals did not reach the full experimental term of 60 days. Ethically, these 
animals were electively euthanized due to procedural requirements. Specifically, one 
male that had received the treatment of PBMCs alone followed by saline injections had a 
survival of 57 days. The total tumour volume of this particular animal was approximately 
1615 mm3 and had 3 tumours distant to the primary solid tumour (Table 15). The second 
animal was a female that received the treatment of SpeCD203A, and had a survival day of 
58. The total tumour volume for this particular animal was 539 mm3 with 3 tumours 
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Figure 23. Size comparison of primary tumours from in vivo treatment groups  
A) Primary tumour size was evaluated throughout the experimental timeline by external 
caliper measurements, individual animals represented by each graph line. Representative 
photographs of primary tumour at initial injection site at the time of sacrifice as B) 
overview of abdomen showing relative exterior size (dashed circles) and visible distant 
tumour (arrows), C) interior view (dashed outline) developed from peritoneal site and D) 
H&E stained histological sections (5 µm) of respective primary tumours. Black bars 
represent 5 mm. All groups contained n=4, with exception of saline treated, no PBMC 
control group (n=3). 
  
145 
  
146 
Figure 24. Tumour metastases from SpeC-based TTS therapy of established HT-29 
colon cancer  
Tumours distant from the primary injection site at the time of sacrifice shown as 
representative photographs of A) gross pathology overview of peritoneal cavity focused 
on tumours distant from primary site (black arrows) on the right side of animal and B) 
livers removed and analyzed for presence of tumour mass (white arrows). Primary 
tumour and metastases were characterized for metastatic scoring based on C) location 
within the animal (labeled i through vi), where (i) is the primary solid tumour and 
histologically analyzed by D) H&E staining sections (5 µm) of the locations to 
distinguish tissues. All H&E images taken from representative saline treated animal 
control group (n=4) (T, tumour; P, peritoneal wall; L, liver; D, diaphragm; K, kidney). 
Illustration (C) modified from The Anatomy of the Laboratory Mouse 
(http://www.informatics.jax.org/).
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Table 15. Animal characteristics and individual data generated from in vivo 
immunotherapy TTS model with human HT-29 cancer cells 
After solid tumour establishment, mice were divided by sex and subsequently grouped 
(n=3-4) with a random number generator to receive either scFv5T4::SpeCD203A TTS, or 
control. Noted are: animal survival day, wet weight (g) of the primary solid tumour 
located at the site of initial injection site, total tumour volume (mm3), and number of 
visually identified metastases. 
Treatment Group Sex Survival day Primary tumour 
weight (g) 
Total tumour 
volume (mm3) 
Number of 
metastases 
No PBMCs/Saline M 60 1.17 1353.5 4 
 M 60 0.71 1887.5 5 
 M 60 2.50 2677.6 3 
      
Saline M 57 1.44 1615.8 3 
 M 60 0.38 1932.9 2 
 M 60 0.35 1052.0 4 
 F 60 0.63 642.3 2 
      
SpeCD203A M 60 1.17 2046.3 2 
 M 60 1.02 4753.7 4 
 F 58 0.30 539.2 3 
 F 60 1.07 2058.6 3 
      
scFv5T4 M 60 1.08 5893.3 2 
 M 60 1.89 2011.8 3 
 F 60 0.48 674.5 4 
 F 60 0.42 673.7 3 
      
scFv5T4::SpeCY15A/D203A M 60 1.12 1951.9 4 
 M 60 0.62 2020.1 2 
 M 60 0.81 1332.2 2 
 F 60 0.18 938.3 3 
      
scFv5T4::SpeCD203A M 60 0.34 380.0 2 
 M 60 1.07 900.8 2 
 M 60 0.53 123.9 0 
 F 60 0.49 400.6 1 
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distant to the primary solid tumour (Table 15). No other abnormalities were visually 
noted during the necropsy other than dehydration, and weight loss. Furthermore, one 
male that had received the TTS treatment, but not the full dose due to initial injection 
technique, had a notable larger total tumour volume as well as primary tumour size 
(Table 15). A potential sex bias was also noted within the model as the male animals 
responded better to overall tumour growth from human HT-29 cancer cells in comparison 
to the females within this strain of mice (Table 15). 
Overall, this experiment demonstrated a dramatic reduction in the total tumour volume 
and metastastic burden after treatment with scFv5T4::SpeCD203A that was significantly 
different from mice that did not receive PBMCs, sham treated mice (saline), and mice 
treated SpeCD203A alone, or with control treatment scFv5T4::SpeCY15A/D203A (Figure 25A-
B). Importantly, there were no differences in tumour volumes or number of metastases 
between mice that received PBMCs alone and the different control reagents (Figure 25A-
B).  
Immunohistochemistry of the solid primary tumours was performed comparing the TTS 
treated animals to the non-immune inducing scFv5T4::SpeCY15A/D203A treatment group. 
The rate of cellular proliferation, blood vessel formation, as well as cellular apoptosis 
showed no significant difference among the two treatment groups. Furthermore, there 
was no distinction between the numbers of CD3+ cells within the solid tumours at this 
time point (Figure 26A-B).  
Together, these data indicate that although there was no specific differences in the IHC of 
the solid primary tumours, the TTS treated group demonstrated an overall weight 
maintenance and dramatic reduction in the total tumour volume with a significant 
reduction in the total metastases score compared to control treatment groups. 
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Figure 25. Tumour burden from SpeC-based TTS therapy of established HT-29 
colon cancer  
Twenty-eight days post-final injection, A) final tumour volume was measured and B) 
metastatic score evaluated. All groups contained n=4, with exception of saline alone 
control (n=3). *p<0.05, **p<0.005. 
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Figure 26. Immunohistochemistry profiles of TTS treated primary HT-29 tumours 
Twenty-eight days post-final injection, primary tumours were excised, sectioned (5 µm) 
and assessed by IHC.  Similar histological profiles are shown as A) representative images 
of primary tumour sections and B) quantification of staining from animals receiving 
either TTS or control treatments and stained for proliferative marker Ki67, endothelial 
cell marker vWF, apoptosis by TUNEL, and T cell marker CD3. All sections were 
counterstained with nuclear stain DAPI and imaged with fluorescence microscopy. White 
bars represent 50 µm. Images are representative of 1 stained section from each animal 
(n=4). Quantification was generated with blinded counting of positive stains from 5 
random high-power fields (hpf) per section per animal (n=20 per stain per treatment 
group; mean ± SEM). 
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T lymphocytes are recognized as one of the most important immune cells involved in 
tumour regression within the field of cancer immunotherapy, and bacterial SAgs are 
among the most potent naturally occurring specific activators of T cells. Thus, the 
appropriation of SAgs to target cancer cells (309) has received significant attention and 
has become very promising in the advancement of targeted immunotherapies. Of 
particular interest are those where mAbs are used (338, 342) and encouragingly, TTS 
therapeutics are now being evaluated in human clinical trials (323-325, 337, 338, 342, 
348). 
In Canada, cancer is the leading cause of death, responsible for nearly 30% of all deaths 
and in recent reports, it is expected that new cases will dramatically rise over the next 15 
years due to the increasing aging population (3). In this work, the focus was on colorectal 
cancer, one of the four major contributors to new cancer diagnose. This cancer accounts 
for more than half of all cancers within Canada and is the second and third most common 
cause of cancer death for males and females, respectively (3). With few clinical 
symptoms evident until the onset of stage III or IV, this carcinoma is difficult to diagnose. 
As such, ~20% of diagnosed patients present with inoperable CRC and ~25% of operable 
patients will develop metastases due to recurrence, resulting in a relatively high overall 
mortality rate (~45%) for CRC (10, 15). It is clear that advances in treatment, diagnosis, 
and prevention strategies of this carcinoma are of considerable importance.  
Successful treatments of an invasive cancer, in addition to addressing the primary site, 
must also direct targeted effects towards the distant metastases, therefore mAbs have 
been employed to direct targeted cytotoxic responses (398, 399). mAbs of murine origin 
and mouse/human chimeras have been used either alone or linked to a therapeutic agent 
with encouraging results, of which some have been FDA approved for use in the clinic 
(e.g. ibritumomab tiuxetan, rituximab, cetuximab) (400). However, concerns have arisen 
using whole murine and chimeric mAbs in humans. Firstly, the whole murine mAbs can 
induce HAMA responses (153) along with systemic toxicity due to the requirement for 
high doses for effective treatment (323, 337). Furthermore, it has been found that surface 
molecule specific whole mAbs do not efficiently penetrate solid tumours (401), are not 
uniform in final biodistribution, and can have high serum levels leading to toxicities 
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(183). Engineering smaller antibodies can minimize these issues associated with whole 
mAbs and this has led to the development of recombinant molecules such as Fab and 
scFv fragments. This results in much smaller, tumour-penetrating molecules in particular 
for scFv fragments, that retain the binding activity of the full IgG molecule (401, 402). 
However, scFv fragments have decreased stability and tumour retention (183), as well as 
a shorter half-life in serum and are cleared more rapidly compared to larger fragments 
(403). An ideal tumour-targeting reagent would be of intermediate size which could 
provide rapid tissue penetration, high target retention, and rapid blood clearance (183). 
For example, this sized reagent can be generated by incorporating the scFv into a 
complex molecule such as a fusion with an immune stimulatory molecule (402).  
The tumour-associated antigen, 5T4, is of particular interest for advancement of targeted 
immunotherapeutics (226) as its expression is restricted on normal adult tissues, but it is 
upregulated on an array of carcinomas, including CRC (196). Although this antigen is 
expressed throughout cancer progression, it has been most frequently detected on 
malignant cells with no evidence of downregulation (198) and has been associated 
specifically with metastasis in CRC (199). Indeed, further investigation of this antigen 
demonstrated that upon expression it is involved in decreasing cellular adhesion, 
influencing cytoskeletal organization, and promoting cell motility and migration (223, 
224). As a result, poor clinical outcome in some cancers is associated with these altered 
cell properties (223). 5T4 has been the target of a number of developing 
immunotherapies, including chimeric antigen receptors (404), antibody-drug conjugates 
(241), a vaccine undergoing clinical trials (405-407), as well as TTSs (338, 343), all 
demonstrating promising results.  
An effective targeted immunotherapeutic will direct activated cytotoxic lymphocytes to 
the tumour for eradication. SAgs, microbial toxins produced primarily by staphylococcal 
and streptococcal species, are known for having some of the most potent 
immunostimulatory properties. Of the streptococcal SAgs presently studied, SpeC is the 
best characterized and has been extensively described in terms of both structure (272, 
285, 365) and function (277, 286, 366-369) for engagement of host receptors. A complete 
binding map for specific interactions between SpeC and TCR Vβ2.1 (277, 368), as well 
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as the high-affinity zinc-dependent binding interface with MHC II β-chain (369) and low-
affinity MHC II α-chain binding interface (286) of this SAg has been established. With 
this knowledge, strategic SAg mutations may be applied to modulate the T cell 
stimulatory capacity of this SAg, generating, to the best of our knowledge, the first 
streptococcal SAg to be employed in TTS immunotherapeutics, enabling expansion of the 
current TTS repertoire. Specifically, to prevent high-affinity and non-specific binding of 
MHC II molecules, Asp203, a residue involved in the coordination of the zinc ion of the 
high affinity site (272) can be altered to Ala such that the potent immune stimulation, and 
therefore toxicity, of the SAg is reduced (286, 369). Indeed, this study provided further 
evidence that Asp203, when altered to Ala, reduced a stimulated human immune response 
(Figure 8). Importantly however, it was also demonstrated that this reduced stimulation 
was still sufficient for the ability to induce immune-mediated cancer cell death (Figure 
9). Similarly, the high-affinity MHC II binding site of the SAg SEA has been 
characterized (328) and a mutation of Asp227 to Ala has been shown to reduce systemic 
side effects (331, 335, 338). As a result, this mutational design has also been incorporated 
into TTSs currently undergoing human clinical trials. This suggested that this particular 
variant of SpeC would be beneficial in the overall development of TTSs while reducing 
off-target activation of the immune system. Further, within the SAg SpeC, Tyr15 has been 
reported to be a critical residue in the interaction with the TCR binding interface leading 
to T cell activation (368). As such, this residue when mutated to Ala, in combination with 
the altered Asp203, can be used for the generation of precise control reagents that maintain 
structural integrity and targeting, but lack immune stimulation activity. The importance of 
Tyr15 for the engagement of the TCR was further supported by this work, both as a single 
and a double mutant SpeC variant, demonstrating reduced and absence of induced 
immune stimulation, respectively (Figure 8, 9). 
As indicated, the concept for using a TTS as an immunotherapeutic is not novel (309), 
and has great potential for future cancer immunotherapy. Promising results from such 
TTSs have been demonstrated in both murine studies (322, 335, 341) as well as human 
clinical trials (323, 337, 338, 342, 348) where a murine Fab antibody portion, targeting a 
TAA is fused to SEA. The most developed of these TTSs specifically targets the TAA 
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5T4, and in preclinical studies, a reduction in the number of tumours present, as well as a 
reduction in overall tumour mass, with the absence of obvious systemic side effects was 
demonstrated (335). Modifications were engineered within the SAg portion of the TTS 
for use in human clinical trials to reduce systemic immune activation (338) as well as 
alterations designed to reduce host antibody recognition in the most current version, 
naptumomab estafenatox (ABR-217620; Fab5T4-SEA/E-120) (242, 339) for use in Phase 
I (342, 343) and subsequent Phase II/III trials (348). Although this treatment showed 
promise, aside from T cell activating properties, staphylococcal SAgs are also the agents 
of staphylococcal food-borne illness (261), a property not shared among the streptococcal 
SAgs (253, 262). This was noted from side effects seen in Phase I and II/III clinical trials 
that included nausea, vomiting, and diarrhea (337, 338, 342). To date, TTSs have been 
exclusively built using members of the SE class of SAg, all sharing emetic properties. 
Evidence also suggested that the murine Fab portion had led to high levels of HAMA 
after multiple cycles of treatment (337), and unexpectedly, in recent Phase II/III trials, 
patients had higher than anticipated baseline levels of anti-SEA/E-120 antibodies, which 
may have contributed to suboptimal therapy (209, 346, 348). Collectively, this 
information led to the design of a novel “next generation” TTS composed of a scFv 
antibody fragment directed against a TAA and a potent streptococcal T cell activating 
SAg. More specifically, within this study, a scFv directed against human 5T4 fused to the 
streptococcal SAg prototype, SpeC, was developed and preclinically tested in vitro and in 
vivo.  
The earliest form of the TTS molecule consisted of a previously described murine scFv 
antibody specific for human 5T4 (243), genetically fused by a short peptide linker (Gly-
Gly-Pro) to an altered SpeC containing an Asp203 to Ala mutation (scFv5T4::SpeCD203A) 
(372, 373). In addition, the fusion protein was further constructed to contain an Ala 
mutation at residue 15, replacing the endogenous Tyr, to generate a precise non-immune 
stimulating control reagent (scFv5T4::SpeCY15A/D203A) (373). Expression of the 
recombinant fusion proteins from the E. coli bacterial system proved successful, however 
unlike the typical SAg portion alone (Figure 7), the proteins formed insoluble, misfolded 
aggregates termed inclusion bodies. Over-expression of heterologous proteins in E. coli is 
frequently hindered by the formation of inclusion bodies, and is incidentally common 
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amongst scFv proteins (408-411). As a result, isolating and refolding of proteins from 
inclusion bodies has become an essential requirement in the study of proteomics and this 
method has been quite useful as a means of recovering functional proteins (412). 
However, in protein expression studies, optimization of the host culture conditions, or the 
fusion to a large affinity tag can often prevent the necessity of isolating these misfolded 
aggregates (389). Within this study, the preparation and refolding methods used for 
inclusion bodies, although successful, were not ideal for the downstream processing 
requirements of large-scale therapeutic production; therefore, the optimization of protein 
expression continued to be the strategy to obtain a soluble, bioactive protein.  Notably, 
alternative expression organisms may be also used to prevent inclusion bodies, such as 
yeast (Saccharomyces cerevisiae) (390) or eukaryotic cell lines (413, 414), however, 
would prove to be considerably laborious, and non-cost and -time effective when 
compared to the well-established, easily manipulated, and high biomass-to-cost ratio 
(389) that could be obtained from the E. coli platform.  
Over the course of this study, several considerations and alterations were applied to the 
genetic construct containing the murine scFv5T4 fused to SpeCD203A, as well as to the 
expression and purification methods for improved protein yield. Of these, a highlight 
included the addition of a C-terminal high-affinity unique peptide tag (biotin tag; 
AviTag™ Technology, Avidity) to use the strong interaction of biotin and avidin with 
aims to enhance the sensitivity of protein capture and increase protein detection. 
Although this tag was not advantageous to the overall purification of the product, this 
technology was extremely useful for enhanced detection sensitivity of the expressed 
constructs. Additionally, the solubility of a target protein can be enhanced by fusion with 
a highly soluble carrier protein such as maltose-binding protein (MBP) or a hydrophilic 
tag such as a transcription termination anti-termination factor (NusA), TrxA, or protein 
disulfide isomerase I (DsbA) (380). However, hydrophilic tags must be used in 
combination with a smaller affinity tag, for example His6 or FLAG, within an expression 
system for purification (380). This multi-tag approach has become a common tactic to 
address solubility issues (380, 381) and since recognized, have become widely 
commercially available. Notably, TrxA has been widely used to increase protein 
solubility (387-389), including specifically for scFv constructs (390, 391) and therefore, 
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efforts focused on increasing protein solubility for scFv5T4::SpeCD203A generated an 
expression system in which TrxA was fused to the N-terminus of the genetic constructs, 
along with a His6 tag for affinity purification. Through all experimental attempts and 
efforts to optimize and increase soluble protein expression, it was clear that sufficient 
yield of the murine scFv5T4, as a soluble product, remained a significant challenge. 
Due to the limitations associated with generating the murine scFv5T4, an alternate 
approach was applied to generate a recombinant soluble molecule for large-scale 
production as well as to further develop the 5T4-specific streptococcal TTS by designing 
a ‘humanized’ scFv5T4 antibody fragment to also prevent HAMA responses. Indeed, the 
approach of genetically grafting the 5T4-specific CDR loops from the murine fragment 
onto a ‘humanized’ scFv backbone (Figure 11, 12) successfully generated and produced 
a highly soluble protein when fused with TrxA within the E. coli expression system.  
Evaluations of the humanized scFv5T4 demonstrated specific 5T4-targeting ability in 
vitro (Figure 14, 15) and provided further preclinical evidence for 5T4 as a potential 
TAA for targeted immunotherapy. Although this work highlights the binding capabilities 
of the humanized scFv5T4 to its target 5T4, further evaluation to conclusively determine 
the specificity and binding affinity would be beneficial.  For example, while the original 
5T4-targeting mAb was evaluated for distribution on normal and neoplastic tissues (196, 
243), verification that the humanized scFv5T4 retains the consistent non-specific binding 
to various cell and tissue types would be of value. Similarly, further verification of the 
high affinity binding measured for the murine scFv5T4 (Kd = ~10-9) (243) of the altered 
humanized scFv5T4 would advance the application of these targeting therapeutics. 
Although there has not been any evidence to date of 5T4 downregulation throughout 
cancer progression, characterization of the downstream effects as a result of binding from 
this targeted scFv fragment would be of value for elucidating the cellular role and 
consequence of the potential TTSs.  
Upon genetic fusion of the humanized scFv5T4 and SpeCD203A, with the consistent design 
of the multi-tag approach, successful expression and purification of the potential TTS was 
generated (Figure 17). Furthermore, the precise control reagents scFv5T4 alone, as well 
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as the non-immune stimulating scFv5T4::SpeCY15A/D203A were produced. Further in vitro 
work provided evidence that the Asp203 to Ala mutation contained with the TTS reduced 
SAg-induced activity (Figure 19) but was sufficient in the ability to induce immune-
mediated colon cancer cell death (Figure 20). Importantly, immune stimulation was not 
demonstrated by the control reagents, scFv5T4 and scFv5T4::SpeCY15A/D203A, indicating 
that SAg activity was required for tumour cell killing. This was the first account, to our 
knowledge, of a streptococcal SAg-based TTS inducing in vitro cytotoxicity towards 
colon cancer. 
As SpeC does not recognize murine T cells (366), and the human 5T4 targeting scFv has 
minimal cross-reactivity with murine 5T4 (243), limited value would come from the use 
of a syngeneic murine model. Therefore, based on a previously developed model (242, 
335), a xenogeneic model consisting of the engraftment of 5T4+ human HT-29 colon 
cancer cells and the transfer of human immune cells were applied to immunodeficient 
NSG mice. NSG mice lack T, B, and NK cells (394) and represent an optimum mouse 
strain for human tumour engraftment (395, 396) and also permit the survival of human 
immune cells (394, 397). Herein, it was demonstrated that the soluble recombinant fusion 
protein scFv5T4::SpeCD203A was able to specifically target 5T4 to elicit a T cell response 
that substantially reduced tumour burden in vivo. Importantly, a model of established 
tumours was used in order to robustly test the SpeC-based TTS. Within this model 
however, for reasons undetermined, there was a disparity of overall tumour growth 
amongst the male and female animals and though the males supported a more robust 
establishment of HT-29 cancer cells, among the matched groups (Appendix 6), the trend 
of results nevertheless remained. Importantly, the TTS treatment group at this dose had 
no observable side effects on animal health (Figure 22), suggesting that the treatment 
may be safe for further downstream evaluations and continued applications. 
In this model, while the primary tumours did not appear to regress, the data clearly 
demonstrated that scFv5T4::SpeCD203A TTS was able to prevent further tumour growth as 
well as the development of peritoneal metastases. Expectedly however, the PBMC sham 
treatment group, as well as the control reagents, also had a marked decrease in overall 
tumour burden when compared to the saline control group (Figure 25). This can be 
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attributed to an allograft response caused by the mismatch of HLA between the donor 
PBMCs and the HT-29 cancer cells.  
In summary, as scFv5T4::SpeCD203A and SpeCD203A showed similar activity in vitro 
(Figure 19), the inability of SpeCD203A to impact tumour size or metastatic disease 
indicates that the scFv5T4 moiety of the fusion protein was required for in vivo targeting 
of 5T4+ HT-29 cells (Figure 25). Likewise, the inability of scFv5T4 alone, or the inactive 
scFv5T4::SpeCY15A/D203A fusion to show any measurable impact (Figure 25) 
demonstrates that T cell-dependent SAg activity was also required for tumour cell killing. 
Importantly, though the incorportation of the altered SAg was designed to decrease 
systemic T cell activation by reducing MHC II binding by the TTS, in the 5T4Fab-
SEA/E-120 TTS, the mouse Fab moiety has been shown to effectively replace the MHC 
II binding domain such that T cells are efficiently activated when artificially 'presented' 
by the tumour (340). It is suspected that the humanized scFv5T4 moiety here played a 
similar role contributing to the dramatic reduction in tumour volume and metastatic 
disease. Closer analysis suggested that although the primary tumours of TTS treated 
(scFv5T4::SpeCD203A) and the non-immune stimulating control 
(scFv5T4::SpeCY15A/D203A) did not display any immunohistological distinctions (Figure 
26), it is anticipated that differences may be noted among the metastatic sites within 
degree of apoptosis, immune infiltration, and tumour development. The reduction in 
overall metastases in TTS treated animals is presumed to be due to the enhanced immune 
activation at these localized areas, however further investigation is warranted beyond the 
‘snapshot’ captured from the primary tumours.  
While this xenograft model of established human HT-29 colon cancer cells and engrafted 
human PBMCs clearly demonstrated an overall reduction in tumour burden with TTS 
treatment, there are also a number of limitations for consideration. Firstly, as the immune 
system is artificially delivered by means of an intraperitoneal injection of isolated human 
PBMCs, this model lacks the ability to evaluate the TTS to cause immune cell 
recruitment and migration for a localized anti-tumour response. Future experimentation 
may include intravenous delivery of the PBMCs to evaluate this response and any 
systemic effects that may be elicited by the TTS. Furthermore, as PBMC preparations are 
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used, the polymorphonuclear cell (PMN) populations, in general, are absent and therefore 
the full immune effect of the TTS is unable to be fully evaluated within this model. 
Lastly, this model limits the extensive interactions between the developing tumours and 
immune system, lacking the effects of immunoediting and resulting gradual heterogeneity 
development along with the generated immunosuppressive microenvironment typical of 
the tumour. Recently, much work has been achieved to meet the challenging need of new 
therapeutic treatment evaluation in the development of humanized NSG mice for 
immuno-oncological studies (415). For some time, these animals have been known to be 
able to support the development and function of multiple aspects of human immunity, 
including both myeloid and lymphoid cells from engraftment of human hemopoietic stem 
cells (394). As well, further evidence demonstrates that these humanized mice also allow 
the co-engraftment of a wide range of heterologous, allograft human tumours, providing a 
number of options for animal models that can act as the preclinical bridge for current 
immuno-oncology therapies (415). 
Although the specific mechanisms of TTS-induced anticancer immunotherapy have not 
been fully elucidated, it can be speculated from the in vivo model that is it is the 
combined efforts of both the SAg as well as the targeting moiety. From studies focused 
on elucidating the role of 5T4, it has been recently shown with mouse embryonic cells 
that CXCR4/CXCL12 chemotaxis, signaling important for cell mobilization, can be 
blocked with mAbs to 5T4 in vitro (227). Importantly, treatments to block 5T4 antigen in 
vivo was also able to prevent the spread of human 5T4+ B-ALL cells (227), 
demonstrating that the observed reduction may be related to 5T4 function in regulating 
chemokine or signaling pathways. Although this effect has not been specifically observed 
to date within preclinical studies of TTSs, this study inclusive, the ability to have 
comparative analysis with 5T4-targeting alone treatments (scFv5T4 or 
scFv5T4::SpeCY15A/D203A), was generated. Based on this early work, consideration of 
antibody targeting and downstream effects of blocking 5T4 signaling merits further 
investigation. 
Secondly, the ability of bacterial SAgs to induce cytokines that maintain T-cell activity as 
well as those that are tumouricidal are important features (308, 309, 320). Key 
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inflammatory cytokines for these specific effects are IL-2 and IFN-γ, the hallmarks of T 
cell activation, of which SAgs in general, including SpeC (248), are known to induce. 
Indeed, in previous TTS experimental preclinical models, in addition to perforin-
mediated cytotoxicity, release of IFN-γ as well as TNF-α has been shown to be 
particularly important for anticancer effects (320, 355). The initial release of these SAg-
induced cytokines will lead to induced proliferation of CD4+ and CD8+ T cells (416), in 
particular CTLs and NK cells. Early SEA-based TTS work in vivo demonstrated a 
massive influx of both CD4+ and CD8+ T cells into the targeted tumour, suggestive of the 
induced release of T cell specific chemokines to encourage cellular trafficking at the 
tumour site and when T cells were depleted, a complete abrogation of therapeutic effect 
was observed (320). In recent clinical studies with Naptumomab estafenatox (ABR-
217620) therapy, select patient sampling also included PBMCs and analysis of associated 
changes in lymphocyte subsets (348). Most notable was the consistent expansion of TTS 
specific CD4+ and CD8+ T cells in peripheral blood that coincided with pronounced IL-2 
production (348). Furthermore, in additional clinical studies with the same treatment, 
responding patients demonstrated that T cells infiltrate tumours (342). These secondary 
events, in addition to an overall heighted immune response, are also thought to be 
important in killing subsets of neighboring cancer cells that may not express the specific 
TAA (335). Based on evidence from the SEA-based clinical trials, it may be speculated 
that TTSs act mainly by induction of T cell activation, proliferation and maturation into 
effector cells and secondly, by recruitment and T cell killing of the tumour. Although the 
specifics of cytotoxic mechanisms directed toward CRC have yet to be studied for 
streptococcal SAgs, based on the similar T cell activation profiles of staphylococcal and 
streptococcal SAgs, it is predicted that the mechanism of immune-mediated cancer cell 
death of SpeC will be comparable to SEA-based TTS. Future analysis of serum samples 
collected from animals within this study may shed light on the cytokine profile induced 
by the humanized scFv5T4::SpeCD203A. To ultimately determine the types and quantities 
of cytokines released for future therapeutic development would be of importance, in 
particular, should tailoring the response be desired of streptococcal based-TTSs. Of note 
however, compared to native SAg, a higher dose may be required to accommodate for the 
reduced binding capabilities of SpeCD203A to MHC II within patients as demonstrated in 
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this work (Figures 8, 9, 19, 20) and in Phase I dose studies using comparable SEAD227A 
(342). Nonetheless, even with the limited Vβ2 repertoire of SpeC (283, 366), the potent 
response of the induced cytotoxic T cells, in combination with the targeting moiety, still 
resulted in a dramatic reduction in tumour volume and metastatic disease within 
preclinical assessment (Figure 25).  
There are some potential advantages, and disadvantages, in using TTSs for tumour 
immunotherapy that require further consideration. As described, the use of a mouse 
derived antibody as a targeting motif may result in HAMA responses since murine mAbs 
are highly immunogenic (153). This may limit the utility of subsequent treatments and 
thus the use of a humanized scFv containing TTS as developed in this work may provide 
clinical benefit. Second, bacterial SAgs are produced by bacteria that are often frequent 
colonizers in humans and thus many individuals will have pre-existing and neutralizing 
antibodies to many streptococcal and staphylococcal SAgs (417, 418). To overcome this 
issue, it is foreseen in future generations of 'combinatorial' TTSs with different SAgs, a 
panel could be generated such that individual patients could be screened for SAg 
neutralizing antibodies and then treated with an appropriate TTS. Early work in this area 
demonstrated that multiple SEs are capable of inducing T cell-mediated cytotoxicity 
against cancer cells (310); however, it is envisioned that the SAg panel would include 
members from the Group IV and Group V subclass of SAgs (248, 253, 377), as these 
subclasses contain only streptococcal SAgs and SEl SAgs, that collectively lack the 
emetic properties of the bona fide SEs (253, 262). Indeed, the SEl-M, SEl-N, and SEl-O 
SAgs from the egc have recently been demonstrated to induce T cell dependent killing of 
a broad panel of human tumour cells in vitro (419). Also, human serum levels of 
neutralizing antibodies against the egc SEs have been shown to be lower than those 
directed against the 'classic' SEs (264). In addition, each of the Group IV and V SAgs 
have a well-defined zinc-binding motif (248) involved in high-affinity MHC II binding 
(272, 273) that can be targeted for appropriate mutagenesis to prevent systemic immune 
activation as shown here and previously for SEA (328, 331). In anticipation of designing 
a panel of TTSs, the fusion construct was specifically designed within this study to 
include an additional restriction enzyme digestion site on the C-terminal end of the 
scFv5T4 fragment. This not only enables genetic replacement of SpeC with SAg 
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variations with the option to allow for ‘fine-tuning’ of the desired immune response, but 
it may also prove particularly beneficial in the future in the design of a TTS panel with a 
diversity of SAgs and/or targeting scFvs for a variety of TAAs. Indeed, an additional TTS 
has recently been designed, composed of a humanized scFv directed at the human TAA 
Her2/neu [designed from the Fab Herceptin (420)] and a Group VI SAg, SmeZ, with a 
high-affinity site mutation Asp204 to Ala for reduction in systemic immune cell activation 
in preclinical experimentation (McCormick laboratory, unpublished).  
A third important limitation to TTS immunotherapy is that bacterial SAgs are well known 
to induce Vβ-specific T cell deletion or anergy (294), which includes CD8+ T cells (296). 
Thus, repeated administration of the same TTS in humans may result in populations of 
non-responsive T cells. However, using the B16 model of melanoma, a sufficient resting 
period between treatments did restore immune responsiveness resulting in prolonged 
survival with repeated cycles of therapy (322). Nevertheless, this limitation could 
potentially be circumvented by the use of multiple SAgs with different Vβ profiles. From 
this work, CD3+ T cells remained engrafted within the primary tumour after TTS 
treatment (Figure 26). Further investigation warrants the potential activation of this 
subset of T cells for full eradication of the cancer cells with either a repeated dose of 
SpeC-based TTS or an alternative Vβ-targeting SAg TTS. From the prospective of the 
TAA, similarly, a remaining and important issue with TTS immunotherapy is the 
targeting of a single TAA. An effective TTS would likely invoke a form of cancer 
immunoediting (71), and simple down regulation of the TAA may provide a means of 
escape. The TTS immunotherapy platform offers an approach for targeting a number of 
different TAAs, and it will be of future interest to engineer and combine TTSs that utilize 
SAgs with different Vβ profiles. 
As with the majority of cancer therapeutics, it is anticipated that the TTS alone would not 
be sufficient to eradicate the entirety of the cancer. mAbs that target VEGF (e.g. 
Bevacizumab) and EGFR (e.g. Cetuximab or Panitumumab) have shown benefit in 
patients with mCRC (55, 56, 58), and a future area of interest would be to test TTS 
combination therapies with these treatments. Immunotherapies such as the CARs 
targeting CD19 have now demonstrated some extraordinary clinical outcomes in patients 
  
167 
with advanced B cell leukemia (119, 123, 421, 422). In addition, blocking immune 
system regulatory 'checkpoints' with antibodies (e.g. anti-CTLA-4 or anti-PD-1) is 
promising (423). In preclinical combinational therapies, SEA-based TTS directed at 
colon carcinoma antigen C215 has been shown to achieve synergistic antitumour effects, 
prolong long term survival and maintain compatibility with both immune modulators IL-
2 (357) and IFN-α (344) and the well-established cytostatic drug docetaxel (341). 
Furthermore, this TTS in combination with antagonistic CTLA-4 mAb, demonstrated a 
favorable shift in the ratio between T effector and Treg cells in preclinical studies and 
that a CTL response was significantly prolonged, enhancing antitumour activity (361).  
To conclude, within this work, a novel TTS treatment was designed and successfully 
generated as a soluble recombinant fusion protein in a bacterial protein expression system. 
The TTS fusion protein consisted of a humanized scFv targeting 5T4 and an altered SAg 
SpeC as a prototype to reduce systemic immune effects. Following in vitro evaluations, 
the scFv5T4 specifically targeted 5T4 and the TTS was shown to mediate PBMC 
activation and cytotoxicity of colon cancer cells.  Lastly, the TTS demonstrated overall 
reduced total tumour volume and metastases burden in an established colon cancer in vivo 
model. This was, to our knowledge, the first streptococcal SAg to be employed in TTS 
immunotherapeutics, enabling the expansion of the current TTS repertoire. From this 
work, a platform of TTSs may be constructed, offering an additional approach for 
targeting a number of different TAAs, and combinations with alternate SAgs targeting 
various Vβ subsets of T cells. Additionally, this TTS may have prospective use in 
combinational therapies, overall increasing the selection of treatments to achieve 
synergistic and optimal anticancer effects. Evidence suggests that TTSs may represent a 
future 'off-the-shelf' therapy to harness Vβ-specific subsets of T cells without the 
requirement for manipulation of autologous T cells. This mode of action may be highly 
effective against tumours, in particular metastases, and those considered to be non-
immunogenic. This work may help to guide the 'next generation' of TTSs for tailored 
cancer immunotherapy. 
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Appendix 2. Animal ethics approval certification 
 
AUP Number: 2012-026 
PI Name: Mccormick, John 
AUP Title: Next Generation Superantigen-based Immunotoxins For Cancer Therapy 
Approval Date: 09/28/2012 
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal 
Use Protocol (AUP) entitled "Next Generation Superantigen-based Immunotoxins For 
Cancer Therapy" has been APPROVED by the Animal Use Subcommittee of the 
University Council on Animal Care. This approval, although valid for four years, and 
is subject to annual Protocol Renewal.2012-026::1 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through 
the ACVS office. Health certificates will be required. 
The holder of this Animal Use Protocol is responsible to ensure that all associated 
safety components (biosafety, radiation safety, general laboratory safety) comply 
with institutional safety standards and have received all necessary approvals. Please 
consult directly with your institutional safety officers. 
Submitted by: Copeman, Laura  
on behalf of the Animal Use Subcommittee 
University Council on Animal Care 
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Appendix 3. Clinical trial outcome definitions 
Acronym Outcome Definitiona 
AE Adverse event An unexpected medical problem that happens during treatment with a 
drug or other therapy. Adverse events do not have to be caused by the 
drug or therapy, and they may be mild, moderate, or severe 
CR Complete 
response 
The disappearance of all signs of cancer in response to treatment. This 
does not always mean the cancer has been cured; also called complete 
remission 
DFS Disease-free 
survival 
The length of time after primary treatment for a cancer ends that the 
patient survives without any signs or symptoms of that cancer 
DLT Dose-limiting 
toxicity 
Describes side effects of a drug or other treatment that are serious 
enough to prevent an increase in dose or level of that treatment 
DRR Durable response 
rate 
The length of time (usually displayed in months), that a partial or 
complete response is observed, as a result of treatment  
MTD Maximum 
tolerated dose 
The highest dose of a drug or treatment that does not cause 
unacceptable side effects 
OS Overall survival The length of time from either the date of diagnosis or the start of 
treatment, that patients diagnosed with the disease are still alive 
OSR Overall survival 
rate 
The percentage of people in a study or treatment group who are still 
alive for a certain period of time after they were diagnosed with or 
started treatment. The overall survival rate is often stated as a five-year 
survival rate 
PFS Progression-free 
survival 
The length of time during and after the treatment that a patient lives 
with the disease but it does not get worse 
QoL Quality of life The overall enjoyment of life. Many clinical trials assess the effects of 
cancer and its treatment on the quality of life. These studies measure 
aspects of an individual’s sense of well-being and ability to carry out 
various activities 
PR Partial response A decrease in the size of a tumour, or in the extent of cancer in the 
body, in response to treatment 
PK Pharmacokinetics The activity of drugs in the body over a period of time, including the 
processes by which drugs are absorbed, distributed in the body, 
localized in the tissues, and excreted 
aModified from National Cancer Institute Dictionary of Cancer Terms (http://www.cancer.gov/) 
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Appendix 4. Clinical trial phase definitions 
Phase Definitiona 
0 Exploratory study involving very limited human exposure to the drug, with no therapeutic or 
diagnostic goals (for example, screening studies, microdose studies)  
I Studies that are usually conducted with healthy volunteers and that emphasize safety. The goal is 
to find out what the drug's most frequent and serious adverse events are and, often, how the drug 
is metabolized and excreted 
II Studies that gather preliminary data on effectiveness (whether the drug works in people who have 
a certain disease or condition). For example, participants receiving the drug may be compared 
with similar participants receiving a different treatment, usually an inactive substance (called a 
placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are 
studied.  
III Studies that gather more information about safety and effectiveness by studying different 
populations and different dosages and by using the drug in combination with other drugs 
IV Studies occurring after FDA has approved a drug for marketing. These including postmarket 
requirement and commitment studies that are required of or agreed to by the sponsor. These 
studies gather additional information about a drug's safety, efficacy, or optimal use 
aModified from ClinicalTrials.gov Protocol Data Element Definitions
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Appendix 5. TTS developmental timeline citations 
Number Author Title Year Citation 
1 Dohlsten et al. Targeting of human cytotoxic T lymphocytes to 
MHC class II-expressing cells by staphylococcal 
enterotoxins 
1990 (310) 
2 Dohlsten et al. Monoclonal antibody-targeted superantigens: a 
different class of anti-tumour agents 
1991 (308) 
3 Dohlsten et al. Monoclonal antibody-superantigen fusion 
proteins: tumour-specific agents for T-cell-based 
tumour therapy 
1994 (309) 
4 Lando et al.  Tumour‐reactive superantigens suppress tumour 
growth in humanized scid mice 
1995 (319) 
5 Hansson et al.  Genetically engineered superantigens as tolerable 
antitumour  agents 
1997 (326) 
6 Forsberg et al. Identification of framework residues in a secreted 
recombinant antibody fragment that control 
production level and localization in Escherichia 
coli 
1997 (336) 
7 Giantonio et al. Superantigen-based immunotherapy: a phase I 
trial of PNU-214565, a monoclonal antibody-
staphylococcal enterotoxin A recombinant fusion 
protein, in advanced pancreatic and colorectal 
cancer 
1997 (324) 
8 Alpaugh et al. Superantigen-targeted therapy: phase I escalating 
repeat dose trial of the fusion protein PNU-
214565 in patients with advanced gastrointestinal 
malignancies. 
1998 (325) 
9 Søgaard et al. Treatment with tumour-reactive Fab-IL-2 and 
Fab-staphylococcal enterotoxin A fusion proteins 
leads to sustained T cell activation, and long-term 
survival of mice with established tumours 
1999 (357) 
10 Nielsen et al. Phase I study of single, escalating doses of a 
superantigen-antibody fusion protein (PNU-
214565) in patients with advanced colorectal or 
pancreatic carcinoma 
2000 (323) 
11 Forsberg et al.  Therapy of human non-small-cell lung carcinoma 
using antibody targeting of a modified 
superantigen 
2001 (335) 
12 Erlandsson et al. Identification of the antigenic epitopes in 
staphylococcal enterotoxins A and E and design of 
a superantigen for human cancer therapy 
2003 (339) 
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13 Cheng et al. Individualized Patient Dosing in Phase I Clinical 
Trials: The Role of Escalation With Overdose 
Control in PNU-214936 
2004 (337) 
14 Shaw et al. A phase II study of a 5T4 oncofoetal antigen 
tumour-targeted superantigen (ABR-214936) 
therapy in patients with advanced renal cell 
carcinoma 
2007 (338) 
15 Sundstedt et al. Combining tumour-targeted superantigens with 
interferon-alpha results in synergistic anti-tumour 
effects 
2008 (344) 
16 Sundstedt et al. Immunotherapy with tumour-targeted 
superantigens (TTS) in combination with 
docetaxel results in synergistic anti-tumour effects 
2009 (341) 
17 Borghaei et al. Phase I dose escalation, pharmacokinetic and 
pharmacodynamic study of naptumomab 
estafenatox alone in patients with advanced cancer 
and with docetaxel in patients with advanced non-
small-cell lung cancer 
2009 (342) 
18 Forsberg et al. Naptumomab Estafenatox, an Engineered 
Antibody-superantigen Fusion Protein With Low 
Toxicity and Reduced Antigenicity 
2010 (242) 
19 Sundstedt et al. Monotherapeutically Nonactive CTLA-4 
Blockade Results in Greatly Enhanced 
Antitumour Effects When Combined With 
Tumour-targeted Superantigens in a B16 
Melanoma Model 
2012 (361) 
20 Patterson et al. Control of Established Colon Cancer Xenografts 
Using a Novel Humanized Single Chain 
Antibody-Streptococcal Superantigen Fusion 
Protein Targeting the 5T4 Oncofetal Antigen 
2014 (424) 
21 Elkord et al. Immunological response and overall survival in a 
subset of advanced renal cell carcinoma patients 
from a randomized phase 2/3 study of 
naptumomab estafenatox plus IFN-alpha versus 
IFN-alpha 
2015 (348) 
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Appendix 6. Animal group pre-treatment characteristics 
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Appendix 7. 5t4 expression of human cell lines used within this study 
Relative expression of 5t4 compared to housekeeping gene, GAPDH, of HEK293 cells 
compared to human colon cancer cell lines, HT-29 and WiDr determined by qPCR 
analysis (n=3 represented as mean ± SEM. *p<0.05, **p<0.005, compared to HEK293)
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Appendix 8. Citations used for multiple sequence alignment of human scFv proteins 
Definition Reference 
anti-5T4 murine scFv Shaw, D.M., Embleton, M.J., Westwater, C., Ryan, M.G., Myers, K.A., 
Kingsman, S.M., Carroll, M.W. and Stern, P.L. 2000. Isolation of a high 
affinity scFv from a monoclonal antibody recognizing the oncofoetal antigen 
5T4. Biochimica et biophysica acta. 1524, 2-3 (Dec. 2000), 238–246. 
Synthetic backbone 
human scFv 
Yang HY, et al. Construction of a large synthetic human scFv library with six 
diversified CDRs and high functional diversity. Mol Cells. 2009; 27(2):225-35 
single-chain Fv fragment 
[Homo sapiens] 
Kontermann RE, et al. Complement recruitment using bispecific diabodies. Nat 
Biotechnol. 1997; 15(7):629-31. 
anti-(ED-B) scFV 
[Homo sapiens] 
Pini A, et al. Design and use of a phage display library. Human antibodies with 
subnanomolar affinity against a marker of angiogenesis eluted from a two-
dimensional gel. J Biol Chem. 1998; 273(34):21769-76. 
anti-HCS scFv [Homo 
sapiens] 
Pini A, et al. Design and use of a phage display library. Human antibodies with 
subnanomolar affinity against a marker of angiogenesis eluted from a two-
dimensional gel. J Biol Chem. 1998; 273(34):21769-76. 
anti-HER2/neu scFv 
[Homo sapiens] 
Derived sequence from: Cho HS, et al. Structure of the extracellular region of 
HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 
421(6924):756-60. 
anti-HER3 scFv [Homo 
sapiens] 
Merchant AM, et al. An efficient route to human bispecific IgG. Nat 
Biotechnol. 1998; 16(7):677-81. 
anti-Mpl scFv [Homo 
sapiens] 
Merchant AM, et al. An efficient route to human bispecific IgG. Nat 
Biotechnol. 1998; 16(7):677-81. 
anti-tetanus toxin scFv 
[synthetic construct] 
Scott N, et al. Single-chain Fv phage display propensity exhibits strong positive 
correlation with overall expression levels. BMC Biotechnol. 2008; 8:97. 
anti-TeTox scFv [Homo 
sapiens] 
Pini A, et al. Design and use of a phage display library. Human antibodies with 
subnanomolar affinity against a marker of angiogenesis eluted from a two-
dimensional gel. J Biol Chem. 1998; 273(34):21769-76. 
anti-TREM-like 
transcript-1 antibody 
[synthetic construct] 
Giomarelli B, et al. Inhibition of platelet aggregation using human single chain 
Fv antibodies specific for TREM-like transcript-1. Thromb Haemost. 2007; 
97(6):955-63. 
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